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ABSTRACT OF THE DISSERTATION
Elucidating Enhancer Function in Epidermal Development and
Filaggrin Loss-of-Function Variants in African American Atopic Dermatitis
By
Mary Elizabeth Mathyer
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Genetics and Genomics
Washington University in St. Louis, 2019
Cristina de Guzman Strong, Chair

The epidermis is the outermost tissue of the skin and provides the body’s first line of
defense against external assaults. The epidermis is primarily composed of keratinocytes that
terminally differentiate and rise apically toward the surface to form the semipermeable barrier of
the skin. A hallmark of keratinocyte terminal differentiation is the expression of genes from the
Epidermal Differentiation Complex (EDC) locus. Many of the EDC protein products contribute
to the structural integrity of the skin barrier, evidenced by several gene knockouts such as
loricrin, and even genetic variation within gene coding sequences, that modulate the integrity of
the skin barrier. Many of the genes in the EDC are coordinately expressed but the mechanism(s)
to coordinate this expression is poorly understood. Our lab previously identified the conserved
non-coding element 923 in the EDC as an epidermal-specific enhancer. I further hypothesized a
role for the 923 enhancer to activate EDC gene expression. To test this hypothesis, we generated
independent deletions of the 923 enhancer using CRISPR/Cas9 genome editing in mice. The
deletion alleles included a specific 1.2kb deletion of 923 (923del) and a large deletion that
x

included the 923 enhancer and an additional deletion of 40kb downstream (923large). Both
923del/del and 923large/large deletion mice appeared phenotypically normal under homeostatic
conditions. However, both 923del/del and 923large/large newborn skin transcriptomes revealed
decreased Ivl and Rps3a1, and increased Rps3a3, Hist1h2a1, and Gm16011 gene expression
changes in contrast to wild-type. Transcriptomic analysis of involucrin deficient (Ivl-/-) mice also
revealed the same gene expression changes for these 5 genes and demonstrated that the shared
gene expression changes are due to loss of Ivl rather than 923. Ivl is the most proximal gene to
923. Together, I identified Ivl as the primary target gene of 923 enhancer regulation. I further
identified an additional requirement for the 923large allele for late cornified envelope 6a (Lce6a)
expression suggesting the deletion of an additional regulatory element in the 923large allele.
Allele-specific assays for Ivl and Lce6a gene expressions in the skins of 923del and 923large
C57Bl/6 and BALB/cBYJ mouse hybrids allowed us to further determine that the 923 enhancer
regulates gene expression in cis. ATAC-seq on 923del and 923large homozygous epidermis
compared to wild-type mice revealed a shared enrichment of Differentially Accessible Regions
that were less accessible within the EDC. This suggests the 923 enhancer affects local chromatin
accessibility in keratinocytes. Together, my RNA-seq and ATAC-seq experiments identify a cis
regulatory module for the 923 enhancer and Ivl target gene expression in the epidermis, as well
as a functional role for the 923 enhancer to maintain local chromatin accessibility.
Filaggrin (FLG) is an EDC gene with population-specific genetic variation identified in
individuals of European and Asian ancestries. FLG loss-of function (LOF) variants are the most
well-known risk factors for the common inflammatory skin disease atopic dermatitis (AD).
Despite our understanding of FLG LOF for AD in populations of European descent, we have a
poor understanding of the prevalence of FLG LOF variants in African Americans (AA)
xi

populations, who are disproportionately affected with AD. I hypothesized the presence of FLG
LOF variants specific to African ancestry in a well-characterized AA AD pediatric cohort. To
discover FLG LOF, we utilized a tiled array based sequencing approach to sequence the highly
repetitive FLG gene, with further validation by Sanger sequencing. Our targeted sequencing
identified five FLG LOF variants (c.488delG, p.R501*, p.R826*, p.S3101*, and p.S3316*) in
nine AA AD patients. Two variants, c.488delG and p.S3101*, were novel as they were not
previously reported in the dbSNP, ExAC, or the ESP variant databases. Additionally p.S3316*
has only been previously reported in individuals of African ancestry, suggesting a populationspecific African variant. Moreover, a significantly higher frequency of FLG LOF was observed
in our AA AD group (11.5%) compared to the frequency for Africans reported in ExAC (2.5%)
and ESP (1.7%) indicating an enrichment for FLG LOF in the context of AD in this shared
ancestral population. Our results demonstrate a prevalence of population-specific FLG LOF
variants in AA AD patients at higher rates than previously reported and justify future precision
medicine investigations to best address this AD health disparity.
In summary, my dissertation functionally demonstrates the existence of a cis-regulatory
module in the epidermis, namely the 923 enhancer:Ivl expression module, and the 923
enhancer’s remodeling effect on local EDC chromatin accessibility. Furthermore, by using a
tiled sequencing approach, I discovered FLG LOF variants in AA AD patients, including
p.S3316* that was African-specific, highlighting a higher prevalence of FLG LOF in contrast to
previous reports. These two seminal studies together expand our existing knowledge of gene
regulation and variation in the epidermal skin barrier.
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Chapter 1

Introduction

By
Mary Elizabeth Mathyer

Portions have been adapted for dissertation from the published manuscript:
Mathyer, Mary Elizabeth and de Guzman Strong, Cristina (September 2018) Dynamic
Chromatin Architecture of the Epidermal Differentiation Complex (EDC). In: eLS. John Wiley
& Sons, Ltd: Chichester. DOI: 10.1002/9780470015902.a0027960
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1.1 Overview
Tissue-specific gene expression is achieved by the selection of distinct transcriptional
modules from the genome. These transcriptional units and expression patterns are tightly
regulated allowing the genomic code shared by all cells in an organism to be uniquely expressed,
leading to the development of cell fates and their diverse tissues. Within a tissue, cells further
differentiate and express new gene patterns for cellular function. The skin is an ideal tissue to
examine tissue-specific gene regulation due to its accessibility. Keratinocytes are the primary
cells of the skin epidermis and undergo a terminal differentiation process as they move upward
to form the semi-permeable outer skin barrier. This differentiation is marked by the expression of
many of the genes encoded by the epidermal differentiation complex (EDC) locus. The
expression of these genes is tightly regulated through mechanisms that are not yet entirely
understood. Many of the EDC genes encode structural proteins for the epidermal barrier, for
which gene knockouts such as loricrin and loss-of-function genetic variation are known to
modulate the barrier integrity and disrupt proper skin barrier function.
Filaggrin (FLG) is a major protein in the EDC with known common loss-of-function
(LOF) variants that affect barrier function. FLG LOF variants are major risk factors for the
common inflammatory skin disease atopic dermatitis. My thesis focuses on the EDC as a genetic
locus to examine gene regulation and the variations that lead to disease. Here I present current
knowledge of the structure and function of the skin barrier and the role of the EDC in this
formation. I then expand on the known regulatory mechanisms that control EDC gene expression
with particular attention to the role of enhancers. I also present our understanding of the
prevalence of population-specific FLG LOF variants in atopic dermatitis that further emphasizes
the impact of the loss of filaggrin to AD worldwide. Together, this information provides context
2

for the overarching questions that motivated my graduate research which are reported
subsequently in this dissertation.

1.2 Skin Barrier Structure and Function
The human skin is the body’s first line of defense against water loss, pathogens, and the
environment 1,2. At 1.8 microns thick3, the skin is comprised of both the outermost epidermis and
the underlying dermis, separated by a basement membrane. The dermis primarily consists of
fibroblasts and connective tissue2. In contrast, the epidermis is composed of epidermal cells
known as keratinocytes that adhere together in stratified layers to create a selective barrier2.
Upon differentiation, a keratinocyte in the inner proliferative, basal layer of the epidermis
asymmetrically divides. As a result, one daughter cell remains in the basal layer. The other
daughter cell undergoes terminal differentiation as it exits the cell cycle and migrates apically
and outwards toward the skin surface2,4,5. As the keratinocyte migrates sequentially through the
spinous, granular and cornified layers, the cell undergoes a shift in gene expression with the
observed increases of keratin 1 (K1) and keratin 10 (K10) and the concomitant downregulation
of keratin 5 (K5) and keratin 14 (K14)6,7. The keratinocytes also initiate the expression of many
genes encoded by the epidermal differentiation complex (EDC) locus3,8–11. Fully differentiated
keratinocytes in the outer stratum corneum, also known as corneocytes, flatten and enucleate5.
The cells also become permeable to calcium which activates the transglutaminase-1 enzyme
which in turn crosslinks proteins, including loricrin and involucrin, to create the cornified
envelope (CE) scaffold that surrounds the mature keratinocyte. This corneocyte functions as the
basic structural unit or “brick” of the skin barrier12,13.
3

Extruded lipids seal the cornified

envelopes together acting as a “mortar” to the CE’s “bricks”. The resulting highly hydrophobic
lipid and CE matrix acts as a semi-permeable barrier between the body and the outside
environment12. These terminally differentiated keratinocytes are eventually shed from the surface
and are replaced by the next wave of differentiating keratinocytes. The human epidermis selfrenews approximately every 50 days14. The epidermal barrier is acquired during embryogenesis
with the mouse skin barrier formation beginning at embryonic day (E)16 in a dorsal to ventral
pattern with the full barrier formed by E1715.

1.3 The Epidermal Differentiation Complex
The EDC is a gene cluster whose expression pattern is unique to epidermal keratinocytes
found in the stratified epidermis at the surface of the skin. The concomitant expression of many
EDC gene products is the hallmark of keratinocyte differentiation in the suprabasal layers of the
epidermis, in contrast to the innermost proliferative basal cells9,10,16–19. The EDC, which spans a
1.6Mb region on human 1q21 and is located on chromosome 3q in mice, is highly conserved
across mammalian species9,19,20. The human EDC locus contains approximately 65 proteincoding genes grouped into 4 gene families (Figure 1.1). These families include filaggrin (FLG)
and FLG-like genes, late cornified envelope (LCEs), small proline rich region (SPRRs) genes
including loricrin (LOR) and involucrin (IVL), and the S100 genes. Many proteins of the EDC
contribute to specific morphological changes in differentiated cells including the assembly and
reinforcement of the scaffold of the cornified envelope, and the ability to bind calcium, which
further drives terminal differentaiation3.
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Figure 1.1. Schematic of the Epidermal Differentiation Complex. (top) Human EDC hg38.
Protein coding genes in black, long non-coding RNAs in green. (bottom) Mouse EDC, mm10.
Transcript coordinates for human obtained from Ensembl 90, mouse obtained from Ensembl 91.
When multiple isoforms are reported, the longest isoform is displayed here.

Many EDC genes share homology at the N- and C- terminal domains and have a variable
number of internal repeat sequences, suggesting the evolution and divergence of EDC genes
from a common ancestor21,22. This is further supported by the conservation of the EDC in both
eutherian and metatherian mammals, whose EDC loci share linearity and synteny19, and ongoing
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molecular evolution observed across mammalian phylogeny and hominid evolution20.
A majority of the EDC genes are initially expressed at the onset of epidermal
differentiation at mouse E15.5, with subsequent induction of many LCE gene family members by
E16.5 upon outside-in skin barrier formation19. The concomitant expression of EDC genes is a
definitive developmental event during keratinocyte terminal differentiation.

1.3.1 Discovery of the EDC
IVL and LOR were the first discovered EDC genes and act as early scaffolds for the
cornified envelope23–25. The SPRR and S100 genes were subsequently discovered through the
functional cloning of mRNAs obtained from UV and calcium- treated human keratinocytes16,18.
These gene families were later demonstrated to be physically linked using the hybridization of
gene-specific probes applied to electrophoresed genome restriction fragments17. Higher
resolution mapping of this locus with restriction enzymes and southern blotting led to the naming
of this region as the epidermal differentiation complex9. Investigation into the molecular markers
that correlated spatiotemporally with the formation of the skin barrier in mice led to the
discovery of a set of expressed sequence tags (ESTs) that shared great similarity to a previously
discovered SPRR gene. As these ESTs were discovered to be proteins that were expressed in
later stages of epidermal development, they were termed late envelope proteins (LEPs)10,11,26 and
later renamed late cornified envelope (LCEs) genes to more accurately reflect their expression
pattern27,28.

1.3.2 Involucrin
Involucrin (IVL), a member of the SPRR gene family, is a major protein component of the
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cornified envelope. The involucrin gene is composed of multiple repeats, each 10 amino acids
long, that serve as the substrates for the crosslinking of IVL by transglutaminase-1 to form the
cornified envelope23,29. Cross-linked IVL provides a protein scaffold for the cornified envelopes
which are sealed by extruded lipids to form the skin barrier29,30. The IVL repeats have been
extensively studied due to their unique evolution31,32. The IVL repeat has duplicated over time
and acquired mutations, with the more ancient repeat sequences at the 5’ of the gene31,33,34.
Overall, involucrin has 3 segmental domains of repeats with the “early” repeat segment shared
between humans, apes and the owl monkey, the “middle” segment shared only between humans
and apes, and the “late” segment unique to each species32,34–37. The total number of IVL repeats
appears to be continuing to evolve in humans with evidence of between 7 and 11 repeats in the
“late” segment in various human populations38. Although no overt phenotype was observed
under homeostatic conditions in Ivl knockout mice39, triple knock-out mice for Ivl, periplakin,
and envoplakin (additional CE scaffold proteins), which each exhibited no overt skin barrier
phenotype when deleted in isolation, together displayed a delay in embryonic barrier formation,
abnormal ultrastructure of the CE, and abnormal lipid attachment to the CE40. This suggests that
cornified envelope proteins may act in a redundant fashion. Additionally, the effect of a single
gene deletion may have a subtle effect under homeostatic conditions and thus should be
investigated further under barrier challenged conditions.

1.3.3 Filaggrin
Filaggrin (FLG) is another EDC gene member that contributes to the structural integrity
of the skin barrier. FLG and FLG-like gene family members are paralogous genes, given their
shared consensus S100 N-terminal domain fused to gene-specific repeats and the C-terminal
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domain3. The FLG gene contains 3 exons with the first exon containing the noncoding 5’ UTR.
The short 2nd exon contains the N-terminal domain and a truncated repeat. The third and largest
exon contains 10-12 nearly identical repeats that are each 972bp in length41. The filaggrin gene is
initially expressed and translated as profilaggrin (400-kDa) which is post-translationally cleaved
at the 7 amino acid linker regions between each repeat41,42. The nuclear localization signal
located in the C-terminal domain is thought to be required for the cleavage of profilaggrin into
the resulting active filaggrin monomers as evidenced by minimal processed FLG monomers that
were detected from a few patients with FLG LOF variants that had prevented the translation to
the C-terminal domain41,43. Once cleaved, the filaggrin monomers associate with intermediate
filaments and promote the formation of the cornified envelope44. As the corneocytes reach the
surface of the skin the FLG monomers are further degraded into their amino acids which then
contribute to the natural moisturizing factor of the stratum corneum41,44.
FLG was first isolated from the stratum corneum in 198145. Mouse and human
profilaggrin genes were subsequently identified in 1986 and 198946,47. Flg knockout (KO) mice
have been generated and revealed decreased amounts of natural moisturizing factor levels as well
as impaired barrier function with premature shedding of CE cells leading to a less stable
barrier48. The FLG KO mice also showed enhanced responses to contact hypersensitivity, a
well-known inflammatory response in atopic dermatitis48. These mice highlight the role for FLG
deficiency in atopic dermatitis, a disease specifically impacted by FLG loss-of-function variants
which I will expand on later.
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1.4 Regulation of EDC Gene Expression
The clustering and conservation of EDC genes raise an intriguing hypothesis for
molecular mechanism(s) to coordinate the active expression of the locus for epidermal
differentiation. Here I review our current understanding of the molecular and epigenetic
mechanisms that regulate keratinocyte and EDC gene expression.
Tissue-specific gene expression is achieved by the selection of distinct transcriptional
modules from the genome. These transcriptional units and expression patterns are regulated by
higher orders of chromatin structure, accessibility, chromatin contacts, and transcription factor
binding that vary by cell type. The mechanisms underlying these important biological processes
are complex and have been elucidated through multidisciplinary approaches. The discovery of
the impact of epigenetic modifications to the deoxyribonucleic acid (DNA) and histones on cell
behavior and function has been paradigm-shifting in our understanding of transcriptional
regulation49. Furthermore, ground-breaking discoveries of functional chromatin architecture have
been inferred from genome-wide mapping of the intricate networks of physical in vivo protein–
chromatin binding, such as transcription factors via chromatin immuno-precipitation studies
(ChIP), and chromatin–chromatin interactions through chromatin conformation capture50–52.
Paired with RNA-sequencing to capture the corresponding transcriptomes, these approaches
collectively have been used to define physical and regulatory interaction maps and connect key
epigenomic and genomic features for a variety of cell types. From these studies, it is clear that
multiple mechanisms regulating gene expression for cell differentiation exist, thus providing a
framework to further investigate transcriptional regulatory networks for a given tissue-specific
locus including the EDC.
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1.4.1 Epigenetic Modifications of the EDC
In the past decade, we have come to understand the critical role of epigenetic
modifications in the regulation of gene expression for keratinocyte differentiation. The
packaging and compartmentalization of linear DNA within a cell is nonrandom in order to enable
tissue-specific expression. DNA is packaged around nucleosomes comprising histone octamers53.
These ‘beads on a string’ are further folded into 30 nm fibers and subsequently into higher-order
looping structures, thus providing a 3D chromatin architecture54 (Figure 1.2). Many biochemical
modifications to the histone N-terminal tails, including methylation and acetylation, impact the
structure and function of the histone and thus affect transcription. These posttranslational,
epigenetic modifications recruit proteins to either activate or repress transcription51,55. Detection
of specific epigenetic modifications mentioned in the following section using chromatin
immunoprecipitation coupled with next-generation sequencing (ChIP-seq) has enabled the field
to identify epigenetic patterns of a variety of genomic features including active and inactive
genes and enhancers on a genome-wide scale, and more broadly understand chromatin dynamics
with respect to transcription56. Here, I discuss pivotal studies that highlight the roles for DNA
and histone methyltransferases and histone deacetylases in suppressing premature activation of
the epidermal differentiation gene program in the proliferative basal cells.
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Figure 1.2. Schematic of chromatin regulation. Chromatin modifications and structure from
DNA methylation through histone modifications including methylation and acetylation.
Chromatin is subsequently wrapped around nucleosomes and can be remodeled to be open or
closed. Physical looping can create interactions between enhancers and gene promoters.
Chromatin is further packaged into topologically associated domains and heterochromatin within
the nucleus of the cell.

DNA Methylation
Keratinocyte terminal differentiation requires the transcriptional activation of specific
sets of genes which is achieved in part through the loss of DNA methylation57. DNA methylation
is commonly associated with transcriptional repression or gene silencing51,55,58. Methylated DNA
arises from the addition of a methyl group to the C5 position of cytosine, occurring primarily at
CG dinucleotides known as CpG sites58. Methylation is thought to inhibit gene expression by
altering the recognized DNA-binding site and thus preventing transcription factor binding55. In
addition, methyl-CpG-binding proteins recognize methylation and recruit transcriptional
corepressor molecules to silence transcription55.
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In mammalian cells, repressive methylation marks are deposited by DNA
methyltransferases or DNMTs, with DNMT1 as the major methyltransferase of the 3 primary
methyltrasferases DNMT1, DNMT3A and DNMT3B57. DNMT1 methylates cytosine residues on
hemimethylated CpG sites, resulting in stable methylation even after DNA replication58. In
keratinocytes, DNMT1 is distinctly expressed in the proliferative basal and not in the
differentiated epidermal layers, suggesting a potential mechanistic role in the maintenance of the
proliferative state57. DNMT1 knockdown in human keratinocytes resulted in the loss of DNA
methylation and subsequent induction of genes (including EDC genes) associated with epidermal
differentiation leading to premature keratinocyte differentiation57. These data revealed a
mechanism by which DNMT1 regulates epidermal differentiation by suppressing signature genes
associated with epidermal differentiation, thus promoting proliferative function in basal
keratinocytes.

Histone Methylation
Histone methyltransferases and demethylases are enzymes known to regulate histone
methylation and hence affect transcription. Trimethylation of the third histone at the fourth lysine
position (H3K4me3) is found at the transcription start sites of actively transcribed genes51.
Comparably, H4K20me1 also marks active gene bodies. By contrast, H3K27me3 epigenetic
marks are associated with gene repression51. The JMJD3 demethylase removes these methylation
marks and is important for epidermal differentiation59. H3K27me3 marks the promoters of many
differentiation genes, including the EDC genes IVL and S100A8, in proliferating keratinocytes.
Upon calcium-induced differentiation, H3K27me3 marks are lost. Sen et al. also identified an
enrichment of JMJD3 binding at differentiation-induced gene promoters coinciding with
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H3K27me3 loss. Both knockdown of JMJD3 and the expression of a demethylase-inactive Jmjd3
similarly suppressed differentiation, supporting the role of JMJD3 in the removal of H3K27me3
marks and de-repression of EDC gene expression during differentiation59. Together, the data
suggest an epigenetic mechanism in governing the transitional state from proliferation to
differentiation.
In parallel, methyltransferases that deposit histone methylation marks were also
determined to be critical epigenetic modifiers in epidermal differentiation. The polycomb
repressive complex (PRC) is a large complex with known methyltransferase activity. PRC
represses gene expression through the deposition of H3K27me3 by PRC1/2 subcomplexes,
which contain the methyltransferases, EZH1 or EZH260. Loss of Ezh2, endogenously expressed
in the basal layers of embryonic mice, resulted in reduced keratinocyte proliferation and
morphologically thickened granular layer and stratum corneum61. Transcriptional profiling of
Ezh2 epidermal-specific KO cells identified precocious activation of select EDC genes in the
proliferative basal cells in contrast to their normal expression in differentiated suprabasal
keratinocytes, thus supporting a repressive role for EZH2 in premature activation of EDC genes
in basal cells. The deposited H3K27me3 marks are thought to interfere with the binding of the
transcription factor AP1 that targets many epidermal differentiation genes, including EDC
genes61. The histone methyltransferase SETD8 responsible for H4K20me1 methylation, a mark
commonly associated with active gene bodies, was also determined to be required for epidermal
development62. Tissue-specific loss of Setd8 in the mouse basal epidermis resulted in a perinatal
lethality via the loss of keratinocyte proliferation as well as impaired differentiation. Together,
these studies underscore a key role for epigenetic control by histone methyltransferases in
keratinocyte epidermal differentiation.
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Histone Acetylation
Histone acetyltransferases and histone deacetylases also impact gene expression by
modifying histone acetylation51. Histone acetylation is commonly associated with actively
transcribed genes, which are often marked with H3K27ac at their promoters. Histone
deacetylases HDAC1 and HDAC2 (HDAC1/2) are known epigenetic modifiers that remove
histone acetylation marks through complexes formed with DNA-binding factors55. Hdac1/2 are
highly expressed in E13 mouse keratinocytes prior to stratification and in the differentiated
layers of later developmental time points, suggesting that they may be essential regulators of
epidermal development63. Epidermal-specific deletion of Hdac1/2 using K14-Cre mice resulted
in poorly differentiated epidermis characterized by a lack of Lor and K10 expression. There was
also a reduction in proliferating cells as evidenced by a decreased percentage of phospho-histone
H3 (PH3)-positive basal cells compared to control littermates63. The Hdac1/2 double KO mice
phenocopy the loss of the p63 transcription factor, a master regulator for epidermal
development64,65. Loss of Hdac1/2 corresponded with increased levels of p53, which works in
opposition to p63; when p53 is acetylated, it endogenously positively regulates many targets of
p63 repression63. Collectively, Hdac1/2 work in concert with p63 and suppresses p53
hyperacetylation to ensure proper epidermal development. Thus, the work highlighted a
requirement for histone deacetylases Hdac1/2-mediated epigenetic regulation for proper
keratinocyte differentiation.

1.4.2 Nonrandom Nuclear Chromatin Localization and Accessibility
In addition to epigenetic modifications, several key studies have also highlighted
important findings for nonrandom chromatin localization within the nucleus as well as open
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chromatin status, for actively transcribed genes, including the EDC in keratinocytes. Within a
nondividing cell nucleus, a given chromosome appears to occupy a distinct region known as a
chromosome territory, named after the chromosome number. During cell differentiation, the
activation and silencing of a genomic locus often correlates with the locus’ position within its
chromosome territory66. Specifically, fluorescent in situ hybridization (FISH) in mouse and
human cells from a variety of cell types including primary fibroblasts and colon adenocarcinoma
cells, has demonstrated an enrichment of inactive heterochromatin and gene-poor chromosomes
towards the periphery of the nucleus while active loci cluster in the interior of the nucleus66–69.
During late keratinocyte differentiation, the nuclear volume in newborn mouse epidermal
keratinocytes was observed to be decreased as determined by confocal microscopy paired with
3D reconstructions70. This shift occurred as the keratinocytes differentiated from highly
transcriptionally active cells in the spinous layer of the epidermis to the transcriptionally inactive
cells of the granular layer70. A reduction in H3K4me1 immunostaining for transcriptionally
active chromatin provided further evidence for decreased transcriptional activity in granular
keratinocytes, corresponding with an increase in association between chromosome territory 3,
the nuclear region occupied by chromosome 3 (which contains the EDC), and nucleoli,
organelles associated with regions of gene silencing70. Using 3D-FISH in mouse keratinocytes at
E11.5 and E16.5, the EDC was observed to relocate from the nuclear membrane towards the
internal region of chromosome territory 3, a physical shift corresponding with the expression of
EDC genes during differentiation71. Together, these studies provided key evidence for the
remodeling of nuclear architecture during keratinocyte differentiation, opening new areas for
further investigations into the molecular mechanisms that drive the ‘nonrandom’ behavior of
active chromatin in achieving tissue-specific expression.
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The genome organizer SATB1, another downstream target of p63, has also been
implicated in remodeling EDC chromatin in proliferating keratinocytes72. 3D-FISH for the EDC
gene loricrin (Lor) and flanking genes Rps27 and Gabp2 revealed a compression of the EDC
during differentiation in WT cells, which was not observed in either Satb1 or p63 KO mice72.
ChIP revealed SATB1 binding sites throughout the EDC and additional FISH studies in Satb1
KO mice for EDC genes S100a6, Lor-Lce3c and S100a10 showed EDC locus expansion further
supporting a role for SATB1 in compressing the EDC72.
Chromatin remodeling ATPase, BRG1, has also been demonstrated to play a role in
remodeling the chromatin of keratinocytes for differentiation in tandem with its upstream p63
transcription factor71. Brg1 epidermal-specific KO mice exhibited an increased proportion of
EDC loci at the periphery of chromosome territory 3 relative to wild-type mice, as determined by
3D-FISH. Thus, BRG1 was determined to be involved in translocating the EDC locus from the
periphery of the nucleus towards the interior, corresponding with increased EDC gene
expression. Together, it is clear that BRG1 and SATB1, as well as the p63 master regulator
transcription factor, are chromatin remodeling factors required for optimally positioning the EDC
locus for transcription during terminal differentiation.
In the epidermis, the chromatin remodeling BAF enzyme complex, containing BRG1 or
BRM as its ATPase, has been shown to configure the chromatin in keratinocytes by enabling
genome-wide chromatin accessibility73. Using ATAC-seq (assay for transposase accessible
chromatin) to identify regions of open chromatin in normal human keratinocytes (NHEK)
depleted for both BRG1 and BRM catalytic subunits, Bao et al. demonstrated a requirement for
BAF to maintain open chromatin that is bound by p6373. The occupation by BAF positions
nucleosomes away from p63 binding motifs to reinforce open chromatin enabling the
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transcriptional machinery to access and transcribe epidermal-specific genes.

1.4.3 Enhancer-Centric Regulation of the EDC
While I have highlighted critical epigenetic modifiers for keratinocyte differentiation, the
elucidation of sequence-based molecular mechanisms governing tissue-specific gene expression
is more challenging. Regulatory enhancers have been implicated in this process. Enhancers are
non-coding DNA sequences that regulate gene expression when brought into physical proximity
to promoters74–76. This looping of the chromatin concentrates transcription factors and other
proteins required for transcription, resulting in gene expression. Enhancers drive gene expression
of proximal and distal target genes and may be located at distances ranging from hundreds to
hundreds of thousands of base pairs (bp) from their target genes75,77. Multiple enhancers can
activate the same gene in different tissues76 and it is thought that even within a tissue type, a
gene may be regulated by 2-3 enhancers78.

Elucidating Enhancers
The concept of an enhancer was first described in 1981 with the discovery of the SV40
tandem repeat sequence in the SV40 virus79. A 72 bp repeated sequence upstream of the SV40
early gene promoter was demonstrated to ‘enhance’ the expression of rabbit Beta-globin in a
position-independent manner79–81. Further studies identified enhancers as nearby clusters of
transcription factor biding sites that exhibit spatiotemporal specificity 76,82,83.
With the advent of next-generation sequencing, the National Human Genome Research
Institute (NHGRI) launched the Encyclopedia of Non-Coding Elements (ENCODE) whose goal
is to characterize the function of noncoding elements in the genome84,85. This database compiles
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genome-wide data sets from a variety of tissues and assays which have been used to identify
patterns of chromatin modifications unique to non-coding elements, such as enhancer regions.
These patterns are subsequently used to annotate putative enhancers. For example, ChIP-seq was
used to identify characteristic epigenetic mark patterns for enhancers51,76,86. Similar to the
characteristic promoter marks, active enhancers are often marked with H3K4me1 and H3K27ac
while inactive enhancers typically possess H3K9me3 and H3K27me3 marks76. A third category
is poised enhancers which are not yet active but are primed for activation at a later
developmental stage following further histone modifications. Poised enhancers harbor histone
marks associated with both active and repressed enhancers, namely H3K4me1 and H3K27ac76.
Many keratinocyte-specific enhancers in NHEK and primary mouse keratinocytes, including
many within the EDC, have been identified by ChIP-seq using anti-H3K4me1 and anti-H3K27ac
antibodies86,87.
Active enhancers are also accessible, free of nucleosomes and hypersensitive to the
DNase I digestion enzyme88,89. Actively transcribing RNA Polymerase II is also present, with
enhancer-RNA expression widespread throughout the genome and correlated with the
transcription of nearby genes90,91. Enhancers are also often conserved across species as
functional sequences are often under purifying selection. This conservation has led to the use of
comparative genomics techniques to identify conserved non-coding elements (CNE) on a
genome-wide scale which can be subsequently tested as putative enhancers19,76,92.
While molecular patterns are good predictors of enhancer activity, functional validation
of enhancer activity is crucial. Functional studies of enhancers, ideally in vivo, are required to
confirm the activity of a putative enhancer as well as to identify the respective target gene(s)93.
Recent enhancer knockout studies have revealed many predicted enhancers to be nonessential 93–
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95

. In one study, the deletion of two conserved enhancers that were previously demonstrated in

transgenic studies to be functional in limb development, revealed no effect on forelimb
development or changes in expression of the inferred target gene Tbx5 when deleted singularly
or in tandem 95. Another study knocked out 10 individual enhancers at 7 loci required for limb
development and saw no changes in limb morphology. However, subsequent deletion of
enhancer pairs were necessary to produce a phenotype, hence demonstrating functional enhancer
redundancy94. Together these studies illustrate the importance of in vivo functional validation.

CNE 923
Our lab has previously used a comparative genomics approach to glean candidate EDC
enhancers19. We identified 48 CNEs, of which approximately half demonstrated functional
regulatory activity including enhancers. In particular, CNE 923 displayed epidermal-specific
enhancer activity19. 923 is so named due to its location 923 kb from the 5’ most EDC gene in
humans, S100a10. Of all EDC CNE’s tested, 923 demonstrated the highest enhancer activity and
was DNaseI hypersensitive. Moreover transgenic 923 reporter mice exhibited epidermal-specific
activity and demonstrated 923 was sensitive to spatiotemporal cues during epidermal
development96. Using chromatin conformation capture (3C) assays, which identify specific,
individual (one-to-one) DNA interactions, dynamic physical interactions between 923 and EDC
gene promoters in proliferating and differentiated keratinocytes were identified50,96. It was
further determined that the AP-1 (c-Jun) transcription factor binding to the 923 enhancer was
required for activity since pharmacological inhibition of AP-1 binding led to repressed EDC
expression and aberrant EDC chromatin remodeling within in vitro differentiated keratinocytes.
The study’s identification of chromatin spatial interactions between the 923 epidermal-specific
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enhancer and EDC gene promoters in both proliferative and differentiated keratinocyte
developmental states translated our understanding of the EDC from a linear model to a more
structurally regulated unit that is dynamically remodeled for differentiation. However, there is
much more to elucidate regarding the functional role of 923 in vivo, a question driving much of
my thesis research, discussed in further detail later.

1.4.5 Chromosome Conformation Capture Further Elucidates Dynamic Chromatin
Remodeling
Understanding the functional interconnectivity between enhancers and their target genes
is crucial to understand gene regulation. This comprehension has been aided by the development
of chromatin conformation capture techniques which have revolutionized our understanding of
chromatin architecture in specific cell types50,52. From the conceptual development as Chromatin
Conformation Capture (3C) to more high-throughput methods that capture all-vs-all interactions
genome-wide with HiC, our understanding of complex chromatin interaction networks have
emerged. These interactions led to the identification of regions of enriched chromatin looping
events which reveal a higher level of chromatin organization into 3D networks known as
topologically associating domains (TADs)97,98. TADs consist of highly self-interacting spatial
connections in a specific region separated by boundaries where the chromatin interactions end
abruptly98. TADs include interactions between promoters and regulatory elements associated
with controlled gene expression and cell identity. The elucidation of physical contacts between
enhancers and promoters and the highly organized nature of TADs provided the much-needed
biochemical evidence to support the mechanics of gene activation and nonrandom
compartmentalization of the genome.
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Chromatin conformation capture carbon copy (5C) (many-by-many) studies in
proliferating mouse keratinocytes revealed EDC specific TADs87. Physical interactions observed
between ∼750 probes that tiled the EDC revealed a spatial folding of the locus into four TADs
that were either gene-rich or gene-poor. Furthermore, inter-TAD contacts occurred only slightly
less frequently than intra-TAD contacts between the EDC TADs suggesting gene regulation via a
functional interconnectivity of neighboring, multi-TAD regions. A majority of EDC enhancers
(characterized by H3K27ac and H3K4me1 modifications) identified in the 5C experiments
exhibited interactions with multiple promoters suggesting an enhancer–promoter network within
the EDC87.
A variation of 3C that detects promoter contacts, named Capture Hi-C (Chi-C) (all-by-all
with an enrichment of selected sequences prior to sequencing) identified two classes of
enhancer–promoter interactions in primary human keratinocytes99. A core set of keratinocytespecific enhancer–promoter interactions were identified as occurring between differentiationinduced promoters and enhancers in both proliferating and differentiated cells, with consistent
H3K27ac marks on the enhancers. A second class of enhancer–promoter interactions included
gained contacts in differentiated cells in concert with increased H3K27ac at the enhancers. LCE
genes were among the many induced genes associated with these gained contacts in the
differentiated cells. Many of the core interactions observed to be present at all stages of
keratinocyte differentiation included differentiation-induced EDC genes, suggesting the
involvement of poised enhancers99.
These two studies present a model of two classes of enhancer–promoter interactions in
keratinocytes: (1) pre-established, lineage-specific and (2) differentiation-induced interactions.
Together, they further our understanding of dynamic chromatin architecture changes during
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keratinocyte differentiation.

1.4.6 Beyond Enhancer Predictions
Despite a genome-wide, comprehensive catalogue of regulatory elements in many tissues,
we still have a poor understanding of which enhancers and their genetic variants affect target
gene expression. CRISPR/Cas9 technology has greatly facilitated the genome editing of
candidate enhancers in mice, revealing that genes may possess an array of at least partly
redundant enhancers94,100. Moreover, we are just beginning to understand genetic variation
within enhancers that affect transcription factor binding sites and subsequent transcription.
Expression quantitative trait locus (eQTLs) mapping is a powerful tool to determine candidate
loci and variants involved in differential gene expression in specific tissue types. Comprehensive
proof-of-concept was demonstrated by GTEx for human-specific gene expression in over 50
tissues101,102. It is also important to note that many of these genome-wide studies are measured on
bulk cell populations. Higher resolution studies offered by single-cell techniques will
undoubtedly establish newer paradigms for transcriptional regulation. Overall, knowledge of the
molecular mechanisms that govern gene expression is critical to the development of new
strategies to engineer specific cell types and to treat disease. Only by understanding and
capitalizing on these complexities to activate or repress desirable loci in specific cell types can
we make strides towards individualized precision treatment.
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1.5 Atopic Dermatitis
It is crucial to understand the structure, function, and regulation of the skin barrier to
better understand what has changed in disease states. Atopic Dermatitis (AD) is a chronic,
inflammatory skin disease with known impaired skin barrier etiology. AD is characterized by dry
skin and severe pruritus103. AD-triggered pruritus causes severe scratching which elicits the
hallmark rash or flare. The scratching can cause the skin at the site of lesion to thicken and
lichenify, producing thick, leathery skin. The open AD lesions are also susceptible to secondary
skin infections such as Staphylococcus aureus and Staph epidermidis104–106. In addition to dry,
itchy skin, many AD patients subsequently develop additional atopic diseases such as food
allergies, then asthma, and then allergic rhinitis, a progression known as the atopic march107,108.
Quality of life is impacted, particularly in moderate-to-severe cases as AD comorbidities can
include sleep disturbance, depression, anxiety, and frequent clinic visits109–114. While AD usually
begins in infancy and resolves through childhood, AD can persist into adulthood115.

1.5.1 Epidemiology
AD is relatively common worldwide affecting 15-20% of the pediatric population and 13% of adults116. The prevalence of AD is also increasing, having nearly tripled in the past few
decades117,118. In the US alone, it is predicted that up to 13% of children suffer from AD118–120.
AD is heritable and the prevalence of AD differs between populations117,121. In the US, up to
15.9% of African American children are diagnosed with AD compared to 9.7% of Caucasian
children119. In the UK, children of African descent are 6 times more likely to have AD than
Caucasian children122. The risk factors for this population discrepancy are not entirely clear.
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Environmental influences are thought to play a role particularly considering that there is also an
increased prevalence of AD in urban compared to rural areas119. This goes hand-in-hand with the
“Hygiene Hypothesis” that posits that individuals in urban areas have less exposure to soil
microbes and are thus too clean111. Yet the increased prevalence of AD cannot be attributed to
cleanliness alone. Increased risk of AD has also been associated with early exposure to
environmental industrial pollutants like carbon monoxide and high traffic areas, as well as
increased use of antibiotics123,124. There are also genetic risk factors that contribute to the
population specific heritability of AD susceptibility such as loss-of-function variants in the
filaggrin gene125. Together, it is clear that AD is a multifactorial disease with many contributing
factors.

1.5.2 FLG in AD
While not all AD risk factors are fully understood, loss-of-function variants in the EDC
gene FLG have been reported as the greatest risk factor for AD126. FLG’s role in disease was
initially identified as causative in patients with ichthyosis vulgaris (IV), a disease characterized
by rough, dry, scaly skin with hyperlinearity on the palms of the hands41,125. IV patients exhibited
decreased FLG expression prompting the investigation of the underlying genetic variants which
revealed loss-of-function (LOF) FLG variants125. These variants introduce premature stop
codons leading to the expression of a truncated profillagrin lacking the C-terminal thus
preventing the cleavage of the filaggrin monomers127. The first FLG LOF variants identified
were R501X and 2282del4, both common variants found in European populations125.
Investigation of the family pedigrees of these IV patients with FLG LOF variants revealed many
of the patients also suffered from AD. The significant strong association of FLG LOF variants to
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AD established these variants as risk factors for AD126. FLG LOF variants account for 50% of
moderate to severe AD cases of patients of European descent44,126. To date, over 100 AD
associated FLG LOF variants have been identified128. FLG LOF variants are population-specific
with African and Asian populations possessing different variants than European populations41,128.
Patients with FLG LOF associated AD have more persistent and severe disease and have
decreased natural moisturizing factor129–132. While FLG LOF variants increase the likelihood of
AD, it is semi-penetrant. Nevertheless, Flg deficiency is a well-known mouse model for AD. The
Flg knockout mouse exhibits dry, scaly skin, enhanced sensitization and higher serum IgE levels
consistent with AD48. The flaky-tail mouse (Flgft) is another AD mouse model with a frame-shift
mutation in Flg that prevents the processing of profilaggrin into filaggrin, resulting in reduced
Flg protein133,134. Flaky-tail mice show reduced stratum corneum hydration and low-level
inflammation under basal conditions in contrast to wild-type mice when contact dermatitis was
induced135,136. Together, the discovery of FLG LOF variants in AD and the findings of features
of AD in Flg-deficient mice highlight the impact of FLG deficiency on AD disease outcome.

1.6 Scope of Thesis
My dissertation work has focused on two specific questions related to the skin barrier: 1)
What is the functional role of the epidermal enhancer 923 in the EDC? And 2) Do AfricanAmerican pediatric patients with severe AD have FLG LOF variants? In the following chapters, I
will present my graduate studies research aimed to address these questions. In Chapter 2, I report
my research findings regarding the role of the epidermal enhancer 923. Through CRISPR/Cas9
mediated knockouts of the 923 enhancer in mice, I have identified that the 923 enhancer
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activates involucrin target gene expression in a cis-regulatory manner. I further demonstrate that
the 923 enhancer facilitates open chromatin accessibility within the EDC. In Chapter 3, I
examined the role of FLG LOF variants in an African American pediatric patient cohort for
moderate to severe AD. I identified five FLG LOF variants (c.488delG, p.R501*, p.R826*,
p.S3101*, and p.S3316*) two of which are novel (c.488delG and p.S3101*), and one of which
(p.S3316*) is population-specific, having been only reported in individuals of African ancestry.
Additionally, the frequency of FLG LOF variants in our African American AD cohort was
significantly higher than previously reported for AD. In my appendix chapters, I further detail
my ongoing work in A) examining the role of the 923 enhancer and involucrin under barrierchallenged conditions by treating the mice with MC903, which induces AD-like inflammation
and B) characterizing the role of the 923 enhancer in Smcp gene regulation in the testes through
sperm motility assays. This body of work together expands our existing knowledge of gene
regulation and variation in the epidermal skin barrier.
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2.1 Abstract
Enhancers facilitate the expression of genes in a tissue-specific manner. Despite the
genome-wide discovery of enhancers in the skin, the functional impact of enhancers in skin
biology is poorly understood. Here we address the function of the epidermal-specific enhancer
923 in the epidermal differentiation complex (EDC) locus in mice. Targeted deletion of the 923
enhancer in mouse zygotes using CRISPR/Cas9 genome editing resulted in two independent
deletion (923del, 923large) 923 enhancer alleles. Our results using RNA-sequencing and allelespecific expression experiments identify a requirement for the 923 enhancer to regulate proximal
Ivl gene expression in cis and an additional requirement of the 923large allele for Lce6a
expression. Using ATAC-seq, we further determined that deletion of the 923 enhancer also led to
an enrichment of less accessible chromatin in and around the EDC, further suggesting a role for
the 923 enhancer in facilitating open chromatin accessibility in the EDC in keratinocytes.
Together, our in vivo results demonstrate a requirement of the 923 enhancer for activating Ivl
gene expression in cis and promoting chromatin accessibility, thus establishing a 923-Ivl
enhancer-gene regulatory module.

2.2 Introduction
Enhancers are regulatory elements that drive tissue-specific gene expression and are often
critical for cell fate decision and function1. Large, publicly available datasets by the ENCODE
Consortium and others have led to the prediction of many putative enhancers on a genome-wide
scale2 based on sequence conservation, enhancer-associated histone marks and chromatin
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accessibility1. Despite the discovery of enhancers across a wide and diverse range of tissues and
cell types, we know very little about how the enhancers regulate gene expression in vivo.
While techniques exist to predict enhancers based on their genome-wide discovery of
epigenetic characteristics such as histone methylation marks and chromatin accessibility,
subsequent studies to further elucidate their function have relied on ectopic introduction of a
given putative enhancer using in vitro or transgenic models that does not rigorously determine
the function of the endogenous enhancer in vivo3. The advent of CRISPR/Cas9 genome editing
technology has greatly facilitated the functional analyses of enhancers in vivo and in a more
efficient and cost-effective manner4–7 due to the relative ease of targeting these sites via
appropriately designed gRNAs. Recent studies have successfully used CRISPR/Cas9 to
introduce mutations in enhancers ranging from specific nucleotide substitutions to deletions over
10 Kb in a variety of human and mouse cell lines, as well as in mouse models in order to study
the roles of these enhancers 5,8,9. Recently, CRISPR/Cas9 genome editing was utilized in mice to
knock-in orthologous enhancers of Sonic hedgehog, a gene critical for limb development,
individually from 16 vertebrates each approximately 1.3kb in length. These knock-in studies
demonstrated that sequence changes within this single enhancer contributed to the evolutionary
progressive loss of limb development in snakes10. Other studies have demonstrated enhancers
can work in concert, as individual knockouts of 10 enhancers at loci required for limb
development resulted in no phenotypic changes, but the subsequent double enhancer knockouts
(KO) did result in reduced proximal target gene expression11. The lack of phenotypes for single
enhancer deletions but the presence of phenotypes for multiple enhancer deletions supported
findings from ENCODE and FANTOM genome-wide databases reporting as many as 20 distal
regulatory elements interacting with a given transcription start site suggesting many enhancers
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work cooperatively and often in a redundant fashion to regulate target gene expression12,13. From
investigating the effects of enhancers on nearby gene expression, to understanding their roles in
maintaining broader genomic architecture, enhancer knockout/knockin studies via CRISPR-Cas9
genome editing have enabled investigators to more rigorously dissect the functions of noncoding elements within their native loci.
The epidermal differentiation complex (EDC) locus contains approximately 60 genes, of
which a majority are coordinately expressed in the stratified skin epidermis14. The regulation of
this coordinate expression is poorly understood. The discovery of enhancers within the EDC
provides a unique opportunity to investigate enhancer-driven events in EDC activation specific
to the skin. We initially identified several candidate enhancers within the EDC locus based on
sequence conservation across a wide range of mammalian species14. Their enhancer activities
were determined in cell-based reporter assays and were dynamic and physiologically dependent.
The 923 enhancer in the human EDC, named after its kb distance away from the most 5’EDC
gene, S100A10, demonstrated the highest activity in this assay and was DNaseI hypersensitive.
Moreover, 923 exhibited epidermal-specific activity and was sensitive to the spatiotemporal cues
of epidermal development

14,15

. Chromosome conformation capture studies further revealed

remodeling of the mouse EDC surrounding the endogenous 923 enhancer upon epidermal
differentiation and a requirement for the AP-1 transcription factor binding to 923 to induce EDC
expression15. Given these results, we hypothesized that the 923 enhancer is required for EDC
gene activation and the development of the epidermis.
Here we tested this hypothesis by generating mice with a deletion of the 923 enhancer
using the CRISPR/Cas9 genome editing tool. Loss of the enhancer alone, as well as the loss of a
broader region including the 923 enhancer and 40kb of proximal DNA exhibited allele-specific
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decrease in proximal gene expression, namely Ivl and Lce6a. The loss of the 923 enhancer in
both deletion mouse models also led to less accessible chromatin within the EDC. Together, our
data identifies a requirement for the 923 enhancer for the expression of the proximal target gene
Ivl in cis and for facilitating proximal chromatin accessibility in keratinocytes.

2.3 Results
2.3.1 Generation and Phenotypic Characterization of 923 KO mice
To determine the function of the 923 enhancer, we generated knockouts for the
orthologous 923 enhancer in mice using CRISPR/Cas9 genome editing (Figure 2.1a). Two
independent deletions and a floxed allele (923fl) were successfully generated (Figure 2.1b).The
sequences of these alleles were confirmed using Sanger sequencing and revealed a specific
deletion of the 923 enhancer (923del) and a large 40kb deletion that included the 923 enhancer as
well as the proximal genes, Smcp and 2210017I01Rik (923large) (Figure 2.1b, Table S2.1).
923del and 923large knockout mice were viable at birth and did not deviate from the
expected genotype ratios for both heterozygous parental crosses (Χ2 test, α=0.05) (Table S2.2).
No overt skin phenotypes were observed for any newborn or adult 923del and 923large
heterozygous and homozygous mice compared to WT under barrier-housed, homeostatic
conditions (Figure 2.2a,b). Furthermore, cornified envelope morphologies were not affected as
923del/del and 923large/large epidermal extracts exhibited equal ratios of angular and balloon shaped
cornified envelopes compared to their wild type littermates (Figure 2.2c). We next examined
trans-epidermal water loss (TEWL) in the newborn skins of homozygous 923del, 923large and
wild-type mice and found no significant differences, thus indicating that skin barrier
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permeability was not affected by the deletion of the 923 enhancer (Figure 2.2d). We also sought
to determine if the development of the skin barrier was affected in 923del/del and 923large/large
mouse embryos. The patterning and temporal development of skin barrier formation from
embryonic (E)16.0 to E17.5 were similar in the homozygous 923del and 923large -/- embryos
compared to wild-type and heterozygous littermates with no delay in skin barrier formation
(Figure 2.2e). Together, the similarities of skin morphology in newborn and adults,
transepidermal water permeability, cornified envelope formation, and skin barrier development
observed in 923del and 923large heterozygous, homozygous, and wild-type mice indicate that the
923 enhancer is not required for skin barrier formation and skin homeostasis under barrierhoused conditions.

Figure 2.1
a hg19 chr3:

NHEK H3K27Ac
152,879,500

152,877,000

152,882,000

Human 923 Enhancer
Deleted in mouse

b

mm10 chr3:
92,570,000
Ivl 923

92,595,000
2210017l01Rik

Smcp

92,620,000
Lce6a

WT
923del
923large
923fl

Figure 2.1. 923 enhancer schematic a) Schematic of the human 923 enhancer as defined by
H3K27Ac marks in NHEK; hg19; chr1:152,877,349-152,879,610 and the orthologous deleted
enhancer sequence in the mouse (orange). b) Generation of two 923 enhancer deletions and a
floxxed allele by CRISPR/Cas9 genome editing in mice, 923del: Deletion of mouse orthologous
923 enhancer; 923large: ~40kb deletion (mm10: chr3: 90,575,863 – 92,577,075) that includes 923
enhancer, Smcp, and 2210017I01Rik annotations. Intact flanking loxP sites (triangles) were also
successfully introduced via homologous recombination (923fl).
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Figure 2.2. 923del/del and 923large/large mice exhibit no morphological or barrier defects under
homeostatic conditions a) Both 923del/del and 923large/large mice are viable and appear normal.
Homozygous 923del/del and 923large/large mice do not appear different under normal barrier-housed
conditions, at newborn or 8 weeks when compared to aged matched wildtype mice. b) Normal
histology of 923 deletion mouse epidermis. 923 deletion mice appear to have normal epidermal
structure based on H&E staining of epidermal sections from newborn mice, and 8 week old
(adult) mice. c) Normal cornified envelope morphology in 923del/del and 923large/large mice. Similar
quantities of angular and balloon shaped cornified envelopes with smooth edges were isolated
from newborn skin of homozygous deletion, heterozygous and wildtype littermates of 923del and
923large. d) Normal inside-out skin barrier function in 923 deletion mice. Barrier function was
measured by transepidermal water loss (TEWL). e) Normal patterning of skin barrier
development in 923 deletion mice. The extent of skin barrier formation was assessed by an
outside-in X-gal dye penetration assay. Blue stain indicates X-gal reactivity with endogenous βgalactosidase where the X-gal solution has penetrated the epidermis where the skin barrier has
not formed.
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2.3.2 Deletion of the 923 Enhancer in Mice Results in Decreased Expression of the Proximal
Gene Involucrin in the Skin
We next examined the molecular impact of the 923 enhancer deletion on the skin
transcriptome. RNA-seq on 923del and 923large homozygous, heterozygous, and wild-type (WT)
newborn skins was performed (Table S2.3-6). Given the close proximity of the 923 enhancer to
involucrin (Ivl), we included the Ivl knockout mouse16 in our analyses in order to further
determine the direct effect of the loss of the enhancer compared to the hypothesized loss of
involucrin (Table S2.7).

Analysis of the skin transcriptomes identified 6 significantly

differentially expressed genes in 923del/del skins, in contrast to 157 and 222 genes in 923large/large
and Ivl-/- skins, respectively (FDR < 0.05, log2(FC)>|2|) (Figure 2.3a,b). Strikingly, 5 of the 6
differentially expressed genes in 923del/del, (Rps3a3, Hist1h2aI, Gm16011, Rsp3a1, and Ivl) were
also differentially expressed in both 923large/large and Ivl-/- skins, exhibiting the same directional
changes for decreased Ivl and Rps3a1 and increased Rps3a3, Hist1h2aI, and Gm16011
expression (Figure 2.3a,b). Differential Rps3a1, Rps3a3, Hist1h2aI, and Gm16011 expressions
are likely secondary effects associated with decreased Ivl expression given the shared genetic
commonality of the loss of Ivl expression among the two enhancer deletion and Ivl-/- skins.
Together, our results identify a functional role for the 923 enhancer in the regulation of Ivl target
gene expression.
The effect of the enhancer deletion on the expression of its most proximal gene, Ivl,
motivated us to further examine local transcriptional effects with respect to the EDC genomic
region. RNA-seq analyses of the EDC identified one differentially expressed gene (Ivl) in
923del/del,10 in 923large/large, and 10 in Ivl-/- skins (Figure 2.3c,d) (FDR < 0.05, log2(FC)>|2|).
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Smcp, the most proximal gene 3’ of 923 (Figure 2.1b), was below our detection limits for this
assay, consistent with the low numbers of transcripts detected in whole skin scRNA-seq17.

Figure 2.3. Deletion of the 923 enhancer in vivo identifies involucrin as a target gene a)
Venn diagram (FDR<0.05, log2(FC)>|2|) and b) volcano plots of ribosomal-zero RNA-seq
differential gene expression analyses of 923del/del, 923large/large, and Ivl-/- newborn mouse skins
each compared to WT reveal significant decreased expressions for Ivl. n=3/genotype. c) Venn
diagram of differentially expressed EDC genes (FDR <0.05, log2(FC)>|2|) and d) volcano plots
of EDC subset from differential gene expression analyses of 923del/del, 923large/large, and Ivl-/newborn mouse skins each compared to WT (n=3/genotype).
We validated the significance of decreased Ivl expression in all 3 mouse lines via qPCR
(ANOVA; Tukey post-hoc P<0.05) (Figure 2.4a) which resulted in decreased IVL protein as
determined by Western blot (Figure 2.4b). By contrast, 923large/large mouse skins also exhibited
significantly decreased expressions of Lce6a, the most proximal gene 3’ of the deletion, that was
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not observed in the other 2 mouse lines, which suggests the presence of an additional enhancer
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Figure 2.4. Validation of decreased involucrin upon loss of 923 enhancer a) Confirmatory
qPCR validations for decreased Ivl expression for Ivl-/-, 923large/large and 923del/del and additional
decreased Lce6a expression specific to 923large/large newborn mouse skins; n=3/genotype; Error
bars, +SEM. b) Western Blots of mouse epidermis. Ivl expected major band at around 80 kDa.
GAPDH loading control at 37kDa. Major band only observed in WT epidermis lysates with
minor band in 923del/+, 923large/+ and Ivl+/-, and no Ivl detected in 923del/del, 923large/large or Ivl-/-.
2.3.3 923 Enhancer Regulates Ivl Target Gene Expression in Cis
To determine if the 923 enhancer regulates gene expression in cis, we assessed allelespecific gene expression for Ivl and Lce6a in heterozygous 923del[C57BL/6]/[BALB/cBYJ] and
923large[C57BL/6]/[BALB/cBYJ] mouse skins. The BALB/cBYJ (hereafter, BALB) genetic
strain was selected given the presence of single nucleotide polymorphisms (SNPs) in the Ivl and
Lce6a coding sequences that can be distinguished from the C57BL/6 (hereafter, B6) background
(923del, 923large). Targeted sequencing of Ivl and Lce6a cDNAs obtained from 923delB6/BALB
and 923largeB6/BALB heterozygous mouse skins revealed a significantly lower proportion of B6
SNPs from the 923del and 923large alleles for Ivl (13%) compared to 50% of B6 SNPs from the
control WT B6/BALB mice (Figure 2.5) (ANOVA, Tukey post-hoc, P<0.01). However, a
significantly lower proportion of B6 SNPs (3%) for Lce6a was observed only in the
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923largeB6/BALB heterozygous mice compared to 42% observed in the control B6/BALB WT
skins (ANOVA, Tukey post-hoc, P<0.01). This further supports the hypothesis of the loss of a
regulatory enhancer in the 923large allele that regulates allele-specific Lce6a expression. Together,
our genetic findings identify cis regulation by the 923 enhancer for Ivl and additionally for Lce6a
by the 923large allele.

Figure 2.5. 923del regulates Ivl expression in cis and 923large regulates both Ivl and Lce6a
expression in cis. The proportions of allele-specific (SNP) Ivl and Lce6a expression are shown
in pie charts for each mouse strain. Two SNPs per allele were measured and exhibited identical
allele frequencies. C57BL/6 SNP bolded, *P<0.01, ANOVA compared to WT
C57BL/6/BALB/cBYJ mice.

2.3.4 Deletion of 923 Enhancer Affects the Chromatin Landscape in the EDC
We next sought to determine the effect of the 923 enhancer deletion on the EDC
chromatin landscape. Open (or accessible) chromatin in the keratinocytes of newborn 923del/del,
923large/large, and WT littermates epidermis was determined using ATAC-seq (assay for
transposase accessible chromatin using sequencing)18. Four biological replicates were sequenced
for each genotype using Illumina HiSeq2500 (2x50bp). The insert size distribution of all
sequenced libraries showed the expected nucleosome periodicity (Figure S2.1). Reproducibility
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between biological replicates was ensured by including replicates that were below (or very near)
the cut-off of 2 for the rescue and self consistency IDR values according to the ENCODE
ATAC-seq pipeline. (Table S2.8)19. A total of 383,971 accessible chromatin regions were
collectively identified in the keratinocytes among the 3 mouse lines. We next determined
differential genome-wide chromatin accessibility between WT and 923del/del and also 923large/large
keratinocytes. Ten differentially accessible regions (DARs) were identified between 923del/del and
WT mice in contrast to 23 DARs found in the 923large/large comparison (Figure 2.6a, Table S2.910) (FDR<0.05, log2(FC)>|2|). Six of these DARs were shared between the 923del/del and
923large/large comparisons (Fig. 2.6a) including two peaks on chromosome X and four peaks on
chromosome 3, three of which are within or near (<250kb) the EDC (Figure 2.6b, Figure S2.2).
The distribution of sex within each genotype likely accounts for observed changes in chromatin
accessibility on chromosome X (WT=2F, 1M, 923del/del=4M, 923large/large=3M). Of the EDC
adjacent DARs, two DARs, intergenic to Lce3e/Lce3f and corresponding with pseudogene
Gm29950 (intergenic to S100a11/S100a10), were less accessible whereas an intergenic DAR at
Tdpoz4/Tdpoz3 was more accessible in both 923del/del and 923large/large skins compared to WT.
Although none of the DAR proximal genes in the 923del/del comparison were significantly
differentially expressed in 923del/del skin, 3 of the 23 923large/large DARs correlated with significant
changes in nearby expression of 4 genes in 923

large/large

mice, all located within the EDC (Ivl,

2210017l01Rik, Lce3e, Lce3f) (FDR <0.05). (Figure 2.6b, 2.7). Together, we determine that
deletion of the 923 enhancer results in less accessible chromatin in the EDC, with a greater effect
observed with the 923large allele, that together highlight a functional role for the enhancer to
facilitate proximal chromatin accessibility.
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Figure 2.6. Differential chromatin accessibility is enriched in and around the EDC in
923del/del and 923large/large newborn epidermis. a) Venn diagram (FDR <0.05) of all differentially
accessible regions (DARs) using comparative ATAC-seq in 923del/del and 923large/large newborn
epidermis that were each compared to WT with b) an enrichment of shared DARs in the EDC.
Peaks shown as fold change signal per genotype (WT n=3; 923del/del n=4; 923large/large n=3) with
shared less accessible (red) and more accessible (blue) DARs indicated in the 923 deletion lines
compared to WT.

2.4 Discussion
In summary, we have successfully deleted the orthologous mouse enhancer using
CRISPR/Cas9 editing and identified Ivl as the primary target gene of 923. Our findings thus
establish a 923 enhancer-Ivl regulatory module. We further demonstrate that this enhancer
regulates Ivl in cis. Finally, utilizing ATAC-seq, we demonstrate that the deletion of 923 results
in less accessible chromatin within the EDC.
Since the inception of the “enhancer” concept in 198120, we have come to understand that
enhancers drive gene expression by binding and concentrating necessary transcription factors to
the transcription start site of genes1,12. The field has also generated genome wide predictions of
putative enhancers based on characteristic epigenetic marks for a vast array of tissue types and
single cells. Yet we are challenged to functionally validate enhancers and correctly assign their
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predicted target genes21. Even more challenging is the growing body of recent literature reporting
a lack of phenotypes for enhancer deletions, even for putative developmental enhancers, and
further evidence of enhancer redundancy consistent with the ENCODE findings of 2-3 enhancers
per target gene3,11–13. As Ivl expression was not completely lost in our enhancer knockout mice,
there is likely redundancy in the regulation of Ivl, yet we have firmly established the 923
enhancer as a prominent proximal regulator for Ivl. 5C studies in keratinocytes identified
physical interactions between the Ivl promoter and enhancers that were located in the first
topologically associated domain (TAD) of the EDC, which supports additional putative
regulators for Ivl22. Our discovery for the 923 enhancer regulation of Ivl expression was
premised on extensive previous analyses14,15 and offers a framework to prioritize such ongoing
and future enhancer in vivo deletion studies.
Our CRISPR/Cas9 methodology to target deletion of the 923 enhancer also led to the
serendipitous generation of a larger deletion (923large) that resulted in decreased Lce6a
expression. As Lce6a expression was not altered in the 923del/del or Ivl-/- mice, the data suggests
an additional regulatory element was deleted in the 923large allele that regulates Lce6a expression.
A likely target would be CNE 877, identified by the same methods as 92314, though the CNE did
not exhibit enhancer activity in luciferase assays, or a nearby ATAC-seq accessible region (AR)
(~375bp) located 3’ to CNE 877 as an additional putative enhancer (Figure 2.7). Similar to 823,
877 did not correspond with an ATAC-seq AR in WT mice but did have a notable AR nearby.
The lack of accessible chromatin directly at 923 and 877 likely stems from the dense occupation
of transcription factors at these active and putative enhancers. As a result, transposase insertion
may be biased to the flanking ends as well as downstream resulting in the interpretation of
‘closed’ chromatin at the active enhancer site. This finding raises an important question for
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assessing the true “boundaries” of chromatin accessible regions that are often used as genomewide predictors of enhancers.

Figure 2.7. 923 and 877 proximal accessible regions in mice. ATAC-seq signal track of each
genotype for the Ivl-Lce6a region showing the 923 deletion alleles. Proximal CNE 877 is also
marked Displayed DARs are unique to 923large/large allele.

Another interesting finding is the effect of the loss of the enhancer on DARs that were
enriched within the EDC that minimally suggest a role for the enhancer in governing physical
chromatin accessibility within the EDC.

The shared EDC DARs between 923del/del and

923large/large were also located in different TADs than 923 which further supports inter-TAD
cross-talk as previously described22. However, none of the DARs overlapped with CTCF binding
sites23, an insulator protein that helps establish the three-dimensional structure of chromatin24,
suggesting that the accessibility of these regions may not directly contribute to chromatin
conformation regulation (Figure 2.8). No physical interactions were identified between 923 and
these DARs in previous 5C analysis of the EDC22. A caveat of this 5C analysis is that they did
not directly query interactions with 923 as the nearest probes are located 2.2 kb downstream and
2.8kb upstream of 92322. This suggests 923 interactions may not have been detectable.
Additionally, the resolution of 5C experiments may not detect weak interactions between 923
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and the DARs or indirect effects of the 923 enhancer deletion to chromatin accessibility.
Moreover, our previous 3C analysis only examined interactions between 923 and gene
promoters, and hence was not inclusive of the DARs that were discovered by ATAC-Seq. Even
when looking at the gene promoters of the genes most proximal to the shared EDC DARs
(Lce3e, Lce3f, S100a11, and S100a10), only the S100a10 promoter was queried, and showed no
interaction with 92315. Also of note, one of the shared DARs almost completely overlaps the
pseudogene Gm29950, whose expression has previously only been detected in mouse
multipotent progenitor cells25 and was not detected in our whole skin RNA-seq in 923del/del,
923large/large, Ivl -/- and WT keratinocytes but warrants further higher resolution investigation of
this region. Comparing our EDC DARs to previously published mouse keratinocyte genomic
data sets, neither of the DARs overlap the putative EDC enhancers identified by H3K4me1 and
H3K27ac Chip-seq22 nor our conserved non-coding elements (Figure 2.8)14,22 suggesting these
DARs may not be traditional enhancers. It is worth noting that our 923 enhancer was also not
predicted as an enhancer based on H3K27ac and H3K4me1 marks in mice22 (Figure 2.8) which
highlights the importance of functional in vivo validation of enhancers. Overall, our ATAC-seq
illustrates a role for the 923 enhancer in governing local chromatin accessibility, though further
investigation is needed to determine this specific mechanistic role.
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Figure 2.8. EDC epigenetic marks. DARs in and around the EDC marked for both shared and
923del/del and 923large/large epidermis. TADs and enhancers determined in mouse keratinocytes22.
CTCF binding sites determined in keratinocytes25. Conserved non-coding elements were
determined from sequence conservation across 14 mammals14.
The lack of an overt phenotype under barrier-housed conditions in our enhancer deletion
mice is consistent with that of the targeted deletion of the Ivl gene in mice16. The findings
support a tolerance for decreased and even lack of Ivl in barrier-housed conditions and is
consistent with human population genetic studies for differential IVL expression that we have
discovered in our laboratory (Mathyer, Brettmann et al., 2019 submitted). Our laboratory
identified a recent selective sweep for an IVL haplotype in Europe that is associated with
increased IVL expression and increases in Northern latitudes in contrast to a relative decreased
IVL in the Yoruba, Nigeria and the Han Chinese/Japanese populations. The significance of this
finding is not entirely clear yet the data suggest a possible link between cutaneous vitamin D
production and IVL expression as a mechanism of environmental adaptation for the skin barrier.
Vitamin D is known to stimulate the differentiation of keratinocytes and promote the expression
of CE genes, including IVL. As our 923del/del and 923large/large mice express reduced Ivl, they could
be used test the interplay between Ivl expression levels and vitamin D production.
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In summary, our results highlight the significance of the enhancer 923 to regulate
proximal Ivl gene expression in cis and affect chromatin accessibility in the EDC. By firmly
establishing the 923-Ivl regulatory module, we have created a framework in which we can
examine IVL selection in human populations. This framework can also be used to analyze a role
for variation within this enhancer for disease states.

2.5 Materials and Methods
2.5.1 Mice Genotyping
Tails were clipped from 7-10 day old mice and dissolved in tail lysis buffer (0.1M TrisHCl pH 8.0, 5mM EDTA pH8.0, 0.2% SDS, 200mM NaCl). Genomic DNA was isolated using
isopropanol and washed with 80% EtOH. 100ng of purified gDNA was genotyped using NEB
Taq Polymerase with Thermopol Buffer (New England BioLabs, Ipswich, MA) according to
manufacturer’s recommendations using the primers listed in Table S2.11.

2.5.2 Histology
Dorsal skin was excised from 8-week old mice and preserved in 4% paraformaldehyde
(Electron Microscopy Sciences, Hatfield, PA) prior to paraffin sectioning. Sections were stained
with hematoxylin and eosin by the Washington University Developmental Biology Histology
Core. Slides were imaged on a Nikon Eclipse 80i brightfield microscope (Nikon, Tokyo, Japan).
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2.5.3 Dye Penetration Barrier Assays
Barrier assays were performed as previously described26 with X-gal solution incubations
for at least 4 hours at 37°C. Images were captured on a CanoScan 5600F scanner (Canon,
Melville, NY).

2.5.4 Cornified Envelope Preparations
Epidermis (cut into 1cm2 pieces) was incubated at 95°C in a solution of 2% SDS to obtain
cornified envelopes in a single-cell suspension as previously described. The suspension was
placed on a slide and inspected using phase contrast light microscopy.

2.5.5 Trans-epidermal water loss assay
TEWL was measured on the abdominal skin surface of newborn mice using the nail
attachment of a VapoMeter (Delfin Technologies, Kuopio, Finland, courtesy of Jeff Miner).

2.5.6 Generation of 923 enhancer knockout alleles in mice by CRISPR/Cas9 genome editing
Deletion of the 923 enhancer was targeted using 2 small guide RNAs to facilitate Cas9mediated double stranded breaks on either side of the orthologous mouse 923 enhancer sequence.
LoxP insertions at these flanking sgRNA targeted sites were generated using two single stranded
oligodeoxynucleotides ssODNs (containing loxPsites with specific 80bp homology arms on
either side of loxP and restriction enzyme sites (SphI for 5’ end, HindIII at 3’ end) which were
simultaneously introduced via by site-directed homologous recombination (Integrated DNA
Technologies, Coralville, IA). Sequences of sgRNAs and ssODNs are listed in Supplementary
Material (Methods Table S1). Three rounds of injection in 779 zygotes were performed having
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confirmed target specificity using in vitro pilot studies prior to zygote injection. Founders were
initially screened for large deletions via PCR using flanking primers designed outside the
homology arms and 5’ and 3’ loxP-specific primers that were resolved on 1% agarose gel
electrophoresis. Of the 779 C57BL6/6XCBA hybrid zygotes injected, 80 F0 newborns were
recovered, of which 75 survived to weaning age. Seven out of 80 mice whose 923 allele size
deviated from the wild-type allele were identified via PCR (8.75% targeting efficiency) with
further analysis by Sanger sequencing. Two 923 enhancer knockout alleles were confirmed.
923del allele contains a ~1250bp deletion of the 923 enhancer and the 5’ loxP site. The 923large
allele includes the 923 deletion flanked by both 5’ and 3’ loxP sites and a 40kb deletion between
proximal gene Lce6aand 923, including the genes Smcp and 2210017I01Rik. Genotyping primers
are listed in Supplementary Material (Methods Table S2). All mice were housed in pathogenfree, barrier facilities at Washington University School of Medicine (St. Louis, MO). All animal
procedures were approved by the Division of Comparative Medicine Animal Studies Committee
at Washington University. All animal work was conducted in accordance with the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. Morning observation of
a vaginal plug was designated as embryonic day (E) 0.5. Both 923del and 923large mouse lines
were backcrossed at least 7 times to the C57BL/6 background to generate isogenic strains and to
exclude potential off-target effects arising from CRISPR/Cas9 editing.

2.5.7 RNA-seq
Total RNA from whole skin was isolated by TriZol extraction (Life Technologies,
Frederick, MD). Ribo-zero (ribosome-depleted) RNA sequencing libraries were prepped
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according to the manufacturer’s library kit protocol, indexed, pooled, and sequenced on Illumina
HiSeq 3000 (1 X 50bp) by the Washington University Genome Technology Access Center.
Basecalls and demultiplexing were performed with Illumina’s bcl2fastq software and a
custom python demultiplexing program with a maximum of one mismatch in the indexing read.
RNA-seq reads were then aligned to the Ensembl release 96 top-level assembly with STAR
version 2.0.4b. Gene counts were derived from the number of uniquely aligned unambiguous
reads by Subread:featureCount version 1.4.5. Sequencing performance was assessed for the total
number of aligned reads, total number of uniquely aligned reads, and features detected. The
ribosomal fraction, known junction saturation, and read distribution over known gene models
were quantified with RSeQC version 2.3. All gene counts were then imported into the
R/Bioconductor package EdgeR and TMM normalization size factors were calculated to adjust
for samples for differences in library size. Ribosomal genes and genes not expressed in the
smallest group size minus one samples greater than one count-per-million were excluded from
further analysis. The TMM size factors and the matrix of counts were then imported into the
R/Bioconductor package Limma. Performance of the samples was assessed with Spearman
correlations, and a Multi-Dimensional Scaling plot, and hierarchical clustering. Weighted
likelihoods based on the observed mean-variance relationship of every gene and sample were
then calculated for all samples with the voomWithQualityWeights. The performance of all genes
was assessed with plots of the residual standard deviation of every gene to their average logcount with a robustly fitted trend line of the residuals. Differential expression analysis was then
performed to analyze for differences between conditions and the results were filtered for only
those genes with Benjamini-Hochberg false-discovery rate adjusted p-values less than or equal to
0.05, and a log2(fold change) > |2|.
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The R/Bioconductor package heatmap3 and Pathview was used to display heatmaps or
annotated KEGG graphs across groups of samples for each GO term or KEGG pathway
(respectively) with a Benjamini-Hochberg false-discovery rate adjusted p-value less than or
equal to 0.05.

2.5.8 Real-time qPCR
Real-time qPCR on cDNA (generated using SuperScript II reverse transcriptase (Thermo
Fisher Scientific)) using TaqMan Gene Expression Assay was performed in triplicate (Applied
Biosystems, Life Technologies, Carlsbad, CA) and normalized to β2-microglobulin. Only CT
values with single peaks on melt-curve analyses were included. Primers are listed in the
supplementary material.

2.5.9 Allele-specific gene expression
RNA from newborn whole skins was isolated as described above from C57Bl6 and
BALB/cBYJ wild type mice and from [C57Bl6]/[BALB/cBYJ], [923del/[BALB/cBYJ], and
[923large/[BALB/cBYJ] heterozygous mice. RNA was DnaseI-treated and reverse transcribed into
cDNA using Invitrogen SuperscriptII Reverse Transcriptase (Invitrogen, Carlsbad, CA). 260bp
amplicons targeting the Ivl, 2210017l01Rik, and Lce6a genes were amplified from cDNA using
NEBPhusion High Fidelity PCR 2X master mix (New England BioLabs, Ipswich, MA) (Table
S2.12). PCR products were purified on Qiagen QIAquick PCR columns (Hilden, Germany), Atailed with 1mM dATP and NEB Taq polymerase for 20min at 72°C (New England BioLabs,
Ipswich, MA) followed by an additional column purification on Qiagen MinElute columns.
Next-generation sequencing compatible adapters (Sequence in supplement) were ligated to A58

tailed PCR products in molar excess using the LigaFast DNA ligase kit (Promega, Madison, WI)
at room temperature for 20 minutes. Products were size selected using Agencourt AMPure XP
beads (Beckman Coulter, Brea, CA) at 1.2X product volume to remove excess adapter. Adapter
ligated products were quantitated using Qubit dsDNA High Sensitivity Assay kit (Life
Technologies, Carlsbad, CA). To determine appropriate PCR amplification cycle number to
avoid over amplification, quantitative PCR was preformed using 2X NEB Phusion High Fidelity
PCR master mix, 0.5uM PCR primer1, 0.01uM PCR primer2, 0.5uM unique Index Primer
(sequences in supplement), 100X SYBR Green and 50X ROX Dye and 2ng DNA in 10ul. PCR
cycle number for each template was determined by identifying the cycle where ¼ max
fluorescence was reached. 10ng of each library was amplified using the same reaction, without
SYBR and ROX, scaled up to 50ul. Amplified libraries were size-selected again to remove any
remaining adapter dimer using 1X concentration of AmPure beads. All libraries were pooled at
equal molar ratio and sequenced as a spike-in to a 2x150bp MiSeq sequencing run, averaging
154,000 reads per sample. De-multiplexed reads were mapped using Bowtie2 and visualized
using the IGV viewer. The proportion of nucleotides at each informative SNP in the amplicon
was calculated by IGV. Primers are listed in Supplemental Material (Table S2.12).

2.5.10 ATAC-Seq
ATAC-seq was performed on 75,000 epidermal cells from each mouse as previously
described with variations6. Cells were lysed for 5 mins in 37.5ul ice cold buffer (10mM TrisHCl,
10mM NaCl, 2mM MgCl, 0.5% IGEPAL CA-630). Cells were then pelleted at 500g (4°C) for
15mins. Lysis buffer was replaced with transposition reaction mix (12.5ul TD (2x reaction buffer
from Nextera Kit, Illumina, San Diego California, USA), 2.5ul TDE1 (Nextera Tn5 Transposase
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from Nextera kit, Illumina), and 10ul H2O) and samples were incubated for 1 hr at 37°C.
Samples were purified using Qiagen MinElute PCR Purification Kit (Qiagen, Valencia, CA) and
PCR-amplified. Adapter dimer bands were removed using AMPure XP bead treatment as
previously described (Beckman Coulter, Brea, CA). All Samples exhibited expected nucleosome
perodicioty as assayed by High Sensitivity ScreenTape (Agilent Technologies, Santa Clara, CA).
Samples were sequenced via Illumina HiSeq2500 (2 X 50bp). An average of 93.4% of the reads
were mapped with 14.3-39.8 million qualified reads per sample with only an average of 6.8%
mitochondrial reads (Table S2.8). Prior to sequencing, all samples exhibited the expected
periodicity of insert length and were enriched for reads at transcription start sites (Figure S2.1).
ATAC-seq data was processed using the ENCODE ATAC-seq processing pipeline using Caper
with Conda (https://github.com/ENCODE-DCC/atac-seq-pipeline v1.4.2). Reads were mapped
using Bowtie2, and filtered to remove unmapped reads, duplicates, and reads mapping to chrM.
Peaks were called on each replicate using MACS27. Biological replicates were included if both
the rescue and self consistency IDR values per genotype were below (or very near) 2 (Table
S2.8). Differential accessibility was assessed using EdgeR{Robinson, 2010 #8} within the
DiffBind R package (http://bioconductor.org/packages/DiffBind/)(FDR <0.5, log2(FC) >|2|).

2.5.11 Western Blots
Peeled epidermis was flash frozen in liquid nitrogen and stored at -80°C. Tissue was
pulverized added to RIPA buffer and passed through a 23 gauge needle. Samples were spun
down at 4°C full speed for 20 mins and supernatant was stored at -80°C. 30ug of each sample
was run on a NuPage 4-12% Bis-Tris Gel (Invitrogen, Carlsbad, CA) for 50mins (200V) with
MOPS running buffer. Protein was transferred to nitrocellulose membrane using NuPAGE
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Transfer buffer (30V for 1 hr). Gels were stained with mIVL (anti rabbit 1:125) and GAPDH
(anti mouse, 1:1000) primary antibody overnight. Anti-Rabbit and anti-mouse HRP secondary
antibody (1:1000) was applied (Amersham ECL Western blot detection system), and imaged in
the detection solution for 1 hr.
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2.7 Supplemental Material
Table S2.1. Sanger Sequencing of alleles
ssODN sequences: SphI restriction site, LoxP site, HindIII restriction site, Homology arms
923 WT

TCTTTAGTGCTCAGTTAACAGCTTATTTTATGGAGTTCATCATTAACACTTTT
TTATGAGATCATACAAAATAATATAGTAAAATAATGGAAAGATAAAACTCA
TTTCTAATTAGTCTTGAGAAGTTTTTCAGTTCCCCATAGTTGTCCTGAGG
AGCATATAATCTTTGTCTTAAGCAGATTTGTTTACAATAATTCCCTATGT
TCCTGGGATGTATTCTTTAAAGAGATAGAGGACTGACATGACCCTCTGTC
CTCTAAAACAAGTTTGCCAGGATTTCTCCATTCCCAGAGCCATGAGGCA
TCCTGAACACTACTCTGAACTATATTTCTTTCTTCCTTTCTTTCTTCCTTCCTT
CCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTTCTTCCT
TCCTTCTTTTCTTTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTT
TTCTCTTTTTCTTTCCTTTTTTTGCTTTTATTTATTTTTTTTCTTTTTCTATTAG
ATATTTTCTTCATTTACATTTCAAATGTTATCCCCAAGCCCCCTATACCCTCC
CCCAGTCCTGATCCCCAACCCACCCACACCCACTTCCTGGCCCTGGCACTAC
TTTCTATACCAAAGAAAGCATTCCCCACCCCACCAGAAGAAGTAAGCAAGC
ATTCTCACATGAGCACTTATGCTCCACTTCTGACTTCACATGGGAAGAATCT
GACTCTCCTCAACCTGTGACAGTGCCAGGGCAGCAGACTGGTCAAAAAGTC
ACACTGGTCTTATGGGTTCCCAGAGGCTCAGTATCTGCTCAATCTGTTTCCC
ACCAGCTGATTCAGAGTATGATAAGAATTCAGAAATGATACTGTGTGTGCG
TGAGTGTTTGAGCACTGGGAAAAGCTAAGGTGTGGGAATGAGGGCATAGGA
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923del

923large

TAGAGCCCAGAAACCTGTGTGTAGTTGAAGGAGGGGTTGAAGAAGCTCCAG
ACTTCTAATGCTCAAAGGTCACATATTTTGCCCTAGGATTATCCCACTTAGC
GACTGGGAATGCATGTCAATTTGGCATTTTTTTTTCAGTGTGCTGTGTGACT
GACTTTATAAGTCTCAGATCCTTGTGATGAATCCAAGAAACTATGCAATGCA
AATTATACAAATTCTCCAGTGTAATGAAGGTAACCTTTCCCATAACCCATGA
AGAGGCCTTGACCCAGCTCGGCCTCAGTGTTTAGGAGGATAAGAGAAGGTG
AAGGGATGAATATGACCAGAATGTGTGAAATTGGCAGAGAATGAATTATTT
CTGAAAACTTGCCTTTGAAGAGTTTAGAGTGCTGCAGCTTCTTCAGAGAACA
TCATCTCTGTTGTTAGAGTCCATCTCCTACACCGATAGAGACTGATTCT
GAAAAAAAAGGAAGCTCCCACTGTCCAAGTTCTACAGTAAGCTAGCGCT
AGACTGGAAACCAGACACCCTGGCTGCTGCTCTGAAGGCAACTCTTCCC
TATCAGGCTCCTTAATAGGATTTGATCAGTGTGACAGGTTTCACTACATG
ACTACAGAGACATCCTCTAAGTCCAATAAGTTCCTGTGAGAATTTGGTGAG
GCA
TCTTTAGTGCTCAGTTAACAGCTTATTTTATGGAGTTCATCATTAACACTTTT
TTATGAGATCATACAAAATAATATAGTAAAATAATGGAAAGATAAAACTCA
TTTCTAATTAGTCTTGAGAAGTTTTTCAGTTCCCCATAGTTGTCCTGAGG
AGCATATAATCTTTGTCTTAAGCAGATTTGTTTACAATAATTCCCACTGT
CCACTAAAGCTTATAACTTCGTATAGCATACATTATACGAAGTTATTGGAA
ACCAGACACCCTGGCTGCTGCTCTGAAGGCAACTCTTCCCTATCAGGCT
CCTTAATAGGATTTGATCAGTGTGACAGGTTTCACTACATGACTACAGAG
ACATCCTCTAAGTCCAATAAGTTCCTGTGAGAATTTGGTGAGGCAA

TCCTCTGAATGCCCTAACTATCAGATTGTNTTCAGCTTTAATTAACTA
ATAAATTTTAGTTATTCTATCTATATTTATTTCATATTATTTATCTGTCT
TCCACTGAAAAACAAGTTATATTTTGAGAGAAATATTCTGGGTGTGCTTTCC
ATTGTCTCAAGGACCTATCAAAGTCACTCCATACACTAAAACACTATCAGTA
TTAATTAAAAGAATAAATGACAGCAAATCTCATACCTACAGACAACAACTT
CCTAATATTTTAATGTCAAACAATCTTCATGTGTTTGAAAATGTGTGTGCTA
GGAAAATAAAGCTGAATTGTGGCTTATTTTTGTCTTTAGTGCTCAGTTAACA
GCTTATTTTATGGAGTTCATCATTAACACTTTTTTATGAGATCATACAAAAT
AATATAGTAAAATAATGGAAAGATAAAACTCATTTCTAATTAGTCTTGAGA
AGTTTTTCAATTTCCCATAGTTGTCCTGAGGAGCATATAATCTTTGTCTT
AAGCAGATTTGTTTACAATAATTCCCTATAACTTCGTATAGCATACATTAT
ACGAAGTTATGCATGCTTTAAAGAGATAGAGGACTGATCATGGACTTGGT
AAATAGCCATATAAAATAGGAGCAGGTGGAAAAAAACATTTTCATTTCTGA
TTCTGAAAAAAAAGGAAGCTCCCACTGTCCAAGTTCTAAAGCTTATAACT
TCGTATAGCATACATTATACGAAGTTATTGGAAACCAGACACCCTGGCTG
CTGCTCTGAAGGCAACTCTTCCCTATCAGGCTCCTCAATAGGTGTTCTAC
ATGAATGTATTGCTATGAAGCTACAGAGAACTGAAATACAAATTCCCAGAA
ATCTGTCCCTGAGAGGAGAAGAACCCACTTGAGGGTCCTCTGCACTTCTGAT
CAGGGTCTCAAGAACTCACAGAAATCACAGTTATGCACCATGATCAATTTT
ATTGTTGTTGAACTGAAAGGTAGGCTAAAGAAAGAAACAAGAAATGTTTTT

64

CTAGCCAAGAGAGGTGGAGGG

Table S2.2. Offspring genotype distribution from heterozygous 923del as well as 923large
parental crosses. Calculated for 10-12 litters so total offspring count >75. Chi-squared test
calculations included
923del/+ X 923del/+ parental intercrosses
Genotype Observed
Expected
+/+
22
18.75
+/40
37.5
-/13
18.75
Chi-squared test =0.2875
923large/+ X 923large/+ parental intercrosses
Genotype Observed
Expected
+/+
21
19.25
+/38
38.5
-/18
19.25
Chi-squared test =0.8839
Table S2.3. Ranked list of differentially expressed genes between 923del/del and WT mice
whole skin from RNA. List ranked by log2FC. FDR (adj.P.val) <0.05 and logFC <|2| cutoffs
used.
Feature ID
Gene name gene biotype
logFC adj.P.Val
ENSMUSG00000049128 Ivl
protein coding
-5.119 1.98E-06
ENSMUSG00000028081 Rps3a1
protein coding
-4.879 9.60E-14
ENSMUSG00000081355 Gm15264
unprocessed pseudogene
2.482 3.18E-03
ENSMUSG00000081303 Gm16011
processed pseudogene
4.155 3.46E-02
ENSMUSG00000091383 Hist1h2al
processed pseudogene
7.650 8.65E-10
ENSMUSG00000059751 Rps3a3
processed pseudogene
8.451 5.17E-11

Tables S2.4-S2.7 are located in Appendix C
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Figure S2.1. Insert size distribution of ATAC-seq libraries. X-axis is bp, Y-axis is counts.
WT1

WT2

WT3

WT4

923 del/del 1

923 del/del 2

923 del/del 3

923 del/del 4

923 large/large 1

923 large/large 2

923 large/large 3

923 large/large 4
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Table S2.8. ATAC-Seq library statistics
Library complexity
Post
monoTotal Reads
filtering Alignment
nucleosome
TSS
pairs
read pairs
Rate
peak?
Sample Sex
NFR PBC1 PBC2 NFR?
FRiP enrichment
WT_1
M
44,104,640 39,024,826
79.13 0.829 0.835 6.167
✔
✔
0.036
8.214
WT_3
F
29,518,179 32,720,098
95.79 0.856 0.864 7.539
✔
✔
0.052
9.760
WT_4
F
33,796,509 36,502,990
95.37 0.831 0.831 6.434
✔
✔
0.059
11.093
Del_1
Del_2
Del_3
Del_4

M
M
M
M

58,966,233
43,934,578
26,577,482
26,880,711

28,521,337
21,294,165
14,366,531
14,383,001

92.66
96.73
96.92
97

0.760
0.779
0.842
0.820

Large_1 M
Large_2 M
Large_4 M

74,101,870
60,641,676
47,393,679

39,840,266
39,482,578
39,766,656

99.46 0.837
99.43 0.962
82 0.799

4.254
4.774
7.341
6.303

✔
✔
✔
✔

✔
✔
✔
✔

0.088
0.026
0.106
0.092

14.844
6.913
14.729
13.897

0.841 6.105
0.967 31.580
0.809 5.320

✔
✔
✔

✔
✔
✔

0.033
0.042
0.027

7.750
9.260
7.650

0.765
0.786
0.859
0.837

Reproducibility
naïve
overlap IDR
peaks peaks

IDR Values
Per Genotype Rescue self consistency
WT
1.151
1.3738 169158 78032
923del/del
1.308
1.5896 126285 51601
923 large/large
1.27
2.0893 190190 98605

Table S2.9. Ranked list of differentially accessible regions between 923del/del and WT mice
epidermis from ATAC-seq List ranked by FC. FDR<0.05 and FC <|2| cutoffs used.
Chr
chrX
chrX
chr3
chr3
chr3
chrX
chrX
chr3
chr3
chr3

Start
End
169993996 169994243
169996914 169998486
93176562 93176984
93814593 93815096
79242295 79242558
50591524 50591728
50611755 50611998
78966708 78967396
92978570 92978806
93530552 93530842

Fold FDR
-4.64
2.21E-02
-3.70
2.66E-02
-2.76
4.62E-02
-2.56
8.59E-03
2.89
4.62E-02
3.78
3.78E-02
4.19
3.78E-02
4.34
3.81E-07
4.39
1.04E-03
4.82
3.81E-07
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Table S2.10. Ranked list of differentially accessible regions between 923large/large and WT
mice epidermis from ATAC-seq List ranked by FC. FDR<0.05 and FC <|2| cutoffs used.
Chr Start
End
Fold
FDR
chrX 169993996 169994243
-5.41
9.91E-05
chrX 169996914 169998486
-3.83
4.87E-04
chr8 119234019 119234204
-3.66
2.97E-02
chr7 118642175 118642353
-3.63
4.64E-02
chr12 118918105 118918297
-3.59
4.41E-02
chr8
86904158 86904360
-3.47
2.43E-02
chr15 88995738 88995926
-3.45
1.59E-02
chr14 37306986 37307136
-3.43
4.31E-02
chr14
7972236
7972440
-3.41
7.92E-03
chr5
38901570 38901772
-3.23
3.23E-02
chr3
93780248 93780977
-2.73
7.28E-03
chr3
93814593 93815096
-2.53
7.28E-03
chr13 21172295 21172487
2.99
4.31E-02
chr3
92978570 92978806
3.64
4.31E-02
chr3
92586198 92586460
3.64
4.71E-02
chrX
52243896 52244124
3.72
1.04E-02
chr3
78966708 78967396
3.99
1.19E-04
chr5 123127103 123127309
4.00
1.86E-02
chr3
92579546 92579913
4.54
4.87E-04
chr3
92583166 92583453
4.61
9.91E-05
chr3
93530552 93530842
4.84
8.89E-06
chr3
92609764 92610128
5.50
5.05E-07
chr1
24613142 24615948
5.69
1.04E-02
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Figure S2.2. Chromatin accessibility in and around the EDC in 923del/del and 923large/large
newborn epidermis with all replicates displayed. ATAC-seq signal tracks for each biological
replicate shown as fold change signal per genotype (WT, n=3; 923del/del, n=4; 923large/large, n=3)
with shared less accessible (red) and more accessible (blue) DARs indicated in the 923 deletion
lines compared to WT.
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Table S2.11. Mouse genotyping primers Length in basepairs **Primer doesn’t exactly match
sanger sequence (CAATTTCCCATAGTTGTCCTG)
Allele
923 WT
923del
923large

F Primer

R primer

TCTTTAGTGCTCAGTTAACAGCT

AGAGTAGTGTTCAGGATGCCT

CAGTTCCCCATAGTTGTCCTG

TGCCTCACCAAATTCTCACA

CAGTTCCCCATAGTTGTCCTG**

GGAAGAGTTGCCTTCAGAGC

Length
319
253
317

Table S2.12. Allele-specific amplicons a) Amplicon Primers length in base pairs b)Amplicon
sequences with SNPs bolded, primers underlined
a)
Target
Ivl
m2210017l01Rik
Lce6a

F Primer

R Primer

TGGGTCAGTCACTTAAGCAAGA

TTCTGCTGCTGCTTCTCTGT

GGTCCCCAGGTTCCTACTTC

TCAAAGCTTATCCTGGGCCA

TCCAGAACACTGTCAGCCAT

GCACCATGATCAATTTTATTGTTG

Length
260
267
263

b)
Amplicon
Ivl

Sequence
TGGGTCAGTCACTTAAGCAAG
AGAAAGCTTCAAGGAAACAGC
AGCTAGATTACTCACATCTAG
AACAGGAGAAGGAGCTCTCAG
ACCAGCCACTGGATCAAGCAC
TAGTAAAGAAGGGTAAACAAC
TGGAAAGGAAGAAACACGAAT
TGGAGAACCGGACACAGCAGG
AGAAGTAGatagagcaattagtaccaagc
actgactaagccagtccaaccagtgaaaggaga
cgtgctcactacagagaagcagcagcagaa
2210017l01Rik GGTCCCCAGGTTCCTACTTCAT
GTCTCCCTCTCAGTGCCCCACC
AGCTCCTGCTTGCTGTGTTTCT
ACCTGCTATATTTCTGGTTTGG
GAAGCAGCTGCTCTTTAATATC
TCACCGATTTCCTCGGTTCTAC
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Rs number
Rs32990753
Rs32990750

C57B6
A
T

BALB
G
C

RS32991827
Rs32991824

T
A

G
G

Lce6a

CTCCGCCAGCCTCAGAGTTCTG
AGTGTCCTGAGAAAGAGGCTG
CAGAATGTTCGAGCTGTTGCC
ACAACCCTGGAAACTGTAGCT
AAactgcatccctcgagaaaacaaagaacatg
gcccaggataagctttga
TCCAGAACACTGTCAGCCATA Rs31222976
AGGAAATTCATCACCCACAAC Rs31417097
CTCGCTGTCTTAGGGGTAGTAC
CACCTACCACTGCAAAGAAGA
AGAGTGCTAAgaaactgggcacaaacg
agggtaaatagctacaacaacctttccagataaac
tcatgaatttcaccaggaaggccaggccctccac
ctctcttggctagaaaaacatttcttgtttctttcttta
gcctaccctttcagttcaacaacaataaaattgatc
atggtgc
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Tiled array-based sequencing identifies enrichment of
loss-of-function variants in the highly homologous
filaggrin gene in African American children with
severe atopic dermatitis

By
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3.1 Abstract
Filaggrin (FLG) loss-of-function (LOF) variants are a major risk factor for the common
inflammatory skin disease, atopic dermatitis (AD) and are often population-specific. African
American (AA) children are disproportionately affected with AD, often later developing asthma
and/or allergic rhinitis and comprise an atopy health disparity group for which the role of FLG
LOF is not well known. Discovery of FLG LOF using exome sequencing is challenging given
the known difficulties for accurate short-read alignment to FLG’s high homology repeat
variation. Here, we employed an array-based sequencing approach to tile across each FLG repeat
and discover FLG LOF in a well-characterized cohort of AA children with moderate-toSevere AD. Five FLG LOF were identified in 23% of our cohort. Two novel FLG LOF
singletons, c.488delG and p.S3101*, were discovered as well as p.R501*, p.R826* and p.S3316*
previously reported for AD. p.S3316* (rs149484917) is likely an African ancestral FLG LOF,
reported in African individuals in ExAC (Exome Aggregation Consortium), Exome Variant
Server (ESP), and 4 African 1000G population databases (ESN, MSL, ASW, and ACB). The
proportion of FLG LOF (11.5%) among the total FLG alleles in our cohort was significantly
higher in comparisons with FLG LOF reported for African individuals in ExAC (2.5%; P = 4.3 ×
10−4) and ESP (1.7%; P = 3.5 × 10−5) suggesting a disease-enrichment effect for FLG LOF.
Our results demonstrate the utility of array-based sequencing in discovering FLG LOF, including
novel and population-specific, which are of higher prevalence in our AA severe AD group than
previously reported.
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3.2 Introduction
Atopic dermatitis (AD) is a common and chronic inflammatory skin disease with dry skin
and pruritus1. AD greatly impacts 15%-20% of the pediatric population and 1%-3% of adults
worldwide2. As the incidence of AD worldwide has almost tripled in the past few decades3, the
prevalence also continues to increase in young children and in low-income countries2. In the
United States alone, up to 16% of African American children are disproportionately affected
with AD in comparison with 9.8% reported for Caucasian American children and for which the
risk factors are not clear4. Loss-of-function (LOF) variants in the skin barrier gene filaggrin
(FLG), initially discovered as causative in ichthyosis vulgaris (dry, scaly skin) in Europeans5, are
a major risk factor for AD and for other associative atopic diseases involved in the atopic march
including asthma, allergic rhinitis and food allergies1. FLG is primarily expressed in
differentiated epidermal keratinocytes with FLG LOF variants resulting in filaggrin
haploinsufficiency associated with skin barrier defects. Copy number variations (CNV) in the
number of intragenic filaggrin monomer repeats comprise 3 different FLG alleles (10-, 11-, or
12-repeats)6. The FLG 10-repeat allele harbors 10 repeats, whereas the 11-repeat allele contains
either a duplication of the 8th repeat or the 10th repeat and the 12-repeat allele possess both the
8th and 10th duplicated repeats. FLG CNV has also been linked to disease risk with the addition
of each FLG repeat reducing the odds of developing AD by 0.88 per repeat1,7,8. To date, 110
population-specific FLG LOF variants have been reported in AD (Table S3.1). Specifically,
multiple and rare FLG LOF have been observed in Asian populations in contrast to more
common FLG LOF observed in European populations9. Together, the data suggest recent and
parallel emergences of these variants in each population that are also not well understood.
74

The determination of the prevalence of pathogenic FLG LOF variants in African
Americans (AA) with AD has been a decade-long, active area of investigation. A previous study
in search of four common European FLG LOF (p.R501*, c.2282del4, p.R2447*, and p.S3247*)
found 5.8% of AA AD with FLG LOF10. A higher prevalence of the same European FLG LOF
(22%) was identified among 11 AA children with both AD and ichthyosis vulgaris despite only
11% of FLG open reading frame being Sanger sequenced11. Together, these studies identified
lower percentages of known pathogenic FLG LOF in AA children in contrast to the ~50%
frequency reported in moderate-severe AD European cohorts1 but were limited in detecting
additional FLG LOF.
Discovery of FLG LOF using exome and whole-genome sequencing poses its challenges
for the following reasons. FLG is one of the known high homology genes to determine variants
owing to the difficulties in the accurate alignments of short-read sequencing data for FLG12.
Furthermore, careful consideration of the appropriate reference allele for FLG for either 10-, 11-,
or 12-repeats is needed to properly determine variants, namely in the duplicated 8th and 10th
repeats found in either of the 11-repeat and in both for the 12-repeat alleles. The conventional
human reference allele for FLG, ENSG00000143631, to which most LOF mutations are mapped,
is the 10-repeat allele. A recent exome sequencing study in African American children with AD
with high read depth (185×) reported a 6.3% proportion of FLG LOF alleles, including 6 newly
reported and 3 previously described for AD to suggest multiple and perhaps rare FLG LOF in
this ethnic group (Table S3.1)13. In support of this finding, the allele frequency for the total
number of FLG LOF is 2.5% for African individuals in the Exome Aggregation Consortium
(ExAC) (whereby each LOF is <1%) and 1.7% in the Exome Variant Server (ESP) for African
Americans with no documented knowledges of AD in these data sets (Tables S3.2 and S3.3)14.
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Moreover, the prevalence of FLG LOF is higher in African individuals compared to those of
European and South and Central American but lower than South and East Asian populations
(1000 Genomes Phase 3) (figure 2 of Eaaswarkhanth et al15). Together, the population genetics
data further support the global existence of FLG LOF variants in individuals of African ancestry
that warrants further investigation with respect to AD disease.
We previously identified that fewer filaggrin monomer repeats correlate with more
severe AD in our AA pediatric patients whose AD was well-characterized according to the
widely accepted AD criteria by the United Kingdom Working Party [UKWP]7. We sought to
discover FLG LOF variants in our AA AD patients (n = 39) using our array-based targeted
sequencing approach for FLG with alignment to the human 12-repeat allele16 in contrast to the
human reference 10-repeat allele [ExAC and EPS]. Our method enables concurrent discoveries
for both intragenic FLG CNV and FLG variant detection that were validated by Sanger
sequencing and long-range PCR, respectively, as previously described16.

3.3 Results
FLG LOF variants were identified in 23% of our AA AD patients (9 of 39 recruited;
eligible age range 3 months to 18 years). A total of five FLG LOF were identified in 9
heterozygous AA AD patients (c.488delG, p.R501*, p.R826*, p.S3101*, and p.S3316*; Table
3.1). c.488delG and p.S3101* are novel FLG LOF as they have not been reported in dbSNP,
ExAC, and ESP variant databases. p.S3316* (also known as rs149484917) was found in 3
unrelated patients and had been previously reported in a separate AA AD group13. The higher
proportion of FLG LOF in our AA AD group (11.5%) compared to the 2.5% African ExAC
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frequency indicated an enrichment for FLG LOF for AA AD and was statistically significant (P
= 4.3E-04, Fisher’s Exact Test). Similarly, the significance was further demonstrated in
comparison with the 1.7% FLG LOF in ESP for African Americans (P = 3.5E-05, Fisher’s Exact
Test).

Table 3.1. FLG LOF variants and FLG repeat alleles in African American pediatric patients with
atopic dermatitis (n = 39) reported with respect to human reference FLG 10-repeat allele.
Location of FLG
FLG LO F hg 19 coordinate/ variant to
repeat
Variant RSID (if known) FLG repeat allele 1
c.488delGa chr1:152,286,874 0
10
p.R501* rs61816761
1
11
p.R501* rs61816761
1
10
p.R826* rs115746363
2
10
p.R826* rs115746363
2
10
p.S3101* a chr1:152,278,060 9
10
p.S3316* rs149484917
9
10
p.S3316* rs149484917
9
10
p.S3316* rs149484917
9
10
Reports of asthma, allergic rhinitis and food allergies are in
a
Novel FLG LOF
b
Peanut
c
Shellfish
d
Seafood
e
Eggs

Ichthyosis
FLG
Total #
Vulgaris
FLG
repeat
Allergic Food
(IV)/
allele 2 repeats Age SCO RAD Asthma rhinitis Allergies Xerosis (X)
10
20
7
73
Yes
Yes
Yesb,c,d
IV
11
22
11 83
Yes
No
None
X
11
21
13 38
Yes
Yes
None
X
10
20
5
51
Yes
No
Yesb
X
10
20
1
65
Yes
No
None
X
10
20
10 41
Yes
Yes
None
X
11
21
4
50
Yes
No
Yese
X
11
21
2
94
No
No
Yesb
X
10
20
0.5 85
No
No
None
X
response to our study questionnaire and obtained during medical exam history.

All patients with FLG LOF (age > 1 year) reported having at least one additional allergic
disease: asthma, allergic rhinitis, or food allergies and either xerosis (n = 8) or ichthyosis
vulgaris (n = 1, c.488delG) and a family history of atopy in at least one-first-degree relative.
Seven of the nine FLG LOF patients (77%) exhibited severe AD (SCORAD > 50). Patients with
FLG LOF exhibited a trend towards a greater percentage of the body affected with the disease
(SCORAD component A mean, 56) compared to non-FLG LOF patients (mean, 40) but this was
not significant (P = 0.13, two-tailed t test, data not shown) and warrants further investigation to
test this emerging hypothesis.
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We sought to further investigate the distribution and frequency of rs149484917 that
results in FLG LOF p.S3316* using ExAC, ESP, and 1000G population data sets given the
concurrent findings for AA AD in our cohort and a previous study13. rs149484917 has been
reported primarily in African individuals with 96% and 100% of the minor allele reported in
Africans in ExAC and ESP, respectively. A closer investigation into the 1000G populations
revealed that rs149484917 was not found in any European, American, East Asian or South Asian
populations. However, of the seven 1000G African (AFR) ancestral populations, rs149484917
was reported as a less common variant in 4 AFR populations; ESN (Esan in Nigeria) (Minor
allele frequency, [MAF], 0.02), MSL (Mende in Sierra Leone) (0.012), ASW (African ancestry
in Southwest US) (0.016), and ACB (African Caribbean in Barbados) (0.010). Taken together,
the population genetics data identify rs149484917 (S3316*) as a population-specific FLG LOF
unique to several populations of African ancestry.
We next sought to determine the genetic background from which our newly discovered
FLG LOF variants arose in the context of the 10-, 11-, or 12-repeat FLG alleles1. The 10-repeat
allele is the major allele in Africans (73%) and is interpreted to be ancestral15. c.488delG was
found in the incomplete, N-terminal repeat (repeat 0)7 and inferred to be on the 10-repeat allele
as the patient was homozygous for the 10-repeat allele (Table 3.1). The other novel FLG LOF
mutation (p.S3101*) was identified on the 9th repeat and also on the 10-repeat allele. Thus, the
existences of c.488delG, p.S3101*, and p.S3316* on the 10-repeat allele suggest that these
variants most likely arose independently and after the separation of the 11-and 12-expanded
repeat, derived alleles.
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3.4 Discussion
In summary, our targeted sequencing strategy to identify FLG LOF variants in a wellcharacterized UKWP-defined AD group of African American children identifies a significant
enrichment of pathogenic FLG LOF variant alleles (11.5% vs 2.5% [Africans; ExAC] and also
1.7% [African American; ESP]). We discovered 2 pathogenic FLG LOF not previously reported
for AD (c.488delG and p.S3101*). The overlap of our p.S3316* findings in our cohort, in an
independent AA AD study13, and in African individuals (ExAC, ESP, and 1000G) supports
p.S3316* as a population-specific FLG LOF variant for African ancestry. Our discovery of five
pathogenic FLG LOF variants (including 2 newly discovered) in African American pediatric
patients with severe AD has brought forth a hypothesis for the wider research community to test,
FLG LOF variants among the African American population are enriched in AD, and thus
justifies more precision medicine efforts for this health disparity group.

3.5 Materials and Methods
3.5.1 Patients
African American children with atopic dermatitis according to the UK Working Party
criteria for AD17 were recruited to the study as previously described7. The study was approved by
the Washington University in St. Louis Institutional Review Board and conforms to the US
Federal Policy for the Protection of Human Subjects. All persons gave informed consent prior to
his or her inclusion in the study. Disease severity was previously assessed using SCORAD18 with
moderate AD (>25) and severe AD (>50).
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3.5.2 FLG array-based sequencing
Targeted sequencing for FLG was performed as previously described16. Briefly, a set of
48 amplicons that overlaps and tiles across the entire FLG coding gene from each patient was
generated using the Fluidigm Access Array 48/48 chip and sequenced using Illumina MiSeq 2 ×
250 bp reads aligned to the FLG 12-repeat allele with at least 100× coverage and confirmed by
Sanger sequencing.
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3.7 Supplemental Material
Table S3.1. Published disease associated FLG LOF variants with ethnic/ geographical origin
included where known (Red = East Asian; Blue = Caucasian; Green = African; Purple = South
Asian)
1

FLG LoF Variant

Ethnic/Geographical
Origin

Publication

Pubmed ID (PMID)

c.424del17

German

Oji et al. 2009

19183181

Chen et al. 2008; Zhang et al. 2011

18239616; 21039602

Mizuno et al. 2015; Wong et al. 2017

24629053; 29056476

Xiong et al. 2012; Wong et al. 2017

22299762; 29056476

Singapore
Chinese
Japanese;
Chinese
Chinese;
Chinese

Chinese;

2

c.441delA

3

c.441_442delAG

4

c.477insA

5

c.478insA

Northern Chinese

Li et al. 2013

22220561

6

c.621del4

German

Oji et al. 2009

19183181

7

c.678delA

Singapore Chinese

Wong et al. 2017

29056476

8

p.G323*

Singapore Chinese

Chen et al. 2011

21428977

9

p.Q368*

Singapore Chinese

Chen et al. 2011

21428977

10

p.S378*

Singapore Chinese

Wong et al. 2017

29056476

11

p.S406*

Singapore Chinese

Chen et al. 2011

21428977

12

p.H440fs

African American

Margolis et al. 2018

29428354

13

c.1249insG

Singapore Chinese

Chen et al. 2008

18239616

14

c.1464delC

Unspecified Asian

Irvine et al. 2011

21991953

15

p.R501*

European;
German;
Singapore
Chinese;
Chinese; Singapore Indian;
African American

Smith et al. 2006; Oji et al. 2009; Marenholz
et al. 2009; Irvine et al. 2011; Chen et al.
2011; Zhang et al. 2011; Margolis et al 2012;
Polcari et al 2014; Quiggle et al 2015; Wong
et al. 2017, Margolis et al. 2018

16444271;
19348926;
21428977;
22951058;
25564772;
29428354

16

p.S507*

Singapore Malay

Wong et al. 2017

29056476

17

c.1640delG

Singapore Chinese

Chen et al. 2011

21428977

18

p.Q570*

African American

Margolis et al. 2014; Margolis et al. 2018

24608987; 29428354

19

c.2282del4

European;
German;
African
American;
Singapore Malay

Smith et al. 2006; Oji et al. 2009; Marenholz
et al. 2009; Margolis et al 2012; Polcari et al
2014; Wong et al. 2017

16444271;
19183181;
19348926;
22951058;
24920311; 29056476

20

p.R826*

Bangladeshi;
Chinese;
African
American;
Singapore Chinese

Sinclair et al. 2009; Zhang et al. 2011; Polcari
et al 2014; Wong et al. 2017; Margolis et al.
2018

19239468;
24920311;
29428354

21

c.2767insT

Bangladeshi

Sinclair et al. 2009

19239468

22

c.2952delC

Singapore Chinese

Chen et al. 2011

21428977

23

c.2974delGA

German

Oji et al. 2009

19183181

24

c.3036delT

Singapore Chinese

Wong et al. 2017

29056476

25

p.S1040*

European

O’Regan et al. 2010

20621340

26

p.Q1070*

Northern Chinese

Li et al. 2013

22220561

Chinese; Northern Chinese

Zhang et al. 2011; Li et al. 2013; Wong et al
2017

21039602;
29056476

27

c.3222del4

Singapore
Singapore

82

19183181;
21991953;
21039602;
24920311;
29056476;

21039602;
29056476;

22220561;

28

c.3321delA

Japanese;
Taiwanese;
Singapore
Chinese;
Chinese; Northern Chinese;
Korean; Singapore Malay

Nomura et al. 2007; Hsu et al. 2009; Chen et
al. 2011; Zhang et al. 2011; Xiong et al. 2012;
Li et al. 2013; On et al. 2017; Wong et al.
2017

17291859;
19416262;
21428977;
21039602;
22299762;
22220561;
PMC5290020; 29056476

29

p.G1138*

European

O’Regan et al. 2010

20621340

30

p.R1140*

Chinese; Singapore Indian

Zhang et al. 2011; Wong et al. 2017

21039602; 29056476

31

c.3673delC

European

Brown et al. 2009

19681860

32

c.3702delG

Irish

Sandilands et al. 2006

16810297

33

p.Q1256*

Chinese

Zhang et al. 2010

20222934

34

p.S1302*

Chinese;
Chinese

Li et al. 2011; Chen et al. 2011

21923666; 21428977

35

c.4004del2

Singapore Chinese

Chen et al. 2011

21428977

36

c.4026delT

Northern Chinese

Li et al. 2013

22220561

37

p.S1405*

Korean

Park et al. 2015

25997159

38

c.424del17

European

Irvine et al. 2011

21991953

39

c.4271delAA

Chinese; Northern Chinese

Zhang et al. 2011; Li et al. 2013

21039602; 22220561

40

c.4275del2

Singapore Chinese

Chen et al. 2011

21428977

41

p.R1474*

European; Chinese

Sandilands et al. 2007; Zhang et al. 2011

17417636; 21039602

42

p.S1515*

Singapore
Chinese;
Northern Chinese

Chen et al. 2011; Li et al. 2013

21428977; 22220561

43

c.4812ins5

Singapore Indian

Wong et al. 2017

29056476

44

c.5024delC

Singapore Indian

Wong et al. 2017

29056476

45

p.S1695*

Japanese

Nomura et al. 2009

19037238

46

p.Q1701*

Japanese

Nomura et al. 2009

19037238

47

c.5187delA

Singapore Indian

Wong et al. 2017

29056476

48

c.5192_5199dup8

Singapore Malay

Wong et al. 2017

29056476

49

p.Q1712*

Northern Chinese

Li et al. 2013

22220561

50

p.Q1745*

Singapore Chinese

Chen et al. 2011

21428977

51

p.Y1767*

Korean

Kim et al. 2011

21747615

52

c.5360delG

European

Sandilands et al. 2007

17417636

53

p.Q1790*

Chinese; Northern Chinese;
Singapore Chinese

Zhang et al. 2011; Li et al. 2013; Wong et al.
2017

21039602;
29056476

54

p.E1795*

Taiwanese

Hsu et al. 2009

19416262

55

p.R1798*

Italian

Cascella et al. 2011

21289640

56

c.5671_5672delinsTA

Korean

Park et al. 2015

25997159

57

c.5757del4

Chinese; Northern Chinese

Zhang et al. 2011; Li et al. 2013

21039602; 22220561

58

p.W1947*

Korean

Park et al. 2015

25997159

59

p.G2025*

Korean

Park et al. 2015

25997159

60

c.6218del2

Chinese

Xiong et al. 2012

22299762

61

p.Q2123*

Singapore Indian

Wong et al. 2017

29056476

62

c.623del2

Ethiopian; South
amaXhosa

Winge et al. 2011; Thawer-Esmail et al. 2014

21692775; 24369804

Singapore

Africa

83

22220561;

63

p.S2080*

European

Irvine et al. 2011

21991953

64

p.Y2092*

European

Irvine et al. 2011

21991953

65

c.6834del5

Japanese;
Chinese;
Northern
Chinese;
Singapore Malay

Nemoto-Hasebe et al. 2009; Zhang et al.
2011; Li et al. 2013; Wong et al. 2017

21039602;
19663875;
22220561; 29056476

66

c.6867delAG

European

Sandilands et al. 2007

17417636

67

c.6950del8

Chinese;
Singapore
Chinese; Singapore Malay;
Singapore Indian

Zhang et al. 2011; Chen et al. 2011; Wong et
al. 2017

21039602;
29056476

68

c.7145del4

Northern Chinese

Li et al. 2013

22220561

69

p.S2344*

Singapore
Singapore Indian

Wong et al. 2017

29056476

70

p.Q2397*

Northern Chinese

Li et al. 2011

21923666

71

p.Q2417*

Chen et al. 2008; Hsu et al. 2009; Li et al.
2011; Zhang et al. 2011

18239616;
19416262;
21923666; 21039602

72

p.E2422*

Sandilands et al. 2007; Chen et al. 2008; Li et
al. 2011; Zhang et al. 2011

18239616;
17417636;
21923666; 21039602

73

c.7267delCA

European

Sandilands et al. 2007

17417636

74

c.7333delC

Singapore Indian

Wong et al. 2017

29056476

75

p.R2447*

German; Irish; African
American;
Singaporean
Chinese; Singapore Indian;
Singapore Malay

Oji et al. 2009 ; Marenholz et al. 2009 ;
Sandilands et al. 2007; Margolis et al 2012;
Wong et al. 2017; Margolis et al 2018

19183181;
19348926;
17417636;
22951058;
29056476; 29428354
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c.7487delC

Javanese; Singapore Indian

Trisnowati et al. 2016; Wong et al. 2017

26340974; 29056476

77

p.S2554*

Japanese

Nomura et al. 2007

17291859

78

p.R2613*

Singapore Indian

Wong et al. 2017

29056476

79

c.7945delA

Singapore
Chinese;
Northern Chinese; Chinese

Chen et al. 2008; Zhang et al. 2011; Li et al.
2013

18239616;
22220561

80

c.8001del4

Northern Chinese

Li et al. 2013

22220561

81

c.8088delG

Singapore Malay

Wong et al. 2017

29056476

82

p.S2706*

Chinese;
Chinese

Zhang et al. 2011; Chen et al. 2011

21039602; 21428977

83

c.8393delA

Singapore Chinese

Chen et al. 2011

21428977

84

p.R2447*

African American

Margolis et al. 2018

29428354

85

p.G2822*

European

Irvine et al. 2011

21991953

86

p.S2889*

Japanese; Korean

Nomura et al. 2008; On et al. 2017

18200065; PMC5290020

87

p.L2933*

European

O’Regan et al. 2010

20621340

88

c.9040_9058dup

Singapore Chinese

Chen et al. 2011

21428977

89

p.E3070*

Korean

Park et al. 2015

25997159

90

p.S3247*

European;
German;
African American

Sandilands et al. 2007; Oji et al. 2009;
Margolis et al 2012; Margolis et al. 2018

17417636;
19183181;
22951058; 29428354

91

p.S3296*

Japanese; Korean

Nomura et al. 2008; On et al. 2017

18200065; PMC5290020

92

p.S3316*

African American

Margolis et al. 2018

29428354

93

p.R3409*

African American

Margolis et al. 2014; Margolis et al. 2018

24608987; 29428354

94

p.R3418*

European

O’Regan et al. 2010

20621340

Malay;

Singapore
Chinese;
Taiwanese;
Northern
Chinese; Chinese
European;
Singapore
Chinese; Northern Chinese;
Chinese

Singapore
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21428977;

21039602;

95

c.10085delC

European

O’Regan et al. 2010

20621340

96

c.10866delA

Singapore Chinese

Wong et al. 2017

29056476

97

p.E3603*

Italian

Cascella et al. 2011

21289640

98

p.R3638*

Italian

Cascella et al. 2011

21289640

99

c.11029delCA

European

Sandilands et al. 2007

17417636

100

c.11033del4

European

Sandilands et al. 2007

17417636

101

p.Q3683*

European

Sandilands et al. 2007

17417636

102

p.Q3684*

European

Irvine et al. 2011

21991953

103

p.S3707*

African American

Margolis et al. 2014

24608987

104

p.R3766*

German

Oji et al. 2009

19183181

105

p.Q3818*

African American

Margolis et al. 2018

29428354

106

p.K4022*

Japanese;
Korean;
Singapore Chinese

Nemoto-Hasebe et al. 2009; On et al. 2017;
Wong et al. 2017

19663875;
PMC5290020;29056476

107

p.E4265*

German

Oji et al. 2009

19183181

108

p.R4306*

Singapore
Chinese

Chen et al. 2008; Zhang et al. 2011

18239616; 21039602

109

p.R4307*

Singapore Chinese

Chen et al. 2008

18239616

110

p.K4671*

Chinese; Northern Chinese

Zhang et al. 2011; Li et al. 2013

21039602; 22220561

Chinese;

Table S3.2. FLG LOF reported in African individuals in ExAC aligned with the human
reference 10-repeat allele (n = 5,203)
FLG LOF
Variant

Ethnic/
Geographical
Origin

Alleles

Minor Allele
Count African

Total
African
Alleles

Frequency of
FLG
LOF
allele

RSID

Associated
with Disease

c.66insA

African

.

C>CT

1

10380

9.63391E-05

-

p.E32*

African

rs114733570

C>A

1

10398

9.61723E-05

-

c.198delC

African

.

TG>T

2

10134

0.000197355

-

c.388del4

African

.

CTTCT>C

3

10390

0.000288739

-

p.S260*

African

.

G>T

1

10404

9.61169E-05

-

c.1297delGA

African

.

GTC>G

1

10406

9.60984E-05

-

p.R501*

African

rs61816761

G>A

46

10406

0.004420527

X

p.S522*

African

rs146559843

G>C

1

10404

9.61169E-05

-

p.Q570*

African

rs192402912

G>A

2

10406

0.000192197

X

p.R572*

African

.

G>A

1

10406

9.60984E-05

-

p.S609*

African

rs145119819

G>T

1

10406

9.60984E-05

-

p.Q650*

African

rs149119521

G>A

4

10404

0.000384468

-

p.R740*

African

.

G>A

3

10406

0.000288295

-

c.2282del4

African

.

CACTG>C

38

10406

0.003651739

X

p.R826X=*

African

rs115746363

G>A

67

10406

0.006438593

X

85

c.2540delC

African

.

TG>T

4

10406

0.000384394

-

p.E1080*

African

.

C>A

1

10406

9.60984E-05

-

c.3673delC

African

.

TG>T

1

10406

9.60984E-05

X

c.3702delG

African

.

AC>A

1

10406

9.60984E-05

X

p.S1280*

African

.

G>T

1

10406

9.60984E-05

-

p.R1474*

African

rs146686141

G>A

4

10406

0.000384394

X

c.4785del4

African

.

CCTGA>C

2

10406

0.000192197

-

p.Q1807*

African

rs140164593

G>A

4

10406

0.000384394

-

c.5945delCA

African

.

CTG>C

1

10406

9.60984E-05

-

p.R2037*

African

.

G>A

2

10406

0.000192197

-

p.S2080*

African

rs147145234

G>T

1

10406

9.60984E-05

X

p.Y2119*

African

.

A>C

1

10406

9.60984E-05

-

c.6453delG

African

.

AC>A

1

10406

9.60984E-05

-

c.6706insA

African

.

C>CT

1

10406

9.60984E-05

-

c.7145del4

African

.

CACTG>C

1

9678

0.000103327

-

p.R2447*

African

rs138726443

G>A

6

10406

0.00057659

-

p.S2508*

African

.

G>T

4

10406

0.000384394

-

p.S3247*

African

rs150597413

G>T

7

10406

0.000672689

X

p.S3316*

African

rs149484917

G>C

64

10406

0.006150298

-

p.R3409*

African

.

G>A

1

10392

9.62279E-05

X

c.10635del4

African

.

CCTGA>C

1

10406

9.60984E-05

-

c.11033del4

African

.

CACTG>C

3

9360

0.000320513

-

p.S3707*

African

.

G>T

1

10366

9.64692E-05

X

p.S3749*

African

.

G>C

1

10406

9.60984E-05

-

p.Q3818*

African

rs148606936

G>A

5

10406

0.000480492

-

p.Q3859*

African

.

G>A

1

10406

9.60984E-05

-

p.E3870*

African

.

C>A

1

10406

9.60984E-05

-

p.Y3872*

African

rs140349291

G>T

1

10406

9.60984E-05

-

c.11851insC

African

.

T>TG

4

10406

0.000384394

-

c.11901delA

African

.

CT>C

1

10406

9.60984E-05

-
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Table S3.3. FLG LOF reported in African individuals in Exome Variant Server aligned with the
human reference 10-repeat allele (n = 2,203) [URL: http://evs.gs.washington.edu/EVS/),
Accession 12/2017]
FLG
LOF
Variants
c.198delC
p.R501*
p.S522*
p.Q534*
p.R572*
p.Q650*
c.2282del4
p.R826*
c.2540delC
c.3673delC
c.4785del4
p.Q1807*
c.5799delG
p.S2080*
p.E2273*
p.S2344*
c.7098del4
p.R2447*
c.7836insTCTG
c.7847delA
c.9417del5
p.S3247*
p.S3316*
p.R3743*
p.Q3818*
p.Y3872*
c.11851insC
c.11901delA

Ethnic/
Geographical
Origin
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American
African
American

RSID

Alleles

Minor Allele
Count
African

.

TG>T

2

4266

0.000468823

-

rs61816761

G>A

27

4406

0.006128007

X

rs146559843

G>C

1

4406

0.000226963

-

rs371670224

G>A

1

4406

0.000226963

-

rs200601767

G>A

1

4406

0.000226963

-

rs149119521

G>A

1

4406

0.000226963

-

.

CACTG>C

34

4234

0.008030231

X

rs115746363

G>A

33

4406

0.007489787

X

.

TG>T

2

4204

0.000475737

-

.

TG>T

1

4262

0.000234632

X

.

CCTGA>C

1

4258

0.000234852

-

rs140164593

G>A

5

4406

0.001134816

-

.

AC>A

1

4266

0.000234412

-

rs147145234

G>T

1

4406

0.000226963

-

rs142969864

C>A

1

4406

0.000226963

-

rs372754256

G>C

1

4378

0.000228415

X

.

CCTGA>C

13

4130

0.0031477

-

rs138726443

G>A

5

4406

0.001134816

X

.

T>TCAGA

2

4132

0.000484027

-

.

AT>A

3

4110

0.000729927

-

.

CTGTGA>C

11

3848

0.002858628

-

rs150597413

G>T

2

4406

0.000453926

X

rs149484917

G>C

25

4406

0.005674081

-

rs142421644

G>A

1

4406

0.000226963

-

rs148606936

G>A

5

4406

0.001134816

-

rs140349291

G>T

1

4406

0.000226963

-

.

T>TG

1

4266

0.000234412

-

.

CT>C

1

4266

0.000234412

-
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Total
African
Alleles

Frequency of
FLG
LOF
allele

Associated
with
Disease

Chapter 4

Conclusions

By
Mary Elizabeth Mathyer
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4.1 Summary
Tissue-specific gene expression is a tightly controlled process that gives rise to the wide
diversity of cells that compose an organism. The advent of high-throughput genomics
methodologies has revolutionized our ability to comprehensively discover and elucidate tissuespecific gene regulation, with respects to shifts in gene expression during development and the
underlying chromatin architecture that is associated with these changes. Elucidation of these
processes for a diverse range of different cell types is an ongoing process. My interest in tissuespecific gene regulation led me to the de Guzman Strong lab where I have addressed the question
of tissue-specific gene regulation by focusing on a specific locus of genes: the epidermal
differentiation complex (EDC) in the epidermis.
The EDC locus encodes 4 gene families including the filaggrin (FLG) and FLG-like
genes, late cornified envelope (LCEs), small proline rich region (SPRRs) genes including loricrin
(LOR) and involucrin (IVL), and the S100 genes. Many EDC gene protein products contribute to
the epidermal barrier structure and function along with the coordinate expression of many EDC
genes that also defines keratinocyte terminal differentiation1–34–9. The EDC locus is
evolutionarily conserved throughout mammalian lineages9,10. Taken together, the evidence of
EDC conservation and coordinate expression during terminal differentiation supports the entity
of the EDC as a regulatory module. Our laboratory sought to elucidate regulation within the EDC
and focused on the significance of conserved non-coding elements (CNE) that were identified
within the EDC assuming evolutionarily conserved regions likely imply biological function11.
923 was identified as one of the 48 CNEs that was further demonstrated to function as an
enhancer and drive epidermal specific gene expression9,12. I sought to further elucidate the
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functional role of the 923 enhancer in mice.
My research also examined loss-of-function (LOF) variation within the EDC gene,
filaggrin (FLG), in the inflammatory skin disease atopic dermatitis (AD). FLG LOF variants are
known risk factors for AD13 with known population specificity14,15. African Americans (AA) in
particular are susceptible to AD16, but have often been reported to not have many FLG LOF
variants17,18.These studies focused on the four common European FLG LOF variants p.R501*,
c.2282del4, p.R2447*, and p.S3247*, which were later determined to be population specific and
hence not likely to be found in AA patients. Thus, I aimed to discover FLG LOF variants in an
AA pediatric cohort for moderate-to-severe AD using tiled amplicon sequencing of FLG to
identify all FLG LOF variants.
In this chapter, I summarize the findings of my graduate research, discuss the broader
significance, and propose future directions. Together, my work furthers our understanding of the
regulation and variation of the EDC as it pertains to the epidermal tissue and African American
population-specific AD.

4.1.1 The Epidermal Enhancer 923 Regulates Involucrin Expression in Cis
In Chapter 2 I report my findings on the role of the epidermal EDC enhancer 923 for
gene activation and chromatin accessibility. I utilized 923 deletion mice 923del and 923large that
were previously generated using CRISPR/Cas9 genome editing. I confirmed appropriate deletion
of the 923 enhancer using Sanger sequencing and found an additional deletion of a 40kb flanking
region that included the proximal genes Smcp and 2210017I01Rik in the subsequently named
923large allele. This likely resulted from off-target effects of the Cas9 protein that was targeted to
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either sides of 923 in order to induce double stranded breaks with homology-mediated repair
using single stranded oligodeoxynucleotides to introduce flanking loxP sites. I also confirmed
via Sanger sequencing that the 923del allele contained a 1250 bp specific deletion of 923. I
utilized these two independent alleles of 923 deleted from its endogenous location, 923del and
923large, to elucidate the role of the 923 enhancer in vivo.
Upon validating previous studies on these mouse models from previous work in the
laboratory, I identified no defects in the morphology or barrier acquisition in neither the 923del/del
nor the 923large/large deletion mice. However, given that 923 is an enhancer, I performed RNAsequencing to determine the impact of the loss of the 923 enhancer on gene expression in the
skin. Whole skin RNA-seq revealed 5 differentially expressed genes (DEG) that were shared
between the 923del/del and 923large/large mice. These 5 genes were also DEGs shared with the Ivl-/mice. The data thus identified Ivl as the primary target gene of 923 as the other 4 genes, (Rps3a3,
Hist1h2aI, Gm16011, and Rsp3a1), are secondary effects due to the loss of Ivl rather than the
loss of 923. I also discovered significant decreased expression of the EDC gene Lce6a that was
unique to the 923large/large mouse skin, and likely explained by an additional putative enhancer that
was deleted in the 923large allele. My findings that the 923 enhancer regulates proximal Ivl
expression establishes a 923-Ivl regulatory module.
Using allele-specific expression studies in the mouse skins, I further determined that both
the 923del and 923large alleles are required for Ivl expression in cis, and the 923large allele is
required for Lce6a expression in cis. I demonstrated this by crossing the 923del and 923large alleles
on the C57BL/6 (B6) background to BALB/cBYJ (BALB) mice and measuring the relative
proportions of 2 informative SNPs per gene for the Ivl and Lce6a transcripts that were specific to
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the B6 and BALB backgrounds. B6 SNPs in Ivl transcripts from both the 923del and 923large
alleles were significantly reduced proportionally than those from the BALB allele. B6 SNPs
from the 923large allele in Lce6a transcripts were also significantly reduced. The findings
demonstrate cis regulation by the 923 enhancer for Ivl target gene expression and by the 923large
allele for both Ivl and Lce6a expression.
I next sought to determine the effects of the loss of the 923 enhancer on chromatin
accessibility in mouse epidermis using ATAC-seq. Active chromatin, including enhancers and
expressed genes, are not tightly wound around nucleosomes but rather open and accessible thus
susceptible to cleavage when treated with Tn5 transposase. By performing and comparing
ATAC-seq data obtained from WT, 923del/del, and 923large/large mouse epidermis, I aimed to
identify the chromatin accessibility changes associated with the loss of the enhancer in
keratinocytes. ATAC-seq identified changes in chromatin accessibility that were enriched within
the EDC. Specifically, two differentially accessible regions (DARs) in the EDC were shared
between the 923del/del and 923large/large mice. The first DAR overlapped the Gm29950 pseudogene
that was not expressed in the skin (fell below our limits of RNA-seq detection) and whose
function is unknown but has been previously detected in multipotent progenitor cells19. The other
shared DAR lies in an intergenic region between Lce3e and Lce3f but differential expression of
these genes was only observed in the 923large/large mouse. Overall, I established the 923-IVL
regulatory module which highlights the importance of the EDC enhancer 923 in regulating
allele-specific proximal gene expression and chromatin accessibility.
My work that functionally defines the 923-IVL cis regulatory module further extends
previous work that identified proximal regulatory sequences for IVL. In the early 90’s, the human
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IVL promoter was cloned to generate two independent transgenic mice to demonstrate skinspecific expression, more specifically in the spinous layer of the epidermis20,21. This 2500bp
promoter (-2473/-1 bp from IVL exon1), also called the Upstream Regulatory Region (URR),
included 2 functional subunits, the Distal Regulatory Region (DRR) (-2473/-1953) and the
Proximal Regulatory Region (PRR) (-241/-7) (Figure 4.1)20,22,23. Through a series of luciferase
assays, transgenic experiments, and point mutations, the Eckert group identified five specific
regions within the DRR and PRR subunits that collectively regulate IVL expression in the
epidermis thus revealing tissue-specificity23–29. Within the DRR, the 5th AP1 transcription factor
binding site identified in the URR (AP1-5) was found to act as an on/off switch that was further
confirmed by mutation of this site resulting in complete loss of expression in all tissues, in
transgenic mice25,27,29. The adjacent SP1 binding site works with the AP1-5 site to drive full
expression24,29, but it is the proximal ISE (immediate suprabasal expression) element that lends
the epidermal specificity of expression25–27,29. While this DRR is necessary and sufficient to
drive gene expression25, two elements in the PRR also contribute to full endogenous expression,
namely the C/EBP and AP1-1 binding sites23,28,30.
This well characterized DRR identified as a regulator of IVL expression, overlaps with
our 923 enhancer (Figure 4.1). In fact, CNE 923 encompasses the entire DRR, and demonstrates
the same epidermal-specificity that was observed for the DRR9. Within CNE 923, we previously
identified 4 PhastCon blocks that likely impart function as they that represent highly conserved
sequences found in 28 vertebrate species31. By deleting each of these PhastCon blocks from the
broader CNE 923 and assaying enhancer activity through luciferase assays, we determined that
PhastCon blocks 1 and 4 play a functional role in 923’s enhancer activity12. Interestingly, our
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PhastCon blocks 2 and 3 overlap the previously identified AP1-5, Sp1 and ISE regulatory
regions, but showed no significant reduction in enhancer activity when deleted in vitro
suggesting discrepancies between in vitro and in vivo studies. This is consistent with previous
work from the Eckert group that showed reduced activity from mutated AP1-5 sites in vitro
luciferases assays but complete loss of expression in vivo mutated transgenic mice23,24,26. Our
further analysis of transcription factor binding sites within PhastCon block 1 identified an AP-1
binding site, that when mutated, significantly reduced 923 enhancer activity12. It is interesting to
note that this AP1 site was not previously identified by the Eckert group and thus not previously
tested. Our data and the previous work identifying the functional role of the AP1-5 binding site
both demonstrate a requirement for the transcription factor AP1 for 923 regulation but implicate
different binding sites. This suggests AP1 binding may occur at both sites and work in concert to
contribute to 923’s enhancer activity and subsequent target gene regulation.
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hIVL Exon1
Hg19 Chr1:152,877,700-152,881,500
Upstream Regulatory Region
PRR

DRR

C/EBP AP1-1

CNE 923
Conserved sequence deleted in 923del

Distal Regulatory Region
CNE 923
PhastCon 1
...

AP1

AP1-5 SP1

ISE

PhastCon 2 PhastCon 3 PhastCon 4
Conserved sequence deleted in 923del

...

Figure 4.1. Genomic regions upstream of hIVL that confer tissue specific regulation.
Upstream Regulatory Region containing the Proximal Regulatory Region (PRR) and Distal
Regulatory Region (DRR) (orange) defined by the Eckert Group32 include 5 specific regulatory
regions: The AP1-5 and SP1 binding sites and the immediate suprabasal element within the DRR
and the the C/EBP and AP1-1 binding sites in the PRR. Our CNE 923 (green), including tested
PhastCon blocks included for comparison9,12. Finally, the conserved region that has been deleted
in the 923del mouse allele is in blue.

Advances in technology have greatly expanded our ability to determine enhancer
boundaries. Previous studies were restricted owing to the technological limitations of testing
segments defined by the positioning of restriction enzyme cut sites to facilitate segment isolation.
We can now test more isolated regions using CRISPR/Cas9 genome editing as I have done,
including both CNE 923 and the DRR in my 923del allele that encompasses a broader functional
enhancer region. Epigenetic histone modifications further suggest the expansion of the
boundaries of 923. Based on H3K27ac marks, a characteristic mark of active enhancers, the
human 923 enhancer may be 1kb broader than the region deleted in the 923del allele (Figure 1.1).
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Our work identifying regulatory transcription factor binding sites has already identified
additional functional sites that were overlooked when defining the DRR and generates the
hypothesis that even more transcription factor binding sites could exist in this expanded
H3K27ac domain that may contribute to enhancer function. My research has expanded our
understanding of the 923 enhancer/DRR boundaries by deleting the 923 enhancer in vivo,
however future studies may determine further functional activity for this expanded regulatory
region.

4.1.2 Filaggrin Loss-of-Function Variants in African American Atopic Dermatitis
In chapter 3, I addressed a knowledge gap for FLG LOF variants in African American
pediatric patients with Atopic Dermatitis (AD). African Americans (AA) are disproportionately
affected by AD with 16% of AA children affected compared to 9.8% of Caucasian American
children16. However, AA AD patients are thought to have proportionally less FLG LOF variants,
despite FLG LOF mutations being the most significant risk factor for AD17,18. Atopic dermatitis
is a highly heritable disease, with a child’s risk of AD nearly doubling if both parents also have
AD, implicating genetic contributions33,34. The perceived absence of FLG LOF variants in AA
suggests AA AD patients have different genetic modifiers of their AD. A caveat to these previous
studies is that only the presence of the 4 most common European FLG LOF variants (p.R501*,
c.2282del4, p.R2447*, and p.S3247*) were queried17,18, despite our knowledge that FLG LOF
variants are highly population-specific35. This led me to hypothesize that AA AD patients may
have FLG LOF variants that are endogenous to individuals of African ancestry that impact the
development of their AD.
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Our lab previously recruited a cohort of AA AD pediatric patients in St. Louis and
identified that these patients genotyped for fewer filaggrin monomer repeats, another previously
described risk factor of AD36,37. However, we could not completely exclude the possibility that
FLG LOF variants may also be present in this cohort36. Using a targeted, array-based sequencing
approach that tiles across each of the 10-12 repeated FLG monomers to identify variants38, we
identified 5 FLG LOF variants ( c.488delG, p.R501*, p.R826*, p.S3101*, and p.S3316*) in 23%
of our AA AD patients. Furthermore, 2 of these variants were novel (c.488delG and p.S3101*),
having never been previously reported in dbSNP, ExAC, and ESP variant databases. An
additional mutation, p.S3316*, which had been previously reported in only 1 other AA cohort,
was found in 3 unrelated patients in our cohort, suggesting this variant may be more frequent in
the AA population than previously understood. This is further supported by the presence of
p.S3316* in the ExAC and ESP databases reported primarily in African populations that suggests
p.S3316* is an African population-specific FLG LOF variant yet with ExAC reports p.S3316* in
one Latino and one South Asian allele which may be due to admixture. My data provides
evidence of FLG LOF variants including African-specific that likely genetically contribute to
their Atopic Dermatitis.
I further phased the FLG LOF variants with respect to the 10-, 11- or 12-repeat alleles to
determine on which FLG allele, and thus genetic background, each variant arose. The two novel
FLG LOF variants c.488delG and p.S3101*, as well as the African specific p.S3116* were found
on the 10-repeat allele. The 10-repeat allele is the major allele in African populations (73%)35 is
thought to be ancestral, with the 11- and 12- repeat alleles resulting from duplications of either
repeats 8, 10 (both 11-repeat) or both (12-repeat). The presence of our three FLG LOF variants
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on only the 10-repeat allele further supports population specificity of these variants as the
variants likely arose independently and after the emergence of the 11- and 12-repeat derived
alleles.
Our discovery of African American-specific FLG LOF variants corroborates other recent
findings that report the presence of FLG LOF in African Americans. Recent massively parallel
sequencing of the FLG gene, an approach that can sensitively detect variants in the highly
repetitive gene FLG, in 741 pediatric AD patients from the PEER cohort in the US revealed
15.3% of the African American patients carried a FLG LOF variant, with 7 of those variants
found only in African American patients39. If the prevalence of FLG LOF variants in this same
cohort was evaluated based on solely the 4 most common FLG LOF variants in Europeans
(p.R501*, c.2282del4, p.S3247*, and p.R2447*), as often previously reported17,18 only 5.5% of
the AA patients would have been reported to have a FLG LOF variant39. The genetic basis of AD
also extends beyond FLG LOF variants. Recent genome-wide association studies (GWAS) have
identified 31 genetic loci that are associated with AD skin barrier deficiencies and immune
regulation40. To identify genetic loci specifically associated with African American AD, one
GWAS study focused on two African American cohorts and identified one loci that reached
genome-wide significance, rs381141941. Expression quantitative trait loci (eQTL) analysis
identified rs3811419 as an eQTL for the gene THEM4, previously associated with allergy42, and
the non-coding RNA FLG-AS that is encoded antisense to FLG and whose functional role has yet
to be determined. As the GWAS association between rs3811419 and AD was replicated in an
AD cohort of European ancestry, the AD association with this loci does not appear to be
population specific. However, other loci identified as associated with AD did not replicate in this
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AA cohort suggesting that there may be population-specific differences in AD genetic factors41.
My work, together with these recent genetic studies of AA AD, justify investigation of
population-specific genetic factors of AD that can lead to more precision medicine efforts for
this health disparity group.

4.2 Future Directions
My dissertation research has established a functional cis-regulatory module in the EDC
and highlights the significance of underreported prevalence of FLG LOF variants in African
American AD patients. However, more research is needed to fully understand the regulatory
landscape of and genetic variation within the EDC. My work characterizing the role of the 923
enhancer further highlights the need to do in vivo studies that delete enhancers if we are to best
determine the functional role of enhancers in contrast to bioinformatic predictions based on
epigenetic marks. In the EDC alone, there are nine CNEs that exhibit enhancer activity in
luciferase assays9. Eleven EDC enhancers have been predicted based on H3K4me1 and
H3K27ac marks43, two of which overlap with our CNEs (CNE 3 and Enhancer 11, and CNE 461
and Enhancer 9). In vivo deletion studies of these additional putative enhancers may establish
more EDC enhancer-target gene regulatory modules, such as between CNE 184 and its proximal
genes hornerin and Flg, or between CNE 877 and Lce6a. While in vivo studies are crucial to
functionally validate enhancers, characteristic epigenetic marks greatly aide in prioritizing
putative regions to test. Large consortium databases such as ENCODE and 1000 Genomes
Project with their genomic datasets include a wide array of tissues but are still limited. For
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example, epidermal keratinocytes, especially in the mouse, are often excluded from these
databases, and when present are often included in bulk analysis of whole skin. I anticipate future
collaborations between consortiums from the genomics community and experts in the skin
biology field to generate and publicly share these high-quality datasets as invaluable resources
for future investigations.
Furthermore, while previous chromatin conformation studies have been performed on
WT keratinocytes to ascertain physical interactions between 923 and specific gene promoters12
as well as identify topologically associated domains (TADs) in the EDC43, there is an
opportunity to determine additional physical interactions between 923 and our regions of
interest. Such regions of interest include the differentially expressed genes and differentially
accessible regions that were identified in our RNA- and ATAC-seq studies which could help
provide the mechanistic link between 923 and chromatin accessibility and gene expression. 4C
chromatin conformation assays44 using 923 as a bait in WT mice would be invaluable to
expanding our understanding of 923 regulation. Additional 4C on identified targets of 923
regulation as bait in 923 deletion mice, would further validate their physical interactions and
establish 923’s physical network providing a comprehensive understanding of 923’s regulatory
landscape.
Additionally, single-cell approaches using 923del/del and WT keratinocytes would
deconvolve the observed changes in gene expression and chromatin accessibility that I observed
in my bulk cell analyses. This high-resolution approach would enable one to determine if these
changes occur in the same cells or are isolated to specific subpopulations. For example, are the
downregulated genes all found in the proliferating keratinocytes while the observed upregulated
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genes in the differentiated cells? This finer resolution will allow us to dissect the regulatory
networks at the cell type-specific level and provide molecular maps of the single cell states.
In Chapter 2, I determined that an additional regulatory element was likely deleted in the
923large allele that contributes to the regulation of Lce6a. Experiments similar to those performed
in this dissertation, such as luciferase assays followed by in vivo deletion and subsequent RNAsequencing, could be utilized to identify and characterize the functional role of this regulatory
element. Specifically, I hypothesize that the region including CNE 877 may be regulating Lce6a
expression as it is conserved or alternatively the proximal ATAC-seq accessible region 3’ of the
CNE 877 (Chapter 2). While luciferase assays of the narrow CNE 877 did not demonstrate
enhancer activity, I expect the functional enhancer region may be broader as demonstrated in
923.
As my work reported here focuses on understanding 923 enhancer function under
homeostatic conditions, the role of the enhancer in response to skin barrier challenges such as
those experienced during AD are not known and needs to be addressed. Our human skin is in
constant contact with sun and pathogen exposure in contrast to mice that live in barrier housed
conditions. Follow-up studies are needed to further investigate the skin barrier response to
barrier challenges in the 923 deletion mice. I performed preliminary experiments by treating
WT, 923large/large and Ivl-/- mouse ears with MC903, a vitamin D analog that induces Atopic
Dermatitis-like inflammation, where I found loss of involucrin may reduce inflammation
(Appendix A). These experiments are preliminary and need to be expanded and replicated to
validate these findings. Moving beyond established mouse models, I could see the benefit of
exposing the mice to a less controlled environment that better mimics natural conditions. In light
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of the lack of feasibility of importing naturally occurring wild mice in the laboratory to assess
environmental effects on the skin barrier in our mouse barrier facility, an appealing alternative
would be to use the deer mouse Peromyscus. Separated evolutionarily from the commonly used
Mus musculus by approximately 25MY45, Peromyscus has recently emerged as a model
organism to study natural variation and adaptation. Wild Peromyscus species are found
throughout North America and are highly diverse, with each species having adapted to their own
unique habitats46. Laboratory colonies are currently maintained for 8 separate Peromyscus
species46. Genetic comparisons of the 923 enhancer and Ivl gene among these different
Peromyscus species could help identify genetic variants in this regulatory module that arose due
to adaptation to different environmental pressures. These studies would give us a better
understanding of how genetic variation in 923 and varying levels of Ivl expression may facilitate
adaption to environmental pressures
My RNA-seq data identified the 923 proximal genes Ivl and Lce6a as target genes, but an
interesting proximal gene that I haven’t elaborated on is Smcp, the sperm mitochondrial
associated protein. This gene lies ~20 kb upstream of 923 and is very lowly expressed in the
skin47, likely the reason why the expression was not detected in my RNA-seq data. Due to its
proximal location to 923, Smcp could feasibly be a target gene of 923 regulation. However, Smcp
is primarily expressed in the testes. If 923 regulates Smcp expression, 923 would provide dual
tissue regulation in both the skin and testes. I have outlined my initial work in 923large/large male
mice to determine if the loss of the 923 enhancer impacts Smcp expression and sperm motility in
Appendix B. Additional research is needed to identify potential sperm motility and fecundity
phenotypes in the 923del/del mice in contrast to the Smcp knockout48 and 923large/large mice, that is a
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923-Smcp double knockout. These experiments will further our understanding of how the 923
enhancer may affect both skin and sperm biology and could potentially lead to new insights
regarding sperm motility and associated male fertility.
Variation within the FLG gene is also important to examine, particularly in atopic
dermatitis as FLG LOF variants result in a reduction in FLG monomers. Copy number variation
of the FLG monomers has also been implicated to impact AD severity, with fewer FLG
monomers associated with more severe AD36,37. However, additional unknown factors could
impact FLG expression and subsequently contribute to AD.

For example, a currently

uncharacterized long non-coding RNA FLG-AS is encoded antisense to FLG and could feasibly
impart regulation based on its proximity. The eQTL linkage between FLG-AS and the AD
associated SNP rs3811419 further implicates that FLG-AS may play a role in the genetic factors
of AD41. Furthermore, an additional EDC enhancer, CNE 184, overlaps one of these FLG-AS
transcripts which could further contribute to FLG regulation9.

FLG regulation is worth

considering in identifying the multi-factorial contributions that may lead to AD.

4.3 Final Thoughts
My dissertation work demonstrates the role of an epidermal enhancer in regulating
proximal gene expression and chromatin accessibility within the EDC. I have established a cisregulatory module between an EDC enhancer and its proximal gene in the epidermis. Similar
regulatory modules likely exist throughout the EDC locus, throughout the genome, and across
tissue types. Enhancer deletions and subsequent identification of target genes can help establish
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these modules and further our understanding of the regulatory network that governs tissuespecific gene expression.
I have further emphasized the presence and importance of population-specific FLG LOF
variants in African American Atopic Dermatitis patients. The genetic components of AD are
complex and population-specific investigations of these components are necessary to address
population-specific health disparities leading to more tailored precision medicine treatments.
Altogether, my research illustrates the skin’s resiliency and adaptation through genetic
variation. My enhancer deletions demonstrate that the skin can tolerate reduced Ivl expression
while maintaining the barrier. The presence of population-specific FLG LOF variants suggests
these variants have independently arose repeatedly. And while FLG LOF does increase the risk
of AD, not everyone who possesses these variants develop the disease. It is possible that
variation in other skin genes could compensate for this loss to maintain the barrier. Afterall, the
skin is the first line of defense and must continue to evolve to provide constant protection.
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Appendix A

MC903 Treatment
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A.1 Introduction
As outlined extensively in Chapters 1 and 3, Atopic Dermatitis is a chronic inflammatory
skin disease that is prevalent in 15-20% of children world wide1. In addition to the pruritus and
dry skin, AD elicits a characteristic inflammatory response. A number of mouse models have
been developed to better understand the disease pathophysiology2. Models range from
spontaneously generated mutations that lead to AD-like symptoms, such as in the Flaky Tail
(ft/ft) mouse that has a frame shift mutation in the filaggrin gene3, to genetically engineered
models such as the ADAM17-deficient mice that exhibits a high degree of similarity to the
human AD transcriptional profile as well as chronic puritus4,5. One widely-used AD mouse
model involves the topical treatment of vitamin D3 or its analog MC903 to the skin6. MC903
treatment induces the overexpression of the skin alarmin, Tslp, that triggers AD–like symptoms6.
MC903 treatment also elicits a mix of Th2 and Th1 immune response including increased levels
of IL-4, UL-5, IL-13, IL-31,IL-10, IL-8, IFN-γ, and TNF-β and increased serum IgE, consistent
with AD, which is characterized by initial Th2 immune response with subsequent Th1 response7–
9

. I hypothesized that MC903 treatment used to induce AD-like symptoms would be exacerbated

in 923large/large that have decreased Ivl, as well as in involucrin knockout mice. To test this
hypothesis, I treated 923large/large, Ivl-/-, and WT mice with MC903 on their ears and measured
their inflammatory responses in their skins.
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A.2 Results
To date, I have performed MC903 treatments on WT, Ivl-/-, and 923large/large mice with
treatment durations ranging from 12 to 16 days (Table SA.1). Mice ears were treated daily with
either MC903 or ethanol (negative control) and the thickness of the ear was measured. Mice
were assigned either to the treatment or control group based on age and weight with the goal of
equal distributions in each treatment group for comparison (Table SA.1). Mice were sacrificed a
day after the last treatment day and samples were taken for RNA and protein.
Overall, MC903-treated mice exhibited increased inflammation and scabbing of the ear
compared to control mice (Figure A.1). Furthermore, the thickness of the MC903 treated ears
continued to increase in both males and females in contrast to ethanol-treated ears and remained
relatively stable over the treatment time course (Figure A.2, A.5 ).

EtOH

MC903

Figure A.1. MC903 treatment triggers inflammation in mouse ears. Wild-type mouse ears
exhibited inflammation and scaling with daily MC903 treatment compared to the ears of ethanoltreated control mice.
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A.2.1 MC903 Treated Ivl-/- Mice Exhibited Less Inflammation Compared to WT
I next sought to determine the effect of MC903 treatment in both female and male Ivl

-/-

mice in comparison to WT mice over a 16-day course of treatment. Surprisingly, MC903-treated
Ivl-/- females exhibited less inflammation compared to WT with significant reduction observed at
day 11 (T-test p=0.04) and with near significance at days 10 and 13 (T-test P=0.09, P=0.06). Ivl-/males also showed decreased inflammation compared to WT, notably at days 10 and 11 but was
not significant (T-test P=0.42 and P=0.38). After day 13, ear inflammation was greater in an Ivl -/male compared to WT males but was likely an outlier as it was only observed in a single male
(Figure A.2). The other three Ivl-/- males were only treated for 12 days. Decreased inflammation
observed in both females and males was confirmed via H&E staining of the treated and untreated
ear skins (Figure A.3).
The relative decreased inflammation in the Ivl-/- mouse skins motivated me to determine
the levels of Tslp expression in these mice. Tslp expression levels were decreased in MC903
treated Ivl-/- skins compared to WT harvested at day 12 but not significant (T-test P =0.13)
(Figure A.4). The observed decrease in Tslp expression led us to investigate if Vitamin D
receptor (Vdr) expression was decreased in the Ivl-/- skins and hence the lack of MC903 vitamin
D agonist-induced inflammation. Vdr expression was also decreased in Ivl-/- skins treated with
MC903 in comparison to WT skins but was not significant (T-test P=0.24) (Figure A.4). Overall,
my data identifies a surprising reduction of MC903-induced inflammatory response in Ivl-/mouse skins compared to WT mice. Decreased expression for both Tslp and Vdr in the Ivl-/- skins
suggests a mechanism by which involucrin may regulate the vitamin D receptor signaling
pathway.
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Figure A.2. Ivl-/- mice exhibit less inflammation when treated with MC903 compared to WT. Ear
thickness of WT and Ivl-/- mice treated with MC903 or EtOH vehicle control over a 16-day time
course. All mice were treated daily for total number of either 12, 15, or 16 days. The change in
inflammation was determined relative to baseline at day 1. MC903 WT males (n=4 treated for
12 days; n=4 treated for 15 days); MC903 Ivl-/- males (n=3 for 12 days; n=1 for 16 days); EtOH
WT males (n=3 for 15 days; n=1 for 16 days); MC903 WT females (n=3 for 12 days; n=4 for 16
days); MC903 Ivl-/- females (n= 3 for 12 days; n=2 for 16 days); EtOH WT females (n= 4 for 16
days); and EtOH Ivl-/- females (n=1 for 16 days). Mean +/- SE shown.

WT Untreated

WT Mc903

Ivl-/- Untreated

Ivl-/- Mc903

Figure A.3. MC903 treatment induces inflammation and thickening of the ear skin. H&E
staining of MC903 treated and untreated internal control ear for representative WT and Ivl-/males. Scale bar represents 50 µm.
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Figure A.4. qPCR of Tslp and Vdr expression in MC903 treated ears from WT and Ivl-/- male
mice (n=3 per genotype). Values are not significant (T-test P =0.13, P=0.24).

A.2.2 923large/large Young Mice Exhibit More Inflammation Than Aged Mice
I next sought to determine the effects of MC903 treatment in young and aged 923large/large
mice with known decreased Ivl and Lce6a target gene expression. I specifically treated a cohort
of aged 923large/large mice (80 to 90 weeks old) and a cohort of young 923large/large mice (11 weeks
old). Although the data from the young MC903 treated cohort was limited (2 males, and 1
female), the young mice exhibited a higher trend of increased inflammation at the end of
treatment though not significant (P=0.88 for males, not enough data to calculate for females)
(Figure A.5). However, additional mice are needed to repeat the experiment and calculate the
statistics. The current data suggests inflammation impacts young 923large/large mice more severely
than aged mice.

114

EtOH Young

150%
100%
50%

225%
200%

% Change in Thickness

% Change in Thickness

300% 923large/large Females
MC903 Aged
250%
MC903 Young
200%
EtOH Aged

175%
150%

923large/large Males
MC903 Aged
MC903 Young
EtOH Aged
EtOH Young

125%
100%
75%
50%
25%
0%

0%
2

4

6 8 10 12 14
Treatment Day

-25%

2

4

6
8 10 12
Treatment Day

14

Figure A.5. Young 923large/large mice exhibit greater inflammation than aged mice. Ear thickness
of 923large/large mice treated with MC903 or EtOH for both young and aged cohorts over a 15 day
time course. Mean +/- SE shown.

We also analyzed the blood of the aged mice to determine if the MC903 treatment
impacts the blood chemistry. A full list of measured blood chemistries are provided in the
methods. Significant differences between treatments or sex was observed for the mean
corpuscular volume (MCV), a measure of the average red blood cell volume, where females had
higher MCV than males, regardless of treatment (ANOVA, post-hoc Tukey P<0.0001). The
Blood Urea Nitrogen levels (BUN), a measure of the waste product Urea Nitrogen were also
significantly higher in EtOH Females compared to MC903 Females (ANOVA, post-hoc Tukey
P<0.05) (Figure A.6). Overall sex and treatment had minimal effects on the blood chemistries of
aged 923large/large mice with the exceptions of females displaying higher MCV levels than males
and MC903 females exhibiting higher BUN than EtOH females. We also examined the spleen
weights for both young and aged treated and untreated mice to evaluate the immune systems, but
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no differences in average weights between the treatment groups were observed (data not shown).
Although qPCR has not been performed on the 923large/large treated ears for Tslp and Vdr, RNAseq on newborn 923large/large mice did not show a significant change in Tslp, or Vdr expression
(Chapter 2). Overall, given the current data, aged 923large/large mice have less severe inflammation
than young mice.

Figure A.6. Mean corpuscular volume and blood urea nitrogen levels in aged mouse cohort. For
MCV values: MC903 Males n= 4, EtOH males n=2, MC903 Females n=3, EtOH Females n=3.
For BUN values: MC903 Males n= 5, EtOH males n=4, MC903 Females n=4, EtOH Females
n=2. +/- SE

A.3 Discussion
These experiments are in progress and much additional data is needed to fully interpret.
Ideally, each treatment group would have 6-10 mice for statistically powered testing. The Ivl-/and 923large/large mice in particular need additional replicates as these experimental groups have
limited numbers and potential outliers. If differences are still observed after the inclusion of
additional replicates between the Ivl

-/-

and 923large/large mice, treatment of the 923del/del mice may
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also be warranted to further validate these studies. MC903 studies also should be repeated on
both young and aged WT mice. These experiments are particularly important to determine if the
changes are occurring as a result of the age or the deletion.
RNA has been banked from multiple sites from each treated mouse, but I have thus far
only prepared and assayed gene expression in 3 WT and 3 Ivl-/- male mice that were treated with
MC903 for 12 days. Additional qPCR experiments are needed to more accurately measure gene
expression changes occurring in each of the genotypes with respect to age, treatment, and
treatment time points, as some of the observed changes in ear thickness appear to be timesensitive particularly in the 923large/large mice. Protein has also been banked for each mouse,
which should be analyzed to determine if observed changes in gene expressing correspond with
changes in protein expression.
Overall, these MC903 experiments as a trigger for AD induction allows us to determine
how involucrin deficient and our enhancer deletion allele mice functionally respond. Preliminary
experiments suggest that the involucrin deficient mice exhibit less skin inflammation associated
with decreased vitamin D receptor expression and hence reduced Tslp expression. Furthermore,
it appears that aged mice may not have as severe of an inflammatory response as young mice
upon MC903 treatment that further suggests AD inflammation may be age dependent.
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A.4 Materials and Methods
A.4.1 MC903 Treatment
Mice were assigned to MC903 treatment or EtOH control group based on age in order to
have a similar age distribution in each group. Mice were treated daily for 12-16 days. Ear
thickness of both treated and untreated ear was measured in µm with Peacock dial thickness
gauge caliper (Ozaki MFG, Japan). Mice were weighed prior to treatment. 2X stock of MC903
was diluted in EtOH to make 1X working stock. Liquid was pipetted directly onto front of
treated ear and mouse was held for 30sec to allow for air drying. MC903 mice were treated with
10ul of 1X MC903 for a total of 1nmol dose. Control mice were treated with EtOH.

A.4.2 Blood Chemistry
Blood was isolated from aged mouse hearts and sent to the Division of Comparative
Medicine for quantification. Measurements were taken for White Blood Cell count, Red Blood
Cell count, HGB g/dL, HCT%, Mean corpuscular volume, MCH picog, MCHC g/dL, PLAT
103/ul, SEG NEU %, BND NEU %, LYMPHOS%, MONOS%, EOSINO %, BASO% NRBC
n/100, Glucose levels, Calcium levels, TP g/dL, Albumin, Cholesterol, Sodium, Potassium, CL,
Trig, Phos, and BUN. Data not shown.

118

A.4.3 RNA Isolation
RNA samples from treated and untreated ears of all mice were placed in 1mL trizol and
banked at -80°C. Additional testis RNA samples were banked from male mice used in the
February and March 2019 MC903 experiments. RNA has been prepped and converted to cDNA
as previously described (Chapter 2) from the treated and untreated ears of 3 WT and 3 Ivl-/- male
mice from the August 2018 experiment. Additional RNA has been prepped from the treated and
untreated ears of 8 MC903 treated mice from the February 2019 experiment.

A.4.4 Protein Samples
Sections of both the treated and untreated ear from mice in the February and March 2019
studies were flash frozen in liquid Nitrogen and banked in the -80°C freezer for protein analysis.
Testis and cauda epididymis were also frozen for male mice from the February and March 2019
studies.

A.4.4 OCT Sections
Sections of the treated and untreated ears of all mice were frozen in OCT and stored at 80. The liver and thymus are also banked in OCT blocks for all mice from the Aug 2018
experiments. The spleen and thymus are banked for the old mice cohort from the march 2019
experiments. Treated and untreated ears from 3 Ivl-/- (B1, B2 and C4) and 3 WT (2,3,4) male

119

mice from the august 2018 experiment have been sectioned by The Department of
Developmental Biology Histology Core and H&E stained.

A.4.5 Real-time qPCR
Real-time qPCR on cDNA (generated using SuperScript II reverse transcriptase (Thermo
Fisher Scientific)) using SYBR Green was performed in triplicate (Fast SYBR Green Master
Mix ABI ViiA7, Thermo Fisher Scientific) and normalized to β2-microglobulin. Only CT values
with single peaks on melt-curve analyses were included. Primers are listed in the supplementary
material.
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A.6 Supplemental Material

Table SA.1. Mouse cohort

Mouse ID

Treatment
Age
Weight Length
Treatment
Sex Treatment (weeks) (g)
(days)
date

WT +/+ MC903 M (n=8)
C57B6 1

M

MC903

10

21.8

12

Aug 2018

C57B6 2

M

MC903

10

23.6

12

Aug 2018

C57B6 3

M

MC903

10

21

12

Aug 2018

C57B6 4

M

MC903

10

22.6

12

Aug 2018

C57B6 4

M

MC903

11

25.8

15

Feb 2019

C57B6 5

M

MC903

11

23.9

15

Feb 2019

C57B6 6

M

MC903

11

24.6

15

Feb 2019

C57B6 1

M

MC903

11

26.4

15

Feb 2019

WT +/+ EtOH M (n=4)
C57B6

M

EtOH

11

26

15

Feb 2019

C57B6

M

EtOH

11

25.3

15

Feb 2019

C57B6

M

EtOH

11

27.1

15

Feb 2019

C57B6

M

EtOH

11

26.7

16

Mar 2019

WT +/+ MC903 F (n=7)
C57B6 1

F

MC903

8

13.7

12

Aug 2018

C57B6 2

F

MC903

8

16.8

12

Aug 2018

C57B6 3

F

MC903

8

15.9

12

Aug 2018

122

C57B6 1

F

MC903

11

20.9

16

Mar 2019

C57B6 2

F

MC903

11

19.9

16

Mar 2019

C57B6 3

F

MC903

11

20.8

16

Mar 2019

C57B6 4

F

MC903

11

19.4

16

Mar 2019

WT +/+ EtOH F (n=4)
C57B6 1

F

EtOH

11

20

16

Mar 2019

C57B6 2

F

EtOH

11

19.2

16

Mar 2019

C57B6 3

F

EtOH

11

19.9

16

Mar 2019

C57B6 4

F

EtOH

11

19.3

16

Mar 2019

IVL ix F6 B1

M

MC903

14

24.5

12

Aug 2018

IVL ix F6 B2

M

MC903

14

23.5

12

Aug 2018

IVL ix F6 C4

M

MC903

14

27.7

12

Aug 2018

IVL ix F8 B2

M

MC903

14

24.4

16

Mar 2019

IVL ix F6 C3

F

MC903

14

21.3

12

Aug 2018

IVL ix F6 C5

F

MC903

14

21

12

Aug 2018

IVL ix F6 C6

F

MC903

14

23.8

12

Aug 2018

IVL ix F8 C3

F

MC903

9

21.4

16

Mar 2019

IVL ix F8 B4

F

MC903

11

21.4

16

Mar 2019

F

EtOH

11

22.5

16

Mar 2019

Ivl -/- MC903 M (n=4)

Ivl -/- MC903 F (n=5)

Ivl -/- EtOH F (n=1)
IVL ix F8 B5

923large/large Young MC903 M (n=2)
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56-10 ix F12 D4

M

MC903

11

22.6

15

Feb 2019

56-10 ix F12 E1

M

MC903

11

25.7

15

Feb 2019

11

25.8

15

Feb 2019

11

21.3

15

Feb 2019

11

21.6

15

Feb 2019

923large/large Young EtOH M (n=1)
56-10 ix F12 E1+4

M

EtOH

923large/large Young MC903 F (n=1)
56-10 ix F12 D5

F

MC903

923large/large Young EtOH F (n=1)
56-10 ix F12 D1+4

F

EtOH

923large/large Aged MC903 M (n=5)
56-10 ix F9 B1+5

M

MC903

90

27.8

15

Mar 2019

56-10 ix F9 D3

M

MC903

88

32.3

15

Mar 2019

56-10 ix F9 E3

M

MC903

87

26.2

15

Mar 2019

56-10 ix F9 M1

M

MC903

83

25.6

15

Mar 2019

56-10 ix F9 O2

M

MC903

81

28.9

15

Mar 2019

923large/large Aged EtOH M (n=4)
56-10 ix F9 B1+4

M

EtOH

90

29.7

15

Mar 2019

56-10 ix F9 D4

M

EtOH

88

33.3

15

Mar 2019

56-10 ix F9 F3+4

M

EtOH

87

30

15

Mar 2019

56-10 ix F9 M1+4

M

EtOH

83

30.7

15

Mar 2019

923large/large Aged MC903 F (n=4)
56-10 ix F9 E2

F

MC903

87

26.4

15

Mar 2019

56-10 ix F9 M1+5

F

MC903

83

23.6

15

Mar 2019

56-10 ix F9 Q1

F

MC903

80

27.1

15

Mar 2019

124

56-10 ix F9 P3

F

MC903

81

34.1

15

Mar 2019

923large/large Aged EtOH F (n=3)
56-10 ix F9 D1

F

EtOH

88

28.4

15

Mar 2019

56-10 ix F9 B3

F

EtOH

90

23.9

15

Mar 2019

56-10 ix F9 P4

F

EtOH

81

30.5

15

Mar 2019

Table SA.2. qPCR primers

Primer Name

Primer Sequence

mB2mFwd

TGGTGCTTGTCTCACTGACC

mB2mRvs

CCGTTCTTCAGCATTTGGAT

mVDR_F

CACCTGGCTGATCTTGTCAGT

mVDR_R

CTGGTCATCAGAGGTGAGGTC

mTSLP_F

AGAGAAGCCCTCAATGACCA

mTSLP_R

GGACTTCTTGTGCCATTTCC
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Appendix B

923 regulation of Smcp
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B.1 Introduction
The EDC contains approximately 65 genes many of which share structural homology1,2
and are involved in the formation and structure of the skin barrier. Interestingly, the sperm
mitochondria-associated cystine-rich protein (SMCP) gene is located within the EDC and is
thought to be an EDC paralogue3. SMCP is primarily expressed in haploid spermatogenic cells
that are developing within the testes in contrast to the skin where the majority of EDC genes are
expressed4,5. SMCP localizes to the outer mitochondrial membrane of sperm mitochondrial
sheath in the midpiece of the spermatozoa and contributes to sperm motility 4. Smcp knockout
mice were generated on both a mixed C57BL/6J X 129/Sv and pure 129/Sv genetic
backgrounds6. While Smcp-/- males were fertile on the mixed background, 129/Sv Smcp-/- males
were infertile. The 129/Sv Smcp-/- mice did not have a lower sperm count, but the females mated
with the 129/Sv Smcp-/- males did show less Smcp-/- sperm in their oviducts compared to those
mating with WT males, suggesting that Smcp-/- spermatozoa had difficulty migrating through the
female reproductive tract. Interestingly, no difference was observed in the acrosome reaction, the
removal of the acrosome which releases enzymes that enable the sperm to penetrate the zona
pellucida of the egg7. This suggests that Smcp-deficient sperm are able to penetrate and fertilize
the egg, but are unable to reach the egg. To test the role of Smcp in sperm motility, Computer
Assisted Sperm Analysis (CASA)8 was used and identified less motile sperm in the Smcp-/males, specifically less progressive movement. Overall, it was concluded that Smcp-/- mice
exhibited an asthenozoospermia phenotype given the observed reduction in sperm motility.
As previously mentioned, the Smcp gene is also proximal to the 923 enhancer (Figure
2.1). As my previous work discussed in Chapter 2 identified Ivl as a target gene of proximal 923
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enhancer regulation, I hypothesized that the 923 enhancer may also regulate Smcp expression. A
few transcripts for Smcp has been detected in a few single cells in the skin5 and a likely
explanation for our inabilities to detect Smcp in our bulk whole skin RNA-seq data. However, as
Smcp is primarily expressed in the testes4, I hypothesize that the 923 enhancer may have a
regulatory role for its two most proximal genes in two different tissues, regulating Ivl in the skin
and Smcp in the testes. In the following chapter, I will discuss the preliminary experiments I have
performed to assess this hypothesis. The majority of these experiments have been done in the
923large/large mice that have both the 923 enhancer and 40kb of proximal DNA deleted, including
the Smcp coding gene that in essence represents double knockouts of the 923 enhancer and Smcp
in 923largel/large mice. Overall, my experiments in the 923large/large mice recapitulate previous
findings in the Smcp deletion mice6 with additional studies needed in the 923del/del mice to more
rigorously determine 923 regulation of Smcp. Regardless, these subsequent experiments provide
evidence that 923large/large is an appropriate positive control for future experiments.

B.2 Results
B.2.1 Decreased Smcp Expression in 923large/large Testes
To validate Smcp deletion in the 923large allele, I determined Smcp expression from the
testes of 923large/large adult males comparted to WT. PCR revealed no detectable Smcp transcript
in the 923large/large testes (Figure B.1) and validates the deletion of the Smcp gene that was
determined by Sanger sequencing of the 923large mouse allele (Chapter 2).
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B2m (160bp)
-/+/+ H20

Figure B.1. Gel electrophoresis of Smcp and B2m amplified from 923large/large and WT testes
detects no Smcp expression in 923large/large mice.
B.2.2 923large/large Males are Less Reproductively Fit
As the Smcp KO mouse on the 129/Sv genetic background were infertile6, I wanted to
determine if the Smcp deletion in our 923large/large mice on the C57BL/6 background also resulted
in male infertility. To assess 923large/large male mice fecundity, I tracked the number of offspring
from three 923large/large male mice that were mated with WT C57Bl/6 females over a 90 day
period. For each dad, I counted the number of pups sired and how long it took to produce
progeny after crosses were set up. The 923large/large males took significantly longer to produce
offspring, approximately 36 days compared to 22 days for the WT males (T-test P=0.012).
Subsequently, the 923large/large males overall gave rise to significantly less pups in the 90 day
period, an average of 6 pups compared to 16 for each WT male (T-test P=0.006) (Figure B.2).
The findings reveal that the 923large/large mice are not infertile but exhibit reduced fertility. This is
likely due in part to the C57Bl/6 genetic background of the 923large/large mice as Smcp 129/Sv
showed infertility but was not observed in Smcp knockout males on the mixed 129/Sv X C57Bl/6
background6. Additional reproductive fitness studies in the 923del/del specific deletion males are
needed to determine if 923 regulates Smcp expression in the testes and affects subsequent
reproductive fitness.
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Figure B.2. 923
male mice showed reduced reproductive fitness compared to WT males.
N =3 per genotype. Males were mated with WT females and tracked for 90 days. The
923large/large males took significantly longer to produce offspring and produced significantly less
pups. Error bars are mean +/- SE.
B.2.3 Computer Assisted Sperm Analysis Reveals More Slowly Motile Sperm in 923large/large
Males
As Smcp KO males have reduced fertility as a result of less motile sperm, I wanted to
determine if my 923large/large mice also exhibited reduced sperm motility. I utilized computer
assisted sperm analysis (CASA)8 to analyze the sperm motility from 923large/large and WT males
(n=3 each). Sperm were capacitated to induce the necessary physiological changes that the sperm
naturally undergo in the female reproductive tract to prepare to fertilize the sperm7. I then
analyzed the motility of the sperm using CASA which tracks the location of sperm heads from
frame to frame. Given the location of a given sperm head through a rapid succession of pictures,
the software is able to track the movement of the sperm and thus calculates the parameters
describing said movement including curvilinear, average path, and straight line velocities (VCL,
VAP and VSL respectively), linearity of the curvilinear path (LIN), straightness of the average
path (STR), amplitude of the lateral head displacement (ALH) and the beat-cross frequency
(BCF) as well as percentages of motile sperm8,9. Collectively, these parameters can be used to
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categorize the sperm into motility classes. For this pilot experiment, I tracked approximately 100
sperm per mouse and measured motility at 60 mins post-capacitation. I observed a statistically
significant increase in sperm that were categorized as “slowly motile” from the 923large/large males
(T-test P=0.027) (Figure B.3). This suggests that the reduced fertility observed in our 923large/large
mice is due to the reduced sperm motility, consistent with the Smcp KO mouse and justifies

Percent of motile sperm
categorized as slow

using this method to analyze sperm motility in 923del/del mice.

60%

*

50%
40%
30%
20%
10%
0%

WT

large/large

*P=0.027

923

Figure B.3. 923large/large male mice had a significantly higher proportion of slowly motile sperm
compared to WT (N=3 per genotype), ~100 sperm analyzed per mouse. Error bars are mean +/SE.
B.2.4 Generation of 923rec mice
We have demonstrated that CNE 923 acts as an epidermal specific enhancer, but the
hypothesized regulation of the testes gene Smcp suggests a role for 923 regulation in two
different tissues. I have focused my studies on the germline, global deletion of the 923 enhancer
in 923del/del and 923large/large mouse lines where 923 has been deleted from all tissue types.
Functional assays of 923 regulation to date have been performed mostly in keratinocytes. Thus
the effects of 923 deletion in other tissue types have not have been directly investigated. To
investigate the effect of the loss of the 923 enhancer that was specific to the testes, I generated an
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additional deletion of 923 by crossing mice with the floxed 923 allele (generated in the same
CRISPR/Cas9 screen as the 923del and 923large alleles) to a VASA-Cre mouse, a Cre whose
expression is specific to germ cells10. As a result, I successfully generated a recombined 923
allele (923rec) due to the maternal effects of the VASA-Cre for all tissues in the mouse (Figure
B.4). Early RNA sequencing of homozygous 923rec/rec mice revealed more changes in gene
expression than what was observed in the 923del/del or even the 923large/large mice owing to a mixed
genetic background for this allele that was introduced with the Vasa-Cre transgenic cross (Data
not shown). These experiments were done on F3 mice and thus more backcrossing is necessary
to homogenize the genetic background and directly compare to the RNA-seq skin data from the
923del/del experiments.
mm10 chr3:
92,570,000
Ivl 923

92,595,000
2210017l01Rik

Smcp

92,620,000
Lce6a

WT
923fl
923rec

Figure B.4. Schematic of 923fl and 923rec alleles. The 923fl allele was generated by the
CRISPR/Cas9 screen discussed in chapter 2 and has 2 flanking loxP sites inserted at 923. The
923rec allele was generated from the 923fl allele paired with a VASA-Cre that recombined out the
923 enhancer between the two loxP sites.
Despite the mixed genetic background, preliminary assays of Smcp expression in the 923
rec allele have been promising. qPCR of testes’ cDNA from a genotyped Vasa-Cre+,
floxed/recombined male, resulted in a significant decrease in Smcp expression compared to aged
matched wildtype mice (ANOVA p=0.04) (Figure B.5). Although the data was obtained from a
single Vasa-Cre+, floxed/recombined male, this preliminary finding suggests that Smcp may be a
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target gene of 923 and warrants further fertility studies in males that are homozygous for the

Fold Change in Smcp
Expression from WT

recombined 923 allele.

1.2

*

1.0
0.8
0.6
0.4
0.2

* P=0.04

0.0
WT

fl/rec/+, CRE

fl/rec, CRE

Figure B.5. Smcp expression is significantly reduced in homozygous 923rec/rec mouse testes.
Smcp expression assayed by qPCR for WT (n=2), a 923fl/rec/+ heterozygous mosaic mouse, and a
923fl/rec;CRE mouse RNA isolated from the testes. Error bars are mean +/- SE

B.3 Discussion
The experiments discussed in this chapter are preliminary but present an outline of the
necessary steps to determine if 923 regulates Smcp expression in the male reproductive tract.
These experiments should be repeated in 923del/del mice to determine the effects of loss of 923 on
Smcp and use the 923large/large mice as a positive control for the double knockout of 923 and Smcp,
particularly since the Smcp-/- mouse was generated on different genetic backgrounds, specifically
a mixed C57BL/6J X 129/Sv and pure 129/Sv genetic backgrounds6. I have currently banked
both testis protein and cauda epididymis RNA in the -80 freezer for future analysis particularly
from adult males from the MC903 treated experiments (Appendix A) and the allele-specific 923
experiments (Chapter 2) to be used for future experiments.
As the previously discussed experiments are preliminary findings, I recommend some
changes to future iterations of these experiments. It is important to note that when tracking the
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offspring of the 923large/large compared to WT males, I did not track evidence of physical mating
via remnants of a vaginal semen plug. Given this caveat, one can interpret that the observations
for the reduction in time to offspring and offspring number may be due to reduced numbers of
mating events rather than reduced sperm motility as hypothesized. This will be especially
important to track when performing the experiments in 923del/del mice as we know Smcp has not
been deleted in these mice. The Smcp-/- mice saw no reduction in physical mating events, but this
needs to be tracked in the new mouse lines.
In terms of the CASA sperm motility analysis, more sperm tracks will need to be
analyzed. Additionally, overall motility counts should be recorded. I expect decreased Smcp to
decrease overall sperm motility in the deletion mice and not just the increase in the proportion of
weakly motile sperm as mentioned above. These results have previously been observed in the
129/Sv genetic background and may not be consistent with the C57BL/6 background,
particularly as the mixed C57BL/6 X 129/Sv background did not show infertility6. It is worth
noting that they did not investigate sperm motility in the mixed background. In tandem, qPCR
and RNA-sequencing should be performed on the testes to determine if Smcp is downregulated
upon 923 loss and determine if any other genes are dysregulated, and thus also targets of 923
regulation in the testes.
If 923del/del fertility and sperm motility studies identify Smcp as a target gene of 923, this
would implicate 923 for gene regulation in two tissues types. Furthermore, this would support
proximal gene regulation by 923 at both its 5’ and 3’ ends in regulating both Ivl and Smcp.
Overall, these studies will lead to new insights regarded enhancer target genes and regulation.
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B.4 Materials and Methods
B.4.1 Real-time qPCR
Real-time qPCR on cDNA (generated using SuperScript II reverse transcriptase (Thermo
Fisher Scientific)) using SYBR Green was performed in triplicate (Fast SYBR Green Master
Mix ABI ViiA7, Thermo Fisher Scientific) and normalized to β2-microglobulin. Only CT values
with single peaks on melt-curve analyses were included. Primers are listed in the supplementary
material.

B.4.2 Fertility Studies
To analyze reproductive fitness of the 923large/large mice compared to age matched WT
mice I tracked their offspring production over a 90-day period. Three-month-old virgin
923large/large or WT male mice (n=3 per genotype) were each co-housed with a single C57B6 WT
female. Cages were checked daily for newborn pups, which were counted on their day of birth.

B.4.3 CASA
Sperm samples were isolated from dissected cauda epididymis via a swim-up experiment
that selects for living sperm (n=2 for wild type; n= 2 for 923large/large adult male mice). Each
cauda was cut three times and placed in a tube with 1 mL of HS Media (135mM NaCl, 5mM
KCl, 2mM CaCl2, 1mM MgSO4, 20mM HEPES, 10 mM 60% Na Lactate solution, 1mM Na
Pyruvate, 5mM Glucose, 15mM Bicarbonate and 5mg/mL BSA in H2O, pH 7.4). Media has
added bicarbonate to capacitate the sperm. Sperm motility was analyzed on the CEROS II Sperm
Analyzer (Hamilton Thorne Research). Sperm was loaded onto a pre-warmed 2X-Cel Chamber
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using capillary actions to spread out the sperm evenly. The CEROS software tracked at least 100
individual sperm from each sample recording at least 50 frames per second from multiple fields
of view.
Sperm were classified into motility classes by the CASAnova program which utilizes a
common supervised machine learning technique known as Support Vector Machines (SVM)11.
Taking into account the VAP, VSL, VCL, ALH and BCF of each sperm, CASAnova makes 4
binary SVM decisions to categorize sperm into the motility categories of Hyperactive,
Intermediate, Progressive, Slow, Weakly Motile. These SVM calculations were trained on hand
analyzed motility patterns of approximately 1000 sperm and has been validated in multiple
mouse backgrounds including C57BL/6. Motile sperm are first separated into vigorous or nonvigorous classifications. Vigorous sperm include progressive, intermediate and hyperactive
sperm movements. Progressive sperm migrate in straight paths with the angles in head
movement between subsequent frames recorded as less than 90°. Intermediate sperm migrate
more vigorously with their heads moving at approximately right angles. Hyperactive sperm
display the most vigorous motility and migrate at angles of greater than 90°. On the nonvigorous end of the spectrum lie slow and weakly motile sperm. Slow sperm travel much smaller
distances than progressive sperm and the heads show very little displacement from their track,
resulting in little angular movement. Weak sperm display movement, but lack forward motion.
The CASAnova output provides raw track counts of sperm in each motility class as well as the
percentage of sperm tracks that fall in each class.
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B.4.4 Generation of the 923rec allele
Male 923fl/fl mice were mated with female VASA-Cre mice10, with the intention goal of
generating 923 recombination only in the reproductive tract of the offspring mice for which the
VASA-Cre is active. However, maternal VASA-Cre appeared to be present in the egg resulting
in recombination of the 923fl allele during embryonic development (923rec allele). This allele was
backcrossed to C57BL/6 WT mice at least 3 times before sequencing. Additional backcrossing
onto the C57BL/6 background is needed to homogenize the background. Our current mouse
colony for the 923rec allele has been backcrossed 5 times (F5 mice).
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B.6 Supplemental Material
Table SB.1. qPCR primers

Primer Name

Primer Sequence

mB2mFwd

TGGTGCTTGTCTCACTGACC

mB2mRvs

CCGTTCTTCAGCATTTGGAT

SmcpF

TCTGCTGAAACATCCAGGAA

SmcpR

GGATTTGGGACAGCAAGGT
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Table S2.4. Ranked list of differentially expressed genes between 923del/+ and WT mice
whole skin from RNA List ranked by log2FC. FDR (adj.P.val) <0.05 and logFC <|2| cutoffs
used.

Feature_ID

gene name

ENSMUSG00000040852 Plekhh2

gene_biotype
protein_coding

logFC

adj.P.Val

-4.544

1.78E-02

ENSMUSG00000078122 F630028O10Rik antisense

-2.150

4.04E-02

ENSMUSG00000111912 Gm48521

lincRNA

-2.142

3.65E-02

ENSMUSG00000074634 Tmem267

protein_coding

-2.009

2.05E-02

ENSMUSG00000049103 Ccr2

protein_coding

-2.000

3.65E-02

ENSMUSG00000049128 Ivl

protein_coding

-1.827

2.59E-03

ENSMUSG00000039252 Lgi2

protein_coding

2.104

3.85E-02

ENSMUSG00000035769 Xylb

protein_coding

2.602

3.67E-02

ENSMUSG00000035184 Fam124a

protein_coding

2.621

4.72E-02

ENSMUSG00000040289 Hey1

protein_coding

2.711

1.78E-02

ENSMUSG00000016346 Kcnq2

protein_coding

2.924

3.21E-02

ENSMUSG00000066191 Anks6

protein_coding

2.976

1.20E-02

ENSMUSG00000039137 Whrn

protein_coding

3.023

6.02E-04

ENSMUSG00000069227 Gprin1

protein_coding

3.505

3.65E-02

ENSMUSG00000006538 Ihh

protein_coding

3.882

3.02E-02

ENSMUSG00000027517 Ankrd60

protein_coding

3.939

4.36E-02

ENSMUSG00000092675 Gm25262

miRNA

3.974

1.76E-02

ENSMUSG00000098973 Mir6236

miRNA

4.119

4.04E-02

ENSMUSG00000033948 Zswim5

protein_coding

4.237

1.76E-02

140

ENSMUSG00000076258 Gm23935

miRNA

4.258

1.15E-02

ENSMUSG00000092909 Gm25732

miRNA

4.613

2.32E-02

ENSMUSG00000112365 Gm49782

lincRNA

4.871

3.21E-02

ENSMUSG00000044518 Foxe3

protein_coding

5.296

3.21E-02

ENSMUSG00000091383 Hist1h2al

processed_pseudogene

7.024

7.31E-09

ENSMUSG00000059751 Rps3a3

processed_pseudogene

7.605

9.56E-10
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Table S2.5. Ranked list of differentially expressed genes between 923large/large and WT mice
whole skin from RNA List ranked by log2FC. FDR (adj.P.val) <0.05 and logFC <|2| cutoffs
used.
Feature_ID

gene_name

gene_biotype

logFC

adj.P.Val

ENSMUSG00000103523 2210017I01Rik

protein_coding

-5.882

4.39E-08

ENSMUSG00000058172 Krtap6-1

protein_coding

-5.701

3.91E-03

ENSMUSG00000028081 Rps3a1

protein_coding

-5.579

1.24E-15

ENSMUSG00000096534 Krtap16-3

protein_coding

-5.522

1.89E-03

ENSMUSG00000058368 Krtap21-1

protein_coding

-4.793

3.60E-03

ENSMUSG00000086848 Lce6a

protein_coding

-4.648

3.71E-08

ENSMUSG00000069306 Hist1h4m

protein_coding

-4.647

1.51E-03

ENSMUSG00000062400 Krtap6-5

protein_coding

-4.542

7.47E-03

ENSMUSG00000068885 Lce3f

protein_coding

-4.529

1.34E-02

ENSMUSG00000086324 Gm15564

antisense

-4.385

2.88E-02

ENSMUSG00000095992 Krtap22-2

protein_coding

-4.294

3.63E-03

ENSMUSG00000040852 Plekhh2

protein_coding

-3.916

4.13E-03

ENSMUSG00000057174 Krtap19-9b

protein_coding

-3.873

1.14E-02

ENSMUSG00000068075 Gm10229

protein_coding

-3.829

4.20E-03

ENSMUSG00000049128 Ivl

protein_coding

-3.751

1.07E-07

ENSMUSG00000022931 Krtap15

protein_coding

-3.739

3.22E-02

ENSMUSG00000060469 Krtap19-3

protein_coding

-3.581

3.16E-02

ENSMUSG00000081855 Rpl17-ps5

processed_pseudogene

-3.575

8.02E-03

ENSMUSG00000035202 Lars2

protein_coding

-3.405

2.71E-02

ENSMUSG00000068074 Gm10228

protein_coding

-3.402

1.73E-02
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ENSMUSG00000099842 Gm4034

processed_pseudogene

-3.372

3.24E-05

ENSMUSG00000059632 Krtap8-1

protein_coding

-3.331

7.88E-03

ENSMUSG00000049809 Krtap9-3

protein_coding

-3.160

3.95E-02

ENSMUSG00000077506 Scarna9

snoRNA

-3.150

5.51E-11

ENSMUSG00000027908 Tchhl1

protein_coding

-3.047

1.04E-03

ENSMUSG00000117900 AC125101.1

antisense

-3.008

1.67E-02

ENSMUSG00000074433 Lce3e

protein_coding

-3.007

2.99E-02

ENSMUSG00000022229 Atp12a

protein_coding

-3.001

1.22E-03

ENSMUSG00000017300 Tnnc2

protein_coding

-2.968

6.88E-04

ENSMUSG00000082699 Gm12736

processed_pseudogene

-2.899

7.36E-03

ENSMUSG00000087968 Gm25395

scaRNA

-2.863

6.81E-08

ENSMUSG00000024411 Aqp4

protein_coding

-2.855

3.07E-02

ENSMUSG00000062433 Krtap6-2

protein_coding

-2.850

4.39E-02

ENSMUSG00000030237 Slco1a4

protein_coding

-2.818

3.94E-02

ENSMUSG00000079641 Rpl39

protein_coding

-2.786

9.91E-10

ENSMUSG00000069308 Hist1h2bp

protein_coding

-2.784

8.51E-06

ENSMUSG00000065037 Rn7sk

misc_RNA

-2.730

3.90E-10

ENSMUSG00000089281 Scarna6

scaRNA

-2.725

8.00E-08

ENSMUSG00000069722 Krtap3-3

protein_coding

-2.719

2.16E-02

ENSMUSG00000057322 Rpl38

protein_coding

-2.699

5.51E-11

ENSMUSG00000092837 Rpph1

ribozyme

-2.686

2.60E-07

ENSMUSG00000064999 Gm26035

misc_RNA

-2.676

1.29E-04

ENSMUSG00000069309 Hist1h2an

protein_coding

-2.661

1.98E-07
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ENSMUSG00000001773 Folh1

protein_coding

-2.552

1.00E-02

ENSMUSG00000115016 AC158982.1

processed_transcript

-2.543

2.97E-02

ENSMUSG00000036231 Agr3

protein_coding

-2.528

9.99E-03

ENSMUSG00000067288 Rps28

protein_coding

-2.521

5.83E-11

ENSMUSG00000047246 Hist1h2be

protein_coding

-2.504

8.09E-09

ENSMUSG00000047253 Krtap1-5

protein_coding

-2.504

4.29E-02

ENSMUSG00000079013 Serpina3j

protein_coding

-2.451

3.52E-02

ENSMUSG00000093314 Mir5136

miRNA

-2.412

1.99E-04

ENSMUSG00000056706 Krtap7-1

protein_coding

-2.407

3.45E-02

ENSMUSG00000101355 Hist1h3h

protein_coding

-2.397

7.16E-08

ENSMUSG00000060981 Hist1h4h

protein_coding

-2.395

1.67E-08

ENSMUSG00000068855 Hist2h2ac

protein_coding

-2.390

1.36E-09

ENSMUSG00000103084 Gm38119

protein_coding

-2.388

2.24E-02

ENSMUSG00000023078 Cxcl13

protein_coding

-2.385

4.65E-03

ENSMUSG00000047894 Ang2

protein_coding

-2.383

4.74E-02

ENSMUSG00000071478 Hist1h2ad

protein_coding

-2.375

7.24E-05

ENSMUSG00000060678 Hist1h4c

protein_coding

-2.372

6.81E-08

ENSMUSG00000067455 Hist1h4j

protein_coding

-2.369

9.28E-08

ENSMUSG00000093218 Gm25252

miRNA

-2.341

5.66E-03

ENSMUSG00000015665 Awat1

protein_coding

-2.332

3.11E-03

ENSMUSG00000056270 Prr9

protein_coding

-2.328

7.36E-03

ENSMUSG00000069267 Hist1h3b

protein_coding

-2.306

2.07E-07

ENSMUSG00000045566 Sprr4

protein_coding

-2.302

1.82E-02
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ENSMUSG00000064694 Gm24146

misc_RNA

-2.267

1.22E-05

ENSMUSG00000028011 Tdo2

protein_coding

-2.260

4.40E-03

ENSMUSG00000101972 Hist1h3i

protein_coding

-2.254

5.87E-07

ENSMUSG00000058385 Hist1h2bg

protein_coding

-2.237

1.10E-07

ENSMUSG00000041841 Rpl37

protein_coding

-2.229

5.51E-11

ENSMUSG00000041841 Rpl37

protein_coding

-2.229

5.51E-11

ENSMUSG00000064899 Snord118

snoRNA

-2.226

2.60E-04

ENSMUSG00000094443 Sgo2b

protein_coding

-2.225

1.13E-03

ENSMUSG00000062727 Hist1h2bk

protein_coding

-2.218

1.44E-06

ENSMUSG00000069972 Rps13-ps2

processed_pseudogene

-2.208

7.96E-03

ENSMUSG00000078655 Gm10972

protein_coding

-2.191

4.93E-03

ENSMUSG00000101389 Ms4a4a

protein_coding

-2.190

1.12E-03

ENSMUSG00000066364 Serpina3b

protein_coding

-2.175

2.38E-03

ENSMUSG00000027824 Vmn2r1

protein_coding

-2.172

3.97E-03

ENSMUSG00000028359 Orm3

protein_coding

-2.162

1.96E-02

ENSMUSG00000018102 Hist1h2bc

protein_coding

-2.147

1.98E-07

ENSMUSG00000069305 Hist1h4n

protein_coding

-2.140

3.22E-04

ENSMUSG00000048483 Zdhhc22

protein_coding

-2.132

4.22E-04

ENSMUSG00000069302 Hist1h2ah

protein_coding

-2.117

1.35E-07

ENSMUSG00000069266 Hist1h4b

protein_coding

-2.104

7.16E-08

ENSMUSG00000052013 Btla

protein_coding

-2.080

2.88E-03

ENSMUSG00000056054 S100a8

protein_coding

-2.071

2.14E-02

ENSMUSG00000039760 Il22ra2

protein_coding

-2.047

5.83E-03
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ENSMUSG00000094338 Hist1h2bl

protein_coding

-2.044

7.16E-08

ENSMUSG00000114456 Hist1h2bh

protein_coding

-2.034

1.35E-07

ENSMUSG00000114279 Hist1h2bm

protein_coding

-2.021

1.33E-06

ENSMUSG00000037563 Rps16

protein_coding

-2.005

2.94E-09

ENSMUSG00000078252 Krtap17-1

protein_coding

-2.001

1.44E-02

ENSMUSG00000108790 Gm44806

TEC

2.015

1.12E-02

ENSMUSG00000023176 Cpn2

protein_coding

2.017

4.85E-02

ENSMUSG00000038522 Mfsd4b1

protein_coding

2.019

2.24E-02

ENSMUSG00000005373 Mlxipl

protein_coding

2.020

9.35E-03

ENSMUSG00000000183 Fgf6

protein_coding

2.025

2.48E-02

ENSMUSG00000097442 Gm26632

antisense

2.028

1.69E-03

ENSMUSG00000079261 Gm15217

protein_coding

2.055

4.46E-02

ENSMUSG00000040146 Rgl3

protein_coding

2.072

3.27E-02

ENSMUSG00000028427 Aqp7

protein_coding

2.075

2.23E-02

ENSMUSG00000038508 Gdf15

protein_coding

2.090

3.11E-02

ENSMUSG00000030546 Plin1

protein_coding

2.092

3.71E-02

ENSMUSG00000086167 Gm13827

processed_pseudogene

2.094

3.25E-03

ENSMUSG00000020963 Tshr

protein_coding

2.112

2.62E-02

ENSMUSG00000094012 Gm10024

protein_coding

2.118

5.51E-03

ENSMUSG00000044667 Plppr4

protein_coding

2.122

4.82E-02

ENSMUSG00000027335 Adra1d

protein_coding

2.129

3.78E-03

ENSMUSG00000097983 Gm26971

sense_intronic

2.146

1.02E-02

ENSMUSG00000095817 Gm3238

protein_coding

2.146

6.11E-03
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ENSMUSG00000085794 Vax2os

antisense

2.148

1.25E-02

ENSMUSG00000104971 9430087B13Rik TEC

2.170

3.25E-03

ENSMUSG00000004892 Bcan

protein_coding

2.188

3.45E-02

ENSMUSG00000020926 Adam11

protein_coding

2.189

7.47E-03

ENSMUSG00000018554 Ybx2

protein_coding

2.193

1.34E-03

ENSMUSG00000101588 Gm28265

lincRNA

2.195

2.33E-03

ENSMUSG00000054667 Irs4

protein_coding

2.195

3.85E-02

ENSMUSG00000104860 Gm42510

TEC

2.210

3.19E-03

ENSMUSG00000027983 Cyp2u1

protein_coding

2.220

4.48E-02

ENSMUSG00000020264 Slc36a2

protein_coding

2.243

3.57E-02

ENSMUSG00000113764 Gm48617

sense_intronic

2.247

1.19E-04

ENSMUSG00000110631 Gm42047

lincRNA

2.252

8.27E-03

ENSMUSG00000107794 Gm44095

TEC

2.256

4.36E-02

ENSMUSG00000112170 Gm9508

protein_coding

2.281

6.74E-04

ENSMUSG00000026834 Acvr1c

protein_coding

2.290

2.09E-02

ENSMUSG00000087104 Tmem132cos

antisense

2.300

1.02E-03

ENSMUSG00000031535 Dkk4

protein_coding

2.305

2.45E-02

ENSMUSG00000045875 Adra1a

protein_coding

2.323

4.04E-02

ENSMUSG00000102461 Gm37166

TEC

2.334

4.20E-03

ENSMUSG00000112830 Gm47765

processed_transcript

2.340

3.90E-04

ENSMUSG00000083382 Gm6433

processed_pseudogene

2.344

6.82E-03

ENSMUSG00000049241 Hcar1

protein_coding

2.376

3.37E-02

ENSMUSG00000032387 Rbpms2

protein_coding

2.391

5.08E-03
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ENSMUSG00000031489 Adrb3

protein_coding

2.391

1.98E-02

ENSMUSG00000023019 Gpd1

protein_coding

2.410

2.73E-02

ENSMUSG00000118330 AC132148.1

antisense

2.415

2.79E-03

ENSMUSG00000049265 Kcnk3

protein_coding

2.437

3.44E-02

ENSMUSG00000033882 Rbm46

protein_coding

2.455

7.43E-03

ENSMUSG00000108141 Gm44079

antisense

2.500

3.51E-03

ENSMUSG00000048070 Pirt

protein_coding

2.542

3.28E-02

ENSMUSG00000096421 Gm10100

protein_coding

2.680

5.82E-03

ENSMUSG00000064225 Paqr9

protein_coding

2.727

2.15E-02

ENSMUSG00000026347 Tmem163

protein_coding

2.736

2.00E-03

ENSMUSG00000067017 Gm3608

pseudogene

2.797

3.27E-03

ENSMUSG00000090955 Gm17097

processed_pseudogene

2.827

9.88E-03

ENSMUSG00000104696 Gm42946

TEC

2.986

1.72E-02

ENSMUSG00000081303 Gm16011

processed_pseudogene

3.387

2.37E-03

ENSMUSG00000087382 Ctcflos

antisense

3.479

2.53E-03

ENSMUSG00000069584 Gm10272

protein_coding

3.502

2.13E-03

ENSMUSG00000078234 Klhdc7a

protein_coding

3.649

4.41E-03

ENSMUSG00000032401 Lctl

protein_coding

3.700

3.31E-02

ENSMUSG00000055197 Fev

protein_coding

3.974

6.67E-03

ENSMUSG00000115702 Gm5206

processed_pseudogene

4.183

4.01E-05

ENSMUSG00000091383 Hist1h2al

processed_pseudogene

7.455

4.88E-10

ENSMUSG00000059751 Rps3a3

processed_pseudogene

7.741

1.13E-10
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Table S2.6. Ranked list of differentially expressed genes between 923large/+ and WT mice
whole skin from RNA List ranked by log2FC. FDR (adj.P.val) <0.05 and logFC <|2| cutoffs
used.
Feature_ID

gene_name

gene_biotype

logFC

adj.P.Val

ENSMUSG00000069306 Hist1h4m

protein_coding

-7.401

4.05E-03

ENSMUSG00000086324 Gm15564

antisense

-5.189

3.13E-02

ENSMUSG00000027908 Tchhl1

protein_coding

-5.015

4.45E-04

ENSMUSG00000058368 Krtap21-1

protein_coding

-4.940

6.06E-03

ENSMUSG00000096534 Krtap16-3

protein_coding

-4.893

8.47E-03

ENSMUSG00000113267 Gm47969

protein_coding

-4.874

4.71E-02

ENSMUSG00000057174 Krtap19-9b

protein_coding

-4.071

1.62E-02

ENSMUSG00000040852 Plekhh2

protein_coding

-3.949

5.36E-03

ENSMUSG00000068075 Gm10229

protein_coding

-3.791

7.04E-03

ENSMUSG00000035202 Lars2

protein_coding

-3.656

2.82E-02

ENSMUSG00000060469 Krtap19-3

protein_coding

-3.649

4.18E-02

ENSMUSG00000045566 Sprr4

protein_coding

-3.593

6.37E-03

ENSMUSG00000058172 Krtap6-1

protein_coding

-3.374

1.89E-02

ENSMUSG00000062456 Rpl9-ps6

protein_coding

-3.183

1.78E-03

ENSMUSG00000077506 Scarna9

snoRNA

-3.034

1.34E-10

ENSMUSG00000017300 Tnnc2

protein_coding

-3.019

9.18E-04

ENSMUSG00000069309 Hist1h2an

protein_coding

-3.017

1.73E-07

ENSMUSG00000062400 Krtap6-5

protein_coding

-3.010

2.91E-02

ENSMUSG00000069308 Hist1h2bp

protein_coding

-2.996

1.04E-05

ENSMUSG00000099842 Gm4034

processed_pseudogene

-2.973

1.11E-04
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ENSMUSG00000057322 Rpl38

protein_coding

-2.846

1.04E-10

ENSMUSG00000062727 Hist1h2bk

protein_coding

-2.759

2.16E-07

ENSMUSG00000095992 Krtap22-2

protein_coding

-2.743

1.79E-02

ENSMUSG00000087968 Gm25395

scaRNA

-2.680

3.30E-07

ENSMUSG00000069266 Hist1h4b

protein_coding

-2.675

1.03E-08

ENSMUSG00000069972 Rps13-ps2

processed_pseudogene

-2.663

5.53E-03

ENSMUSG00000068074 Gm10228

protein_coding

-2.660

5.00E-02

ENSMUSG00000067288 Rps28

protein_coding

-2.658

1.04E-10

ENSMUSG00000109973 Gm45397

lincRNA

-2.635

9.41E-04

ENSMUSG00000047246 Hist1h2be

protein_coding

-2.577

1.19E-08

ENSMUSG00000069267 Hist1h3b

protein_coding

-2.549

1.44E-07

ENSMUSG00000101355 Hist1h3h

protein_coding

-2.524

1.03E-07

ENSMUSG00000092837 Rpph1

ribozyme

-2.518

1.34E-06

ENSMUSG00000043753 Dmrta1

protein_coding

-2.518

5.48E-04

ENSMUSG00000093218 Gm25252

miRNA

-2.481

6.53E-03

ENSMUSG00000071478 Hist1h2ad

protein_coding

-2.477

8.10E-05

ENSMUSG00000079641 Rpl39

protein_coding

-2.474

1.28E-08

ENSMUSG00000059632 Krtap8-1

protein_coding

-2.460

3.02E-02

ENSMUSG00000067455 Hist1h4j

protein_coding

-2.454

1.44E-07

ENSMUSG00000101972 Hist1h3i

protein_coding

-2.445

5.46E-07

ENSMUSG00000061584 Lyg2

protein_coding

-2.444

4.81E-02

ENSMUSG00000060981 Hist1h4h

protein_coding

-2.442

2.39E-08

ENSMUSG00000065037 Rn7sk

misc_RNA

-2.431

8.33E-09
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ENSMUSG00000060678 Hist1h4c

protein_coding

-2.425

1.03E-07

ENSMUSG00000114279 Hist1h2bm

protein_coding

-2.333

4.68E-07

ENSMUSG00000069722 Krtap3-3

protein_coding

-2.319

4.91E-02

ENSMUSG00000089281 Scarna6

scaRNA

-2.305

1.15E-06

ENSMUSG00000056054 S100a8

protein_coding

-2.268

2.07E-02

ENSMUSG00000041841 Rpl37

protein_coding

-2.258

1.04E-10

ENSMUSG00000041841 Rpl37

protein_coding

-2.258

1.04E-10

ENSMUSG00000114456 Hist1h2bh

protein_coding

-2.254

1.03E-07

ENSMUSG00000064694 Gm24146

misc_RNA

-2.248

2.42E-05

ENSMUSG00000058385 Hist1h2bg

protein_coding

-2.237

2.55E-07

ENSMUSG00000069301 Hist1h2ag

protein_coding

-2.231

1.81E-06

ENSMUSG00000021403 Serpinb9b

protein_coding

-2.229

2.07E-02

ENSMUSG00000068855 Hist2h2ac

protein_coding

-2.226

1.03E-08

ENSMUSG00000094338 Hist1h2bl

protein_coding

-2.202

7.24E-08

ENSMUSG00000069305 Hist1h4n

protein_coding

-2.202

3.82E-04

ENSMUSG00000065254 Gm23973

misc_RNA

-2.186

3.93E-05

ENSMUSG00000018102 Hist1h2bc

protein_coding

-2.182

3.61E-07

ENSMUSG00000069302 Hist1h2ah

protein_coding

-2.174

2.55E-07

ENSMUSG00000056270 Prr9

protein_coding

-2.157

1.51E-02

ENSMUSG00000063767 S100a7a

protein_coding

-2.144

8.27E-03

ENSMUSG00000086848 Lce6a

protein_coding

-2.136

4.24E-05

ENSMUSG00000093314 Mir5136

miRNA

-2.104

6.90E-04

ENSMUSG00000079597 Gm5483

protein_coding

-2.104

3.29E-02
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ENSMUSG00000048483 Zdhhc22

protein_coding

-2.098

6.79E-04

ENSMUSG00000064288 Hist1h4k

protein_coding

-2.095

1.15E-06

ENSMUSG00000074183 Gsta1

protein_coding

-2.086

2.83E-03

ENSMUSG00000086801 Gm15943

antisense

-2.071

3.65E-02

ENSMUSG00000075031 Hist1h2bb

protein_coding

-2.055

2.75E-05

ENSMUSG00000037953 A4gnt

protein_coding

-2.028

2.72E-04

ENSMUSG00000037563 Rps16

protein_coding

-2.012

8.33E-09

ENSMUSG00000064899 Snord118

snoRNA

-2.012

7.30E-04

ENSMUSG00000050063 Klk6

protein_coding

-2.007

4.05E-03

ENSMUSG00000008683 Rps15a

protein_coding

-2.003

4.70E-09

ENSMUSG00000095217 Hist1h2bn

protein_coding

-2.000

9.68E-07

ENSMUSG00000081838 Gm13038

processed_pseudogene

2.005

1.56E-03

ENSMUSG00000074217 2210011C24Rik protein_coding

2.039

2.30E-04

ENSMUSG00000075304 Sp5

protein_coding

2.052

3.38E-03

ENSMUSG00000072589 Gm10371

antisense

2.053

1.32E-02

ENSMUSG00000039683 Sdk1

protein_coding

2.177

4.35E-04

ENSMUSG00000096349 Gm22513

snRNA

2.193

1.02E-04

ENSMUSG00000116657 Gm49774

antisense

2.211

6.94E-04

ENSMUSG00000095817 Gm3238

protein_coding

2.221

5.71E-03

ENSMUSG00000117465 AC102496.1

lincRNA

2.271

1.11E-02

ENSMUSG00000097983 Gm26971

sense_intronic

2.312

7.34E-03

ENSMUSG00000090955 Gm17097

processed_pseudogene

2.316

4.05E-02

ENSMUSG00000104040 Gm37563

TEC

2.369

3.51E-03
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ENSMUSG00000107559 Gm44193

TEC

2.375

1.31E-02

ENSMUSG00000002012 Pnck

protein_coding

2.409

8.40E-03

ENSMUSG00000096421 Gm10100

protein_coding

2.413

1.50E-02

ENSMUSG00000098678 Mroh6

protein_coding

2.492

1.55E-04

ENSMUSG00000104696 Gm42946

TEC

2.723

3.55E-02

ENSMUSG00000084897 Gm14226

protein_coding

2.730

3.75E-02

ENSMUSG00000022957 Itsn1

protein_coding

2.830

2.12E-05

ENSMUSG00000094841 Gm10610

lincRNA

2.924

2.52E-03

ENSMUSG00000081303 Gm16011

processed_pseudogene

3.217

4.31E-03

ENSMUSG00000104232 Gm37590

TEC

3.264

1.33E-02

ENSMUSG00000018263 Tbx5

protein_coding

3.285

3.48E-02

ENSMUSG00000069584 Gm10272

protein_coding

3.311

3.96E-03

ENSMUSG00000100510 Hand2os1

processed_transcript

3.571

3.11E-02

ENSMUSG00000055197 Fev

protein_coding

4.157

5.50E-03

ENSMUSG00000026347 Tmem163

protein_coding

4.281

2.05E-05

ENSMUSG00000115702 Gm5206

processed_pseudogene

4.992

5.80E-06

ENSMUSG00000091383 Hist1h2al

processed_pseudogene

6.467

1.03E-08

ENSMUSG00000059751 Rps3a3

processed_pseudogene

6.870

2.04E-09
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Table S2.7. Ranked list of differentially expressed genes between Ivl -/- and WT mice whole
skin from RNA List ranked by log2FC. FDR (adj.P.val) <0.05 and logFC <|2| cutoffs used.
Feature_ID

gene_name

gene_biotype

logFC

adj.P.Val

ENSMUSG00000069306 Hist1h4m

protein_coding

11.114

1.65E-03

ENSMUSG00000049128 Ivl

protein_coding

-7.675

1.96E-10

ENSMUSG00000086324 Gm15564

antisense

-5.179

4.16E-03

ENSMUSG00000057174 Krtap19-9b

protein_coding

-5.005

6.67E-04

ENSMUSG00000092909 Gm25732

miRNA

-4.925

2.72E-02

ENSMUSG00000028081 Rps3a1

protein_coding

-4.882

5.70E-18

ENSMUSG00000068885 Lce3f

protein_coding

-4.648

3.91E-03

ENSMUSG00000032080 Apoa4

protein_coding

-4.485

1.53E-02

ENSMUSG00000022931 Krtap15

protein_coding

-4.327

3.96E-03

ENSMUSG00000074928 Krtap14

protein_coding

-4.284

8.42E-03

ENSMUSG00000049972 Skint9

protein_coding

-4.260

6.10E-04

ENSMUSG00000027908 Tchhl1

protein_coding

-4.212

1.19E-05

ENSMUSG00000070868 Skint3

protein_coding

-4.166

6.30E-04

ENSMUSG00000055960 Skint4

protein_coding

-4.078

4.67E-04

ENSMUSG00000032083 Apoa1

protein_coding

-4.030

3.77E-02

ENSMUSG00000096534 Krtap16-3

protein_coding

-3.886

1.53E-03

ENSMUSG00000079013 Serpina3j

protein_coding

-3.872

1.13E-03

ENSMUSG00000038567 Cyp24a1

protein_coding

-3.845

1.78E-03

ENSMUSG00000060469 Krtap19-3

protein_coding

-3.746

1.07E-02

ENSMUSG00000082699 Gm12736

processed_pseudogene

-3.707

2.65E-04
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ENSMUSG00000062400 Krtap6-5

protein_coding

-3.640

1.59E-03

ENSMUSG00000017300 Tnnc2

protein_coding

-3.636

1.32E-05

ENSMUSG00000058368 Krtap21-1

protein_coding

-3.564

1.10E-03

ENSMUSG00000069372 Ctxn3

protein_coding

-3.528

4.82E-02

ENSMUSG00000035202 Lars2

protein_coding

-3.518

9.01E-03

ENSMUSG00000058172 Krtap6-1

protein_coding

-3.486

1.66E-03

ENSMUSG00000098973 Mir6236

miRNA

-3.402

2.00E-02

ENSMUSG00000095992 Krtap22-2

protein_coding

-3.370

7.01E-04

ENSMUSG00000087194 Skint6

protein_coding

-3.304

5.59E-04

ENSMUSG00000033948 Zswim5

protein_coding

-3.267

3.11E-02

ENSMUSG00000082678 Gm12818

processed_pseudogene

-3.224

4.59E-03

ENSMUSG00000040852 Plekhh2

protein_coding

-3.199

7.30E-03

ENSMUSG00000028834 Trim63

protein_coding

-3.189

1.87E-02

ENSMUSG00000045566 Sprr4

protein_coding

-3.149

6.59E-04

ENSMUSG00000068075 Gm10229

protein_coding

-3.120

9.87E-04

ENSMUSG00000091573 Serpina3d-ps

unprocessed_pseudogene

-3.119

1.49E-02

ENSMUSG00000024411 Aqp4

protein_coding

-3.102

4.52E-03

ENSMUSG00000065037 Rn7sk

misc_RNA

-3.083

2.24E-11

ENSMUSG00000023078 Cxcl13

protein_coding

-3.013

1.58E-04

ENSMUSG00000106174 Gm43235

unprocessed_pseudogene

-2.982

3.94E-02

ENSMUSG00000093218 Gm25252

miRNA

-2.923

1.96E-04

ENSMUSG00000062433 Krtap6-2

protein_coding

-2.872

1.14E-02

ENSMUSG00000023267 Gabrr2

protein_coding

-2.857

1.33E-02
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ENSMUSG00000060678 Hist1h4c

protein_coding

-2.851

4.63E-10

ENSMUSG00000049809 Krtap9-3

protein_coding

-2.796

1.43E-02

ENSMUSG00000045515 Pou3f3

protein_coding

-2.788

1.67E-02

ENSMUSG00000060560 Ces4a

protein_coding

-2.769

1.19E-03

ENSMUSG00000086298 Gm11716

antisense

-2.764

2.05E-04

ENSMUSG00000057977 Skint11

protein_coding

-2.739

2.18E-03

ENSMUSG00000042985 Upk3b

protein_coding

-2.716

3.19E-03

ENSMUSG00000055298 Ctsj

protein_coding

-2.716

4.11E-03

ENSMUSG00000060981 Hist1h4h

protein_coding

-2.688

3.59E-10

ENSMUSG00000057322 Rpl38

protein_coding

-2.684

3.72E-12

ENSMUSG00000059632 Krtap8-1

protein_coding

-2.661

3.31E-03

ENSMUSG00000090527 Gm5538

protein_coding

-2.608

3.67E-03

ENSMUSG00000074433 Lce3e

protein_coding

-2.606

1.14E-02

ENSMUSG00000024846 Cst6

protein_coding

-2.595

7.32E-08

ENSMUSG00000042045 Sln

protein_coding

-2.575

1.71E-03

ENSMUSG00000052180 Serpinb6c

protein_coding

-2.556

4.33E-04

ENSMUSG00000099842 Gm4034

processed_pseudogene

-2.531

1.09E-05

ENSMUSG00000081169 Gm12551

unprocessed_pseudogene

-2.519

1.61E-03

ENSMUSG00000063767 S100a7a

protein_coding

-2.511

2.83E-04

ENSMUSG00000005716 Pvalb

protein_coding

-2.498

2.54E-02

ENSMUSG00000089948 Far2os1

antisense

-2.497

3.08E-02

ENSMUSG00000064347 mt-Ta

Mt_tRNA

-2.435

7.53E-06

ENSMUSG00000093674 Rpl41

protein_coding

-2.432

1.66E-10

156

ENSMUSG00000053719 Klk1b26

protein_coding

-2.431

1.81E-02

ENSMUSG00000038670 Mybpc2

protein_coding

-2.415

1.64E-02

ENSMUSG00000114279 Hist1h2bm

protein_coding

-2.408

8.74E-09

ENSMUSG00000066364 Serpina3b

protein_coding

-2.403

1.59E-04

ENSMUSG00000021403 Serpinb9b

protein_coding

-2.390

1.86E-03

ENSMUSG00000030237 Slco1a4

protein_coding

-2.389

2.08E-02

ENSMUSG00000069718 Gm11563

protein_coding

-2.384

3.22E-02

ENSMUSG00000075031 Hist1h2bb

protein_coding

-2.380

4.92E-07

ENSMUSG00000069792 Wfdc17

protein_coding

-2.357

8.32E-03

ENSMUSG00000037563 Rps16

protein_coding

-2.345

2.51E-11

ENSMUSG00000030785 Cox6a2

protein_coding

-2.341

1.36E-03

ENSMUSG00000043219 Hoxa6

protein_coding

-2.340

1.27E-02

ENSMUSG00000042212 Sprr2d

protein_coding

-2.329

1.16E-02

ENSMUSG00000082766 1700064H15Rik

protein_coding

-2.326

3.66E-05

ENSMUSG00000026390 Marco

protein_coding

-2.324

3.54E-02

ENSMUSG00000062727 Hist1h2bk

protein_coding

-2.323

8.12E-08

ENSMUSG00000103084 Gm38119

protein_coding

-2.322

6.44E-03

ENSMUSG00000056054 S100a8

protein_coding

-2.321

2.94E-03

ENSMUSG00000068855 Hist2h2ac

protein_coding

-2.319

1.44E-10

ENSMUSG00000112188 Gm47708

lincRNA

-2.317

3.19E-03

ENSMUSG00000031097 Tnni2

protein_coding

-2.316

4.48E-03

ENSMUSG00000021456 Fbp2

protein_coding

-2.313

1.12E-03

ENSMUSG00000067455 Hist1h4j

protein_coding

-2.310

1.06E-08
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ENSMUSG00000080885 Rpl10-ps6

processed_pseudogene

-2.307

9.60E-05

ENSMUSG00000047253 Krtap1-5

protein_coding

-2.305

1.58E-02

ENSMUSG00000092746 Rn7s6

misc_RNA

-2.297

7.71E-07

ENSMUSG00000062077 Trim54

protein_coding

-2.293

5.95E-04

ENSMUSG00000056999 Ide

protein_coding

-2.285

2.29E-06

ENSMUSG00000056706 Krtap7-1

protein_coding

-2.284

1.14E-02

ENSMUSG00000031779 Ccl22

protein_coding

-2.283

3.71E-03

ENSMUSG00000096010 Hist4h4

protein_coding

-2.278

3.59E-10

ENSMUSG00000052819 Best2

protein_coding

-2.252

2.73E-02

ENSMUSG00000038236 Hoxa7

protein_coding

-2.242

1.22E-02

ENSMUSG00000015665 Awat1

protein_coding

-2.241

6.00E-04

ENSMUSG00000030672 Mylpf

protein_coding

-2.232

3.98E-03

ENSMUSG00000037953 A4gnt

protein_coding

-2.226

6.20E-06

ENSMUSG00000031382 Asb11

protein_coding

-2.220

8.82E-03

ENSMUSG00000100190 Krtap28-10

protein_coding

-2.217

4.87E-02

ENSMUSG00000100511 1700111N16Rik

antisense

-2.206

1.36E-03

ENSMUSG00000077391 Gm24336

snoRNA

-2.201

2.27E-08

ENSMUSG00000092837 Rpph1

ribozyme

-2.196

6.51E-07

ENSMUSG00000068877 Selenbp2

protein_coding

-2.192

1.07E-03

ENSMUSG00000087968 Gm25395

scaRNA

-2.190

1.30E-07

ENSMUSG00000107451 Gm44421

lincRNA

-2.170

7.35E-03

ENSMUSG00000061482 Hist1h4d

protein_coding

-2.162

6.72E-09

ENSMUSG00000078131 Krtap1-3

protein_coding

-2.159

3.83E-02
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ENSMUSG00000020475 Pgam2

protein_coding

-2.158

1.83E-03

ENSMUSG00000068074 Gm10228

protein_coding

-2.157

2.32E-02

ENSMUSG00000001773 Folh1

protein_coding

-2.148

4.25E-03

ENSMUSG00000023153 Tmem52

protein_coding

-2.137

1.44E-02

ENSMUSG00000069722 Krtap3-3

protein_coding

-2.121

1.37E-02

ENSMUSG00000030399 Ckm

protein_coding

-2.111

1.10E-02

ENSMUSG00000064288 Hist1h4k

protein_coding

-2.107

8.73E-08

ENSMUSG00000109973 Gm45397

lincRNA

-2.104

2.89E-04

ENSMUSG00000111912 Gm48521

lincRNA

-2.098

9.06E-04

ENSMUSG00000026985 Il1f8

protein_coding

-2.097

1.42E-05

ENSMUSG00000069267 Hist1h3b

protein_coding

-2.091

1.17E-07

ENSMUSG00000050063 Klk6

protein_coding

-2.091

2.93E-04

ENSMUSG00000051748 Wfdc21

protein_coding

-2.086

7.89E-06

ENSMUSG00000056328 Myh1

protein_coding

-2.086

8.43E-03

ENSMUSG00000007877 Tcap

protein_coding

-2.083

8.36E-03

ENSMUSG00000079017 Ifi27l2a

protein_coding

-2.079

4.78E-05

ENSMUSG00000044748 Defb1

protein_coding

-2.077

1.20E-04

ENSMUSG00000042254 Cilp

protein_coding

-2.070

5.46E-04

ENSMUSG00000089281 Scarna6

scaRNA

-2.058

9.56E-08

ENSMUSG00000019933 Mrln

protein_coding

-2.055

9.40E-04

ENSMUSG00000030996 Art1

protein_coding

-2.051

6.46E-03

ENSMUSG00000062694 Cav3

protein_coding

-2.047

1.14E-03

ENSMUSG00000067288 Rps28

protein_coding

-2.043

9.26E-11
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ENSMUSG00000096965 3300005D01Rik

lincRNA

-2.043

1.72E-04

ENSMUSG00000069274 Hist1h4f

protein_coding

-2.037

1.83E-07

ENSMUSG00000006587 Snai3

protein_coding

-2.034

2.53E-02

ENSMUSG00000069309 Hist1h2an

protein_coding

-2.030

2.68E-07

ENSMUSG00000087881 Gm22442

scaRNA

-2.027

8.26E-10

ENSMUSG00000047246 Hist1h2be

protein_coding

-2.027

1.16E-08

ENSMUSG00000041841 Rpl37

protein_coding

-2.023

3.79E-11

ENSMUSG00000041841 Rpl37

protein_coding

-2.023

3.79E-11

ENSMUSG00000022215 Fitm1

protein_coding

-2.017

3.14E-03

ENSMUSG00000006457 Actn3

protein_coding

-2.013

1.72E-02

ENSMUSG00000043681 Fam25c

protein_coding

-2.007

6.75E-09

ENSMUSG00000069266 Hist1h4b

protein_coding

-2.003

6.72E-09

ENSMUSG00000043753 Dmrta1

protein_coding

-2.001

1.54E-04

ENSMUSG00000048483 Zdhhc22

protein_coding

-2.000

9.49E-05

ENSMUSG00000081142 Gm15497

processed_pseudogene

2.001

7.88E-04

ENSMUSG00000079654 Prrt4

protein_coding

2.003

2.69E-03

ENSMUSG00000090255 4921534H16Rik

antisense

2.005

1.92E-03

ENSMUSG00000097983 Gm26971

sense_intronic

2.008

8.30E-03

ENSMUSG00000102160 Gm36944

TEC

2.013

3.90E-03

ENSMUSG00000069583 Krtap12-1

protein_coding

2.020

5.90E-03

ENSMUSG00000083382 Gm6433

processed_pseudogene

2.025

9.70E-03

ENSMUSG00000097520 4930488L21Rik

antisense

2.025

1.11E-04

ENSMUSG00000105265 Sox2ot

processed_transcript

2.036

2.79E-03
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ENSMUSG00000097442 Gm26632

antisense

2.058

5.76E-04

ENSMUSG00000086485 Gm15458

lincRNA

2.069

7.02E-03

ENSMUSG00000085785 Sox5os3

antisense

2.072

3.14E-03

ENSMUSG00000057715 A830018L16Rik protein_coding

2.072

4.63E-02

ENSMUSG00000104801 Gm43834

TEC

2.089

1.63E-02

ENSMUSG00000097245 Gm5421

processed_pseudogene

2.098

1.88E-02

ENSMUSG00000107794 Gm44095

TEC

2.098

3.83E-02

ENSMUSG00000022622 Acr

protein_coding

2.110

5.73E-03

ENSMUSG00000020963 Tshr

protein_coding

2.118

1.42E-02

ENSMUSG00000118330 AC132148.1

antisense

2.130

3.60E-03

ENSMUSG00000109648 Svet1

TEC

2.154

3.47E-02

ENSMUSG00000045875 Adra1a

protein_coding

2.159

3.63E-02

ENSMUSG00000086785 Gm6081

processed_pseudogene

2.190

1.12E-03

ENSMUSG00000102250 Gm38260

TEC

2.208

6.03E-03

ENSMUSG00000112990 Gm47372

TEC

2.213

4.02E-04

ENSMUSG00000064225 Paqr9

protein_coding

2.239

3.78E-02

ENSMUSG00000035226 Rims4

protein_coding

2.249

2.62E-02

ENSMUSG00000117465 AC102496.1

lincRNA

2.252

4.69E-03

ENSMUSG00000081838 Gm13038

processed_pseudogene

2.261

1.49E-04

ENSMUSG00000089783 Gm454

lincRNA

2.280

2.73E-02

ENSMUSG00000070390 Nlrp1b

protein_coding

2.302

8.36E-05

ENSMUSG00000108141 Gm44079

antisense

2.326

3.05E-03

ENSMUSG00000105726 Gm42443

TEC

2.343

8.19E-04
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ENSMUSG00000039200 Atf7ip2

protein_coding

2.359

2.57E-04

ENSMUSG00000044349 Snhg11

protein_coding

2.378

1.09E-03

ENSMUSG00000117666 AC131692.1

protein_coding

2.379

2.43E-03

ENSMUSG00000029167 Ppargc1a

protein_coding

2.380

1.50E-02

ENSMUSG00000111207 Gm8125

processed_pseudogene

2.381

1.49E-02

ENSMUSG00000053054 Adh6a

protein_coding

2.386

4.48E-02

ENSMUSG00000094841 Gm10610

lincRNA

2.387

5.28E-03

ENSMUSG00000108442 Rpl15-ps5

processed_pseudogene

2.388

1.02E-04

ENSMUSG00000050423 Ppp1r3g

protein_coding

2.399

2.34E-02

ENSMUSG00000044667 Plppr4

protein_coding

2.418

1.37E-02

ENSMUSG00000098383 Gm27197

antisense

2.441

1.82E-03

ENSMUSG00000055373 Fut9

protein_coding

2.456

1.62E-02

ENSMUSG00000062093 Gm10110

processed_pseudogene

2.524

1.88E-03

ENSMUSG00000105442 Gm42614

TEC

2.582

3.84E-02

ENSMUSG00000069830 Nlrp1a

protein_coding

2.651

1.52E-03

ENSMUSG00000105622 Gm42615

TEC

2.668

4.14E-02

ENSMUSG00000090955 Gm17097

processed_pseudogene

2.713

7.29E-03

ENSMUSG00000037071 Scd1

protein_coding

2.733

3.28E-04

ENSMUSG00000028341 Nr4a3

protein_coding

3.010

1.09E-02

ENSMUSG00000033882 Rbm46

protein_coding

3.027

6.13E-04

ENSMUSG00000069584 Gm10272

protein_coding

3.091

3.12E-03

ENSMUSG00000104696 Gm42946

TEC

3.125

7.21E-03

ENSMUSG00000027513 Pck1

protein_coding

3.160

2.36E-02
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ENSMUSG00000115702 Gm5206

processed_pseudogene

3.397

1.37E-04

ENSMUSG00000032401 Lctl

protein_coding

3.473

3.02E-02

ENSMUSG00000097532 Gm4349

lincRNA

3.506

2.25E-04

ENSMUSG00000041698 Slco1a1

protein_coding

3.509

4.65E-02

ENSMUSG00000108405 Ywhaq-ps1

processed_pseudogene

3.532

1.10E-03

ENSMUSG00000087382 Ctcflos

antisense

3.575

1.03E-03

ENSMUSG00000081303 Gm16011

processed_pseudogene

3.726

4.66E-04

ENSMUSG00000081824 BC002163

processed_pseudogene

3.801

1.22E-02

ENSMUSG00000033196 Myh2

protein_coding

3.958

1.25E-06

ENSMUSG00000104232 Gm37590

TEC

4.270

7.08E-04

ENSMUSG00000055197 Fev

protein_coding

4.360

1.73E-03

ENSMUSG00000067017 Gm3608

pseudogene

4.369

1.37E-05

ENSMUSG00000117695 AC161579.1

lincRNA

4.741

5.50E-03

ENSMUSG00000043618 Eif5al3-ps

processed_pseudogene

4.924

7.71E-05

ENSMUSG00000083240 Gm13453

processed_pseudogene

6.665

7.43E-06

ENSMUSG00000091383 Hist1h2al

processed_pseudogene

7.008

6.61E-10

ENSMUSG00000099216 Obox8

protein_coding

7.144

1.66E-10

ENSMUSG00000040264 Gbp2b

protein_coding

7.366

5.01E-05

ENSMUSG00000059751 Rps3a3

processed_pseudogene

7.968

5.09E-11
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